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1. Introduction 
The daily human needs are many and different. Other than food and water, the need for 
medication is considered the most important thing at all. In the last decades, several 
diseases have been discovered and correspondingly several human pharmaceutical 
products for diagnosis, treatment or prevention of diseases have been discovered as well. 
Thus, 1200-3000 pharmaceutical compounds with different chemical structures are used 
worldwide in human and veterinary medicine [Halling-Sørensen et al., 1997, Hilton et al., 
2003, Ashton et al., 2004, Carlsson et al., 2006a]. These pharmaceuticals, in some 
countries, are formulated in more than 7000 human and 1000 veterinary medicinal products 
[Carlsson et al., 2006a, Barron et al., 2009]. 
 
Humans are using these pharmaceuticals to get benefits without paying attention to the 
consequence of the uncontrolled emission of these pharmaceuticals into the environment. 
After excretion, unchanged parent compounds or formed metabolites are mainly introduced 
together with municipal wastewater into wastewater treatment plants for elimination 
purposes. A large number of these pharmaceuticals are polar and neither volatile nor 
biodegradable. In wastewater treatment plants, therefore, they are able to escape sorption 
onto the sewage sludge fraction, sedimentation and biotransformation during the activated 
sludge treatment in the aeration tank [Paxeus, 2004]. As a result, pharmaceuticals are 
released via wastewater effluents into receiving waters. Additionally, because 
pharmaceuticals are designed to persist long enough in the human body to perform their 
therapeutic effect, it is expected that they may remain in the aquatic environment for a 
specific time period according to the environmental conditions.  
 
Although the consequence of presence of pharmaceuticals in the aquatic environment is not 
completely known, it should not be forgotten that they are biologically active substances, 
made for living organisms and hence may represent a danger for the ecosystem. 
Bioaccumulation [Halling-Sørensen et al., 1998, Brooks et al., 2005], additive or synergetic 
effects of complex mixtures substance [Cleuvers, 2003, Brian et al., 2005], endocrine 
disrupting activity [Halling-Sørensen et al., 1998, Brian et al., 2005, WHO 2002, Kime and 
Nash, 1999], phytotoxicity [Brain et al. 2004, Schmitt-Jansen., 2007] and the development of 
bacterial antibiotic resistance [Duong et al., 2008] as well as genotoxicity [Hartmann et al., 
1998] are considered the most important harmful effects reported at present. Additionally, in 
water/sediment system, sediments may act as sinks for pharmaceuticals. Later on, under 
changed boundary environmental conditions, e.g., enhanced hydrological potentials or 
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changes from aerobic to anaerobic conditions, pharmaceutical residues may undergo bank 
filtration followed by entering into groundwater used for drinking water. 
 
First studies that identified pharmaceuticals in the environment were published by Garrison 
et al. (1976) and Higaite and Azaznoff (1977) where clofibrate, aspirin and their metabolites 
were discovered in the effluent of a sewage disposal plant in USA. Afterwards, 
pharmaceuticals were detected in UK aquatic environment [Waggot, 1981, Richardson and 
Bowron, 1985]. The systematic research has been started in Germany at the beginning of 
the 1990s for determination of pharmaceuticals in rivers and wastewater treatment plants 
[Stumpf et al., 1996, Heberer and Stan, 1997, Heberer et al., 1997, 1998 and 1999, Ternes, 
1998, and Hirsch et al., 1998, 1999, 2000]. Since this time, pharmaceuticals have been 
identified as a new class of environmental chemicals. Thereafter, the excessively increased 
use of pharmaceuticals allowed dispersing widely in the environment resulting in the 
detection of more than 80 pharmaceuticals of different therapeutic classes such as 
analgesics, antipyretics, human and veterinary antibiotics, antiepileptics, anti-inflammatories, 
antidepressants, beta-blockers, broncholitics, contraceptives, diagnostics, lipid regulators, 
synthetic steroidal hormones, tranquilizers and some of their related metabolites in different 
countries including Australia [Braga et al., 2005, Al-Rifai et al., 2007], Brazil [Stumpf et al., 
1999], Canada [Metcalfe et al., 2003], Chinese [Anon, 2005], Finland [Vieno et al., 2005], 
France [Elbaz-Poulichet et al., 2002, Andreozzi et al., 2003, Comoretto and Chiron 2005, 
Rabiet et al., 2006], Germany [Ternes and Hirsch, 2000, Sacher et al., 1998, 2001, 2002, 
Zuehlke et al., 2004, Wiegel et al., 2004], Greece [Andreozzi et al., 2003, Koutsouba et al., 
2003], Italy [Castiglioni et al., 2004, 2005, 2006, Zuccato et al., 2005], Japan [Nozaki et al., 
2000, Kimura et al., 2007], Netherlands [Belfroid et al., 1999], Pakistan [Scheurell et al., 
2009], Slovenia [Antonic and Heath 2007], Spain [Farre et al., 2001, Gomez et al., 2006], 
Sweden [Andreozzi et al., 2003], Switzerland [Buser et al., 1998a, b, Oellers et al., 2001, 
Golet et al., 2001, 2002, McArdell et al., 2003, Tixier et al., 2003, Tauxe-Wuersch et al., 
2005], UK [Hilton and Thomas, 2003], and USA [Kolpin et al., 2002, Boyd et al., 2003]. 
 
Moreover, the pharmaceutical loads in a small Mediterranean river were found to be as 
important as pesticide loads [Comoretto and Chiron, 2005]. However, in contrast to 
pesticides, pharmaceuticals are used through the whole year meaning that they are 
continuously introduced into the environment [Castiglioni et al., 2006, Buchberger, 2007, 
Vieno et al., 2007]. Therefore, beside pesticides, heavy metals and other industrial 
chemicals, the environmental risk caused by pharmaceuticals has received increasing 
attention by several auothers [Halling-Sørensen et al., 1998, Stuer-Lauridsen et al., 2000, 
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Jones et al., 2001, 2002, Golet et al., 2002, Van Wezel and Jager, 2002, Carlsson et al., 
2006a, b, Letzel et al., 2007, Schmitt-Jansen et al., 2007, Triebskorn et al., 2007, Grung et 
al., 2008, Huschek et al., 2008, Khalaf et al., 2009]. Recently, occurrence and effects of 
human pharmaceuticals in the aquatic environment are considered relevant by the regulatory 
procedure [EMEA, 2001, Roennefahrt et al., 2002]. The authorization of pharmaceutical 
groups has to be combined with environmental risk assessment and/or risk reduction 
measures [Grung et al., 2008]. The risk assessment of novel pharmaceuticals consists of two 
phases in which the second phase is consisted of two tiers [Figure 1]. In phase I, the trigger 
PECwater
 
 > 0.01 µg/L has been established on the basis of an exposure assessment in 
surface water. If this trigger is exceeded, substances have to undergo extended Phase II 
tests. For critical substances, e.g., cytostatica and hormones, those tests are mandatory. In 
Tier A, fate studies and acute ecotoxicological tests in wastewater treatment plants and 
surface water have to be conducted. In Tier B, chronical effects, bioaccumulations, 
transformation, sorption onto soils are to be in the focus of further investigations. In 
Germany, the Federal Environment Agency has been determined the environmental impact 
of 136 veterinary and 134 human pharmaceuticals [Adler et al., 2008].  
Among pharmaceuticals reported in the literature, non-steroidal anti-inflammatory drugs 
(NSAIDs) were found to gain a special relevance from being the most frequently mentioned 
environmental contaminants [Kümmerer, 2004, Woldegiorgis et al., 2007, Silva et al., 2008]. 
The reason might be attributed to the high consumption rate of these drugs. Rather than the 
amounts sold over the counter, their reported annual prescription in developed countries 
achieved several hundreds of tons. As an example, 87.5 million prescriptions were written in 
2001 for the members of this group only in Germany [Cleuvers, 2004]. Furthermore, the 
NSAIDs were found to be stable up to 1 year in the environment which increases their risk for 
accumulation [Khalaf et al., 2009]. Among the NSAIDs, on the other hand, diclofenac has 
been reported by several authors to be ubiquitously present in most of the surveyed waste, 
surface, and drinking waters worldwide [Table 1]. It is considered one of most important 
pharmaceutically active contaminants present in the environmental water cycle [Ternes, 
2001]. Numerous considerations such as physico-chemical properties, annually consumption 
rates, environmental occurrence, phototransformation products, biotransformation products, 
elimination rates, sorption behavior, ecotoxicity data, and the expected environmental hazard 
shown by risk assessment studies could be the main causes for its importance. Therefore, 
diclofenac was selected to be under investigation in the present study. 
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Fate in WWTP and 
surface water, 
acute effects
Phase  II
Chronical effects, bio-
accumulation, transformation 
and sorption in soils
Phase  I Tests on human medicines 
with PECwater > 0.01 µg L-1
and critical substances
(e.g., cytostatica, hormons)
Tier B
Tier  A
PEC/PNEC > 1
→ Requirements for 
environmental protection
Exposure assessment 
for surface water
 
Figure 1: Tiered environmental risk assessment for human pharmaceuticals within the 
regulatory procedure [EMEA, 2001; Rönnefahrt et al., 2002] 
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1.1 Environmental relevance of diclofenac 
 
1.1.1 Structure, physico-chemical properties and pharmacological action  
Diclofenac is an organic compound containing phenyl, amino and acetic acid moieties. The 
structure of diclofenac is shown in Figure 2. 
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Figure 2:  
 
Chemical structure of diclofenac (1a) and diclofenac sodium (1b). 
It is known as 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetic acid (IUPAC name) or acetic 
acid, (o-(2,6-dichloroanilino)phenyl) [ChemIDPlus]. In the neutral form (molecular formula: 
C14H11Cl2NO2, molecular weight: 296.16, and CAS No.:15307-86-5), it has a water solubility 
of 2.37 mg/L [SCR PhysProp Database, 2010]. In acidic solutions (pH 1.1), the solubility of 
diclofenac is lower than 1 mg/mL [Palomo et al., 1999, Merck index, 1996]. Due to the 
presence of carboxylic group and the secondary amino group that can act as proton donor or 
proton acceptor, it has a Lewis acid–base character [Zilnik et al., 2007]. It is mostly used as 
the sodium salt which is known as 2-[(2,6 dichlorophenyl)amino]benzoic acid monosodium 
salt [Merck index, 1996], sodium [o-(2,6-dichloranilino) phenyl] acetate [PharmaDerm], or 
sodium(O-((2,6-dichlorophenyl)- amino)-phenyl)-acetate [Palomo et al., 1999]. It is a salt of a 
weak acid with a pKa of 4.16 [Rafols et al., 1997, SCR PhysProp Database 2010] and a 
distribution coefficient, Dow,(n-octanol/aqueous buffer, pH 7.4) of 13.4 [Palomo et al., 1999, 
Zilnik et al., 2007, Merck index, 1996]. On the other hand, the reported partition coefficient, 
log Pow or Kow, (n-octanol–water) values of diclofenac are 4.5 [SCR PhysProp Database 
2010], 1.9 [Scheytt et al., 2005b], 4.12 [Schmitt-Jansen et al., 2007], and 0.7-4.5 [Johnson et 
al., 2007]. Its vapour pressure was 6.3 x 10-5
 
 Pa at 25 ºC [SCR PhysProp Database 2010].  
Diclofenac sodium is a white to slightly yellow crystalline powder with molecular formula 
C14H10Cl2NNaO2, mol wt 318.13, and CAS No. 15307-79-6 [Merck index, 1996]. Its solubility 
in different solvents is affected by the presence of different heteroatoms (N, O, Cl and Na) 
which cause high polarizability of the molecule and hence specific interactions with solvents 
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[Zilnik et al., 2007]. It is freely soluble in methanol > 24 mg/mL, soluble in ethanol, in water 
(pH 5.2) > 9 mg/mL, in acetone and phosphate buffer (pH 7.2) = 6 mg/mL, in acetonitrile, 
cyclohexane, and HCl (pH 1.1) < 1 mg/mL, and partially insoluble in ether [Merck index, 
1996, PharmaDerm]. At 25 ºC, solubility of diclofenac was found to be 4.45 mg/g in acetone, 
1.26 mg/g in ethyl acetate, and 135 mg/g in dimethyl sulfoxide [Zilnik et al., 2007]. Its water 
solubility varies between 50 g/L (at 25°C, pH 7), 20.4 g/L, and 0.003-21 g/L as published by 
Perez-Estrada et al. (2005), Zilnik et al. (2007) and Johnson et al. (2007), respectively. The 
resonating structure and the interaction of diclofenac with water have been described by 
Iqbal and Chaudhry (2009) as shown in Figure 3. 
 
 
 
Figure 3: The resonating structure of diclofenac (2a) and the interaction of 
diclofenac with water (2b) 
 
Pharmacologically, diclofenac can be classified as analgesics, non-narcotic, antirheumatic, 
cyclooxygenase inhibitors, or NSAIDs [ChemIDPlus]. The latter is the commonly known class 
for diclofenac. Due to its analgesic, antipyretic, and anti-inflammatory properties, it is mainly 
used for the treatment of rheumatic diseases (rheumatoid arthritis, osteoarthritis) especially 
in aged patients and to relieve other pain symptoms such as gout, kidney and gallstones, 
acute migraines, bursitis, swelling, stiffness, joint, post-operative, post-traumatic and 
menstrual pain. Inhibition of cyclooxygenase enzyme, which is responsible for the conversion 
of arachidonic acid to prostaglandin, is the main known mechanism of its action [Pasero et 
al., 1995, Khalaf et al., 2009]. It is well known and commercially available on the market in 
various pharmaceutical dosage forms including oral (tablets, capsules), rectal 
(suppositories), injection (intravenous solutions), ophthalmic (eye drops) and to a large 
extend dermal dosage forms (ointments and gels). Although the dermal application is the 
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popular dosage form, 70 % of the worldwide diclofenac sales in 2007 are administrated orally 
[Zhang et al., 2008]. 
 
1.1.2 Consumption rate 
The estimation of the consumption rate of diclofenac is very important in the prediction of the 
environmental occurrence as well as the influence on the ecosystem. The exact consumption 
rate in any region is very difficult to be calculated since diclofenac can be sold in different 
ways (over the counter or using prescriptions). Additionally, diclofenac can be found in the 
markets under different commercial names. In Sweden there are 38 products of diclofenac 
with different commercial names [Carlsson et al., 2006a]. However, the prescription 
diclofenac data are available in some countries. In Germany, the annual consumption of 
diclofenac has been estimated in 1995 at about 75 t/y [Ternes, 1998], in 1999 at 82–250 t/y 
[BLAC, 2003, Huschek et al., 2004, Scheytt et al., 2005a], in 2001 at 86 t/y [Huschek et al., 
2004, Fent et al., 2006]. In 2002 the literature suggested an average diclofenac consumption 
of 2.5 mg/d person [Ternes, 1998; Heberer, 2002a; Heberer and Feldmann, 2005]. In 2004, 
diclofenac occupied the second place in the number of prescriptions issued in Germany 
[Glaeske and Janhsen, 2006, Stuelten et al., 2008]. In England, there were over a million 
prescription items of diclofenac issued in 1997 [Ashton et al., 2004, Ayscough et al., 2000] 
and the mount of diclofenac used in 2000 was 26 t/y with an average of 1.4 mg/d person 
[Jones et al., 2002, Sebastine and Wakeman, 2003]. Other countries such as France, Austria 
and Australia had reported consumption of diclofenac at 16, 6 and 4 t/y, respectively [Ferrari 
et al., 2003, Strenn et al., 2004, Khan and Ongerth, 2004]. 
 
1.1.3 Metabolization 
The most important factor affecting the occurrence of pharmaceuticals in the environment is 
their pharmacokinetic properties. Pharmacokinetic is mainly established to describe the time 
period of a drug in the body. After administration of human drugs, they subjected to two main 
metabolite pathways in the body before they are excreted with urine, feces or both [Figure 
4]. These pathways are known as phase I and phase II. Phase I metabolism includes 
oxidation, hydrolysis, reduction, hydration, condensation and isomerization processes while 
conjugation with sulphate or glucuronic acid is considered as phase II [Merck, 1999]. These 
transformation processes are very important for pharmaceuticals in order to be more 
hydrophilic and hence can be easily excreted.  
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     Excretion 
 
Figure 4: Metabolization of pharmaceutical drugs in humans 
 
For diclofenac, the predominant process during phase I metabolism is the oxidation which 
can take place in the phenylacetic acid ring, dichlorophenyl ring or in both resulting in several 
single or multiple hydroxylated metabolites. These metabolites are 4'-hydroxydiclofenac (16-
30 %), 4',5-dihydroxydiclofenac (15 %), 5-hydroxydiclofenac (10 %). 4'-Hydroxydiclofenac 
and 5-hydroxydiclofenac undergo autoxidation and the highly reactive hepatotoxic p-
benzoquinone imines could be then formed. Other minor oxidative metabolites are 3'-
hydroxy- (1-2 %) and 3'-hydroxy-4'-methoxy derivatives of diclofenac. Almost 20 % of 
diclofenac able to pass phase I without oxidation. During phase II metabolism, most of these 
hydroxylated metabolites and of almost 15 % of diclofenac undergo glucuronide or sulphate 
conjugations. Conjugations occur either at the carboxyl group of the side chain or at phenolic 
hydroxyl groups. Approximately 6 % of diclofenac can escape phase II unaltered. Thereafter, 
all of these compounds are excreted mainly in urine (50-65 % of the oral dose) [Riess et al., 
1978, Stierlin et al., 1979, Leemann et al., 1993, Sawchuk et al., 1995, Shen et al., 1999, 
Belfroid et al., 1999, Schneider and Degen, 1981, Poon et al., 2001, Ashton et al., 2004, 
Groning et al., 2007, Johnson et al., 2007, Zhang et al., 2008, Perez and Barcelo 2008]. 
Other authors published highly variable excretion rates (1 to 25 %) for diclofenac as a parent 
compound [Landsdorp et al., 1990, Ternes, 1998, Mersmann, 2003, Schwaiger et al., 2004, 
Letzel et al., 2009]. 
 
The hydroxylated metabolites were found to be pharmacologically active but 10 to 50 times 
less potent than diclofenac itself [Menasse et al., 1978, Stierlin et al., 1979, Wiesenberg-
Pharmaceuticals 
Oxidation, reduction, 
hydrolysis, hydration, 
condensation, isomerization 
Phase I Metabolite 
Conjugation 
   Phase II Metabolite 
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Boettcher et al., 1991, Wishart et al., 2006, Zhang et al., 2008]. Recently, the indolinone 
structures of 4'-hydroxydiclofenac and 5-hydroxydiclofenac were identified in urine samples 
as human metabolites of diclofenac [Stuelten et al., 2008b]. The structures of these 
metabolites are shown in Figure 5. In contrast to urinary excretion, very little information is 
available regarding excretion of diclofenac in feces. Riess et al. (1978) reported 42 % of the 
oral dose as the maximum amount of diclofenac and its metabolites (free and conjugates) 
that could be excreted in bile, mainly 10-20 % of 4'-hydroxydiclofenac, 5-10 % of 5-
hydroxydiclofenac, and less than 5 % diclofenac. On the other hand, almost 6 % diclofenac is 
resorbed when applied on the skin and the rest is discharged during washing [Schrey and 
Wilhelm, 1999, Stuelten et al., 2008a].The half-life of diclofenac in the human body is 1-2 h 
[Moore et al., 1990. Moore, 1998, Wishart et al., 2006, Zhang et al., 2008]. 
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Figure 5: Structures of human metabolites of diclofenac 
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1.1.4 Sources  
Understanding of pharmaceutical origins is very necessary for designing effective pollution 
reduction measures. Pharmaceuticals are able to invade the ecosystem in several ways. In 
Figure 6, the environmental sources of pharmaceuticals are outlined and the main sources 
are discussed in the following text. 
 
 
 
Figure 6: Entry routes and distribution of pharmaceuticals in the environment 
 
Wastewater treatment plants 
Wastewater treatment plant (WWTP) effluents are considered the major source for 
introduction of human pharmaceuticals into the aquatic environment [Bernhard et al., 2006]. 
They receive pharmaceutical compounds from different places such as homes, hospitals, 
and cliniks. Disposal of unused or expired pharmaceuticals into toilet is considered to a 
lesser extends additional source [Kümmerer, 2001]. Once pharmaceuticals, as organic 
compounds of anthropogenic origin, enter the wastewater treatment process they are either 
mineralized, deconjugated, degraded, transformed into metabolites or non-extractable 
residues, sorbed, or pass unaltered through the WWTP effluents to the water bodies [Halling-
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Sørensen et al., 1997, 1998, Hartig et al., 1999, Heberer, 2002b, Farre et al., 2001, Kosjek et 
al., 2005]. Because of their polarity, several drugs are not efficiently removed during 
wastewater treatment processes and consequently reach surface and even groundwater 
which are considered the major sources for drinking water [Heberer, 1995, Heberer and 
Stan, 1997, Heberer et al., 2001, Gros et al., 2006]. Therefore, the elimination performance 
during the wastewater treatment process is considered the determining factor for presence of 
pharmaceuticals in the environment [Alcock et al., 1999, McArdell et al., 2003, Ternes, 1998, 
Ternes et al., 1999].  
 
After reaching the water bodies, pharmaceuticals can undergo further processes such as 
biotransformation, phototransformation and/or sorption onto the sediment. It could be 
additionally reach groundwater through bank filtration. Since small amounts of the total oral 
dose are excreted in free form, diclofenac (as a parent compound) is expected to be 
generated by means of different processes. The cleavage of the conjugated form of 
diclofenac by β-glucuronidase enzymes seems to be one of the main sources of regeneration 
of diclofenac in WWTP [Ternes, 1998, Belfroid et al., 1999, Hirsch et al., 1999, Ternes et al., 
1999, Ashton et al., 2004, Schwaiger et al., 2004, Vieno et al., 2007]. This process might be 
responsible for the negative removal results reported for diclofenac [Lishman et al., 2006, 
Sebok et al., 2008]. Another possible source for the formation of diclofenac is the ester 
hydrolysis of aceclofenac. In batch reactors, biodegradation experiments using mixed liquor 
from the conventional activated sludge aeration tank showed that 90 % of the initially applied 
aceclofinac amount is converted to diclofenac [Perez and Barcelo, 2008]. Dermal 
applications are, additionally, considered other major source for diclofenac in the wastewater, 
since small amounts (10 %) are only absorbed through the skin and the remaining amounts 
(90 %) are discharged directly after washing [Heberer and Feldmann, 2005]. 
 
Pharmaceutical industries 
As a result of the good manufacturing practice regulations, the wastewater treatment plants 
of pharmaceutical industry in the developed countries are expected to provide high 
elimination efficiency for most of the wastewater constituents including diclofenac. Therefore, 
pharmaceutical manufactures were excluded for long time as a major emission source for 
pharmaceuticals in Europe and USA [Schroeder, 1999, Sacher et al., 2001]. Recently, in 
New York, pharmaceutical formulation facilities have been reported to release drugs into the 
environment at concentration levels ranging from 10 to 1000 times higher than those typically 
found in WWTP effluents [Phillips et al., 2010]. In the developing countries, several 
companies do not treat its effluents before discharging into rivers. In Pakistan, 
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pharmaceutical industrial waste effluents are considered one of the main sources of 
diclofenac in River Malir [Scheurell et al., 2009]. In Slovenia, the discharge effluent of the 
Novo Mesto pharmaceutical factory is expected to be one the major sources of diclofenac in 
River Krka [Antonic and Heath, 2007]. In Taiwan, diclofenac has been detected in 
wastewater effluents of drug production facilities in a median concentration of 20 µg/L [Lin et 
al., 2008]. Not only diclofenac but also other drugs have been detected at high concentration 
levels due to drug manufactures. As an example, ciprofloxacin was detected in the effluent of 
water treatment plant, receiving wastewater from about 90 bulk drug manufacturers in 
Patancheru, India (a major production site of generic drugs for the world market), at a 
concentration (up to 31 mg/L) exceeds the toxic levels to some bacteria by over 1000-fold 
[Larsson et al., 2007]. Therefore, pharmaceutical industrial effluents are important local point 
sources of drug residues in the environment [Kosjek et al., 2007a, Zuccato et al., 2000]. 
Furthermore, landfills receiving pharmaceutical industrial waste and have no leachate 
collection systems are considered one of the emission sources of drugs into the surrounding 
aquifers. For example, in Denmark several pharmaceuticals were indentified in the ground 
water located adjacent to landfill containing 85 000 t of drug industrial waste [Holm et al., 
1995]. In a similar way, diclofenac can leach from landfills through the subsoil and from 
contaminated surface water through bank filtration into the ground water [Heberer et al., 
1998]. 
 
Fertilizers, water for irrigation and aquaculture 
When used as fertilizers in agriculture, WWTP effluents, sewage sludge, solid and liquid 
manure may result in transport of human or veterinary pharmaceuticals into the surface 
waters via agricultural runoff [Hirsch et al., 1999, Lindsey et al., 2001, Sacher et al., 2001, 
Campagnolo et al., 2002, Pedersen et al., 2003]. Diclofenac, as a human and veterinary 
drug, has a potential to enter the food chain and reach drinking water especially when 
contaminated or untreated wastewater used in crop irrigation [Munoz et al., 2009, Siemens et 
al., 2008]. Although the analysis of runoff samples, from fields irrigated with treated effluent, 
indicated presence of low levels of diclofenac, other pharmaceuticals such as 
carbamazepine, gemfibrozil, carisoprodol have been detected in a concentration up to 2 µg/L 
[Pedersen et al., 2005]. This finding showed that fertilizers should not be neglected as a 
source for pharmaceutical contaminants. Additionally, aquaculture fish farms play a 
significant role in the presence of drugs in the environment [Calamari et al., 2003, Zuccato et 
al., 2006]. 
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1.1.5 Occurrence 
The presence of pharmaceuticals in the environment is closely related to their fate. After 
excretion, the ideal fate of drug residues should be mineralization by the microorganisms to 
carbon dioxide and water. Unfortunately, most of medicinal products do not undego the ideal 
fate. Therefore, they could be detected in the aquatic environment. Own to several aspects 
such as high consumption rate and polarity, diclofenac has been detected in almost all 
surveys of sewage, surface, ground, and drinking water samples at different concentration 
levels ranging from ng/L to µg/L. In Germany, Stumpf et al. (1996) were the first authors all 
over the world who detected diclofenac in sewage and river water. The next was Ternes 
(1998) who detected diclofenac in 49 WWTP effluent samples and 22 river samples at       
90-percentile concentration of 1.6 and 0.8 µg/L, respectively. Afterwards, Heberer et al. 
(1998) investigated waters of Berlin in a screening study. They pointed to diclofenac as the 
most second drug (after clofibric acid) occurring in their collected samples. Although 
diclofenac showed 100 % elimination during bank filtration study [Schmidt et al., 2003], it has 
been detected in ground, drinking and even tap water. It was detected by Heberer et al. 
(1998) for the first time in groundwater of a drinking water plant at concentration level of 0.38 
µg/L and then by Sacher et al. (2001) at concentration of 0.6 µg/L. Furthermore, samples 
taken from a private drinking water tap in Berlin showed presence of diclofenac at trace level 
concentration of less than 0.01 µg/L [Heberer, 2002b]. In the Mediterranean region, 
diclofenac was found in six of seven drinking water wells at concentrations around 2 ng/L 
[Rabiet et al., 2006]. Furthermore, Cleuvers (2004) detected diclofenac in drinking water at 
maximum concentration of 6 ng/L. The highest concentrations of diclofenac, up to 15 and 30 
µg/L, were detected in German surface water and Taiwanese wastewater effluents by Jux et 
al. (2002) and Lin et al. (2008), respectively. An average concentration of diclofenac of 0.15 
μg/L was estimated in German river water [Poseidon, 2006]. From different WWTP, the 
specific average emission of diclofenac for each person was estimated in the range of 0.28-
0.60 mg/d in Germany [Letzel et al., 2009, Heberer and Feldmann, 2005], 0.26 to 0.67 mg/d 
in Switzerland [Buser et al., 1998b, Tixier et al., 2003, Tauxe-Wuersch et al., 2005], and at 
0.088 mg/d in Canada [Lishman et al., 2006]. Some of other data regarding environmental 
occurrence of diclofenac are listed in Table 1. 
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Table 1: Average concentrations (µg/L) of diclofenac in the environment 
 
WWI WWE SW DW MA References 
--- < 4.5 0.5 0.06 GC/MS Stumpf et al. (1996) Germany 
2.1 --- 1.2 --- GC/MS Ternes (1998) Germany 
--- --- 1 nd-0.38 GC/MS Heberer et al. (1998) Germany 
--- --- 0.30-0.42 --- GC/MS Sacher et al. (1998) Germany 
0.5-1.9 0.31-0.93 <0.001-0.37 --- GC/MS Buser et al. (1998b) Switzerland 
0.8 0.72-0.2 0.01-0.10 --- GC/MS Stumpf et al. (1999) Brazil 
0.8-3.2 --- 1 --- GC/MS Werres et al. (2000) Germany 
0.1–0.7 --- n.d-0.15 --- GC/MS Oellers et al. (2001) Germany 
--- --- --- 0.6 GC/MS Sacher et al. (2001) Germany  
--- --- a) 0.02-0.04 b) 0.03-0.39 --- 
a) LC/MS 
b) CE/MS 
Ahrer et al. (2001) 
Austria 
--- nd-0.4 nd-0.6 --- LC/MS/MS Farre et al. (2001) Spain 
--- 0.1-0.7 nd-0.15 --- GC/MS Oellers et al. (2001) Switzerland 
--- --- --- <0.01 CE/MS Heberer (2002b) Germany 
--- --- 0.01-0.03 0.005-0.04 GC/MS 
Heberer (2004) 
Germany 
--- --- 15 --- GC/MS Jux et al. (2002) Germany 
--- 0.99 --- --- GC-MS Tixier et al. (2003) Switzerland 
a) 1.9-8.4 
b) 2-2.4 
a)1.1-2.7 
b)0.1-0.3 
a) 0.01 -0.02 
b) 0.002–
0.006 
nd a) ELISA b) GC/MS 
Deng et al. (2003) 
Austria and Germany 
--- 0.08 --- nd GC/MS Drewes et al. (2003) USA 
--- 0.35-0.46 0.021-0.09 --- LC/MS/MS ESI  
Hilton et al. (2003) 
UK 
--- nd-0.06 nd-0.5 --- LC/MS/MS ESI  
Marchese et al.(2003) 
Italy 
0.07 0.07 --- --- GC/MS Lee et al. (2003) Canada 
--- --- 0.01-0.05 --- GC/MS Wiegel et al. (2004) Germany 
--- <0.02-2.3 <0.02-0.5 --- LC/MS/MS Ashton et al. (2004) United Kingdom 
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Table 1: Continued 
 
WWI WWE SW DW MA References 
0.16 0.12 0.01-0.12 --- GC/MS Bendz et al. (2005) Sweden 
0.35 --- 0.002-0.04 --- LC/MS/MS ESI  
Lindqvist et al. (2005) 
Finland 
--- --- 0.01–0.3 nd GC/MS Kosjek et al. (2005) Slovenia 
0.021-
0.148 
0.032-
1.420 0.03-0.07 nd 
LC/MS/MS 
ESI 
Hernando et al.(2006) 
Spain, Belgium, 
Germany, Slovenia 
--- 0.06–1.9 --- --- LC/MS/MS Gomez et al. (2006) Spain 
--- 0.2-0.5 0.001-0.03 nd-0.003 GC/MS Rabiet et al. (2006)  France 
0.9-1 
 0.26- 0.6 >0.008 --- 
LC/MS/MS 
ESI 
Roberts and Thomas, 
(2006), UK 
1.6-4.4 0.65-1.3 --- --- LC/MS Bernhard et al. (2006) Germany 
---- ---- nd-0.089 --- CE/MS Antonic and Heath (2007), Slovenia 
0.006-5.9 --- --- --- 
LC/MS/MS, 
TOF/MS/ 
ESI  
Bueno et al. (2007) 
Spain 
0.2–3.6 0.14–2.2 --- --- GC/MS Gomez et al. (2007) Spain 
--- --- 0.25 --- GC/MS Moeder et al. (2007) Germany 
--- nd-0.5  nd- 0.04 --- 
LC/MS/ 
ESI  
pedrouzo et al. (2007) 
Spain 
13-17 1-7 --- --- LC/MS/MS Radjenovic et al. (2007), Spain  
--- 1-5.1 --- --- LC/MS/MS ESI  
Stuelten et al. (2008b) 
Germany 
0.05-4.2 --- --- --- GC/MS and LC/MS 
Terzic et al. (2008) 
Balkan Region 
--- <0.002-0.03 0.02-0.06 --- 
LC/MS/MS 
ESI 
Chen et al. (2008)  
Taiwan 
0.002-
0.17 --- 0.004-1 --- GC/MS 
Togola and Budzinski 
(2007), France 
--- 0.21–0.48 0.001–0.03 nd–0.002 GC/MS Togola and Budzinski (2008), France 
--- 0.01-30 --- --- LC/MS/MS ESI  
Lin et al. (2008) 
Taiwan 
2.6 3.2 --- --- GC/MS/MS Sebok et al. (2008) Hungary 
--- 0.12-2.2 0.03-0.14 --- LC/MS/MS ESI  
Letzel et al. (2009) 
Germany 
--- --- 0.1-8.5 --- GC/MS Scheurell et al. (2009) Pakistan 
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Table 1: Continued 
 
WWI WWE SW DW MA References 
--- --- 0.006-0.02 --- LC/MS/MS ESI  
Khalaf et al. (2009) 
Sweden 
--- 0.006- 1.3 --- --- LC/MS/MS 
Munoz et al. (2009) 
Spain 
0.35 0.01 --- --- LC/MS/MS ESI  
Perez and Barcelo 
(2008), Spain 
nd= not detected, --- = not investigated, WWI= wastewater influent, WWE= wastewater 
effluent, SW= surface water, DW= drinking water, MA= method of analysis 
 
1.1.6 Elimination 
The elimination processes of pharmaceutical compounds mainly occur in the WWTP 
following different mechanisms. Biotransformation is considered the most important 
elimination process in which microorganisms are used to mineralize the pharmaceuticals to 
water and carbon dioxide, or degrade them to non-effective forms. Sorption to activated 
sludge is another possible method for elimination. Because the wastewater treatment 
process is performed in the open air, wastewaters are almost exposed to the sun light. 
Hence, some pharmaceuticals can undergo phototransformation. Some non polar 
substances, alternatively, can be removed by volatilization. Therefore, the expected 
elimination mechanisms of diclofenac, either in the WWTP or in surface water, are 
biotransformation, phototransformation or to some extend sorption. The state of art showed 
that extensive field and laboratory elimination experiments have been conducted to 
investigate the removal efficiency of diclofenac in conventional activated sludge, membrane 
bioreactor reactors, column experiments and in surface water. In field studies, the removal 
efficiency of diclofenac is usually calculated as the concentration differences between its 
influent and effluent levels.  
 
Sewage 
The elimination of diclofenac during sewage treatment seems to be rather complicated. No 
clear results and high data deviation have been obtained for its removal efficiencies. The 
results from the EU project Poseidon [Poseidon, 2006] showed that the literature data on its 
elimination is very contradictory. 
 
Following primary sedimentation, aeration and phosphate removal treatment, Ternes (1998) 
reported 69 % reduction in diclofenac concentration. Comparing influent and effluent 
concentrations, Lee et al. (2003) did not report diclofenac removal rates, Poiger et al. (2001) 
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observed removal ranging from 5 % to 50 % while 0 % to 74 % has been reported by Clara 
et al. (2005a). An adapted lotic biofilms (Cytophaga-Flavobacterium and γ-Proteobacteria 
bacterial groups) grown in presence of diclofenac (100 µg/L) showed degradation ranging 
from 10 to 25 % of the initial concentration within 4 days [Paje et al., 2002]. During anaerobic 
digestion of sewage sludge, 69 % removal rates of diclofenac have been reported by 
Carballa et al. (2007). In batch reactors experiments, 50 % of diclofenac was reported to be 
degraded within 6 days in mixed liquor from conventional activated sludge aeration tank 
[Perez and Barcelo, 2008]. The other published removal data were 9-75 % [Stumpf et al., 
1999], 22 % [Bendz et al., 2005], 20-40 % [Joss et al., 2005], 9-60 % [Lindqvist et al., 2005], 
70 % [Roberts and Thomas, 2006], 60 % [Gomez et al., 2007], 40-80 % [Kimura et al., 2007], 
49-59 % [Kosjek et al., 2007a], and 100 % [Thomas and Foster, 2004, 2005]. 
 
On the other hand, several groups described diclofenac as a persistent pharmaceutical 
compound even upon biological treatment. For example, the incubation of water influent with 
activated sludge under aerobic conditions showed no degradation of diclofenac [Buser et al., 
1998b]. Very poor elimination values (1-6 %) for diclofenac was reported in a pilot WWTP by 
Zwiener et al. (2001). In a 55-h biodegradation experiment, diclofenac was reduced to 4 % at 
maximum even when oxic biofilm reactors was used [Zwiener and Frimmel, 2003]. In a 
biodegradation test, concentrations of 20 mg/L diclofenac were shown to be remained 
unaffected by the presence of activated sludge over a period of 28 days [Quintana et al., 
2005]. In a biological filter plant study, diclofenac exhibited removal of only 5-9 % [Johnson et 
al., 2007]. Joss et al. (2006) considered diclofenac as a non-biodegradable pharmaceutical 
compound showing elimination constant Kbiol < 0.1 L/gss d while in the EU project Poseidon 
[Poseidon, 2006] Kbiol at 0.25 ± 0.2 L/gss
 
 d and removal ranging from 15 to 40 % were 
estimated in the aerated compartment of nutrient removing plants (plants in which the 
removal of nitrogen and/or phosphorous from wastewater are performed using biological 
methods of treatment in order to improve the wastewater quality). Other authors reported 
elimination of diclofenac less than 20 % either in batch or field experiments are Moehle et al. 
(1999), Heberer et al. (2002), Strenn et al. (2004), Clara et al. (2005b), Tauxe-Wuersch et al. 
(2005), Knopp et al. (2007), Kimura et al. (2007). 
This variation could be attributed to several factors such as equipment used, treatment steps, 
temperature, weather, solid retention time, microbial activity of the sludge, type(s) of 
microorganisms existed in the sludge, sorption characteristics of the sludge, and toxic effects 
of the industrial wastewater entering the plants that also affect the microbial activity [Ternes, 
1998, Paje et al., 2002, Tixier et al., 2003, Lindqvist et al., 2005, Kimura et al., 2007, Letzel 
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et al., 2009]. Coagulation-flocculation resulting from the action of ferric chloride and 
aluminium sulphate, cations which are frequently added to the biological reactor in order to 
precipitate phosphorus [Suarez et al., 2008], may enhance the binding of diclofenac to the 
suspended solids throughout the trivalent cations [Carballa et al., 2005]. Thus, removal of 
diclofenac by means of such reaction could be another explanation of the discrepancies 
concerning its removal efficiencies reported in the literature. However, Ternes et al. (2002) 
reported no considerable elimination of diclofenac, in lab-scale and waterworks, from row 
water after treatment with ferric chloride. In contrast, high elimination (> 90 %) of diclofenac 
was reported after filtration through activated carbon [Ternes et al., 2002, Westerhoff et al., 
2005, Vieno et al., 2007]. 
 
Addtitionally, it was found that application of membrane bioreactor reactors usually shows 
higher elimination efficiency for diclofenac than conventional activated sludge. Using anoxic 
biofilm reactor, Zwiener and Frimmel (2003) reported an elimination rate of diclofenac up to 
40 %. In a laboratory scale, application of membrane bioreactor reactors resulted in 78-87 % 
removal of diclofenac while application of conventional activated sludge resulted in only 50-
60 % removal [Bernhard et al., 2006, Radjenovic et al., 2007]. Samples collected from 
WWTP showed no diclofenac removal (3 %) during conventional activated sludge treatment 
while  85 % of the initially present concentration was eliminated following passage through 
the membrane bioreactor reactors [Perez and Barcelo 2008]. In contrast, other studies 
reported no [De Wever et al., 2007] or partial removal [Clara et al., 2005b] of diclofenac after 
application of those treatments. Another study proved that the low frequency ultrasound 
irradiation, acidic conditions and presence of dissolved air increased the elimination of 
diclofenac in wastewater [Naddeo et al., 2009]. 
 
The most interesting aspect concerning diclofenac is the phenomenon of increasing effluent 
than influent concentrations during the same study. Lishman et al. (2006) reported negative 
removal rates up to -143 % in several samples (12 of 26). In Hungary, the concentration of 
diclofenac was found to be 2.6 µg/L and 3.2 µg/L in influent and effluent, respectively [Sebok 
et al., 2008]. Other negative removal rates were observed by De Wever et al. (2007) and 
Perez and Barcelo (2008). Several others attributed the increased effluent concentrations to 
the cleavage of glucuronide conjugates by enzymatic processes (β-glucuronidase enzymes) 
in the treatment plants [Ternes, 1998, Miao et al., 2002, Roberts and Thomas, 2006, 
Lishman et al., 2006, Vieno et al., 2007, De Wever et al., 2007, Sebok et al., 2008, Perez 
and Barcelo, 2008]. Such a phenomenon renders the evaluation of biological treatment 
processes very difficult, since exact biodegradation data could not be obtained. Another 
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reason could be the daily concentration fluctuations during the sampling time [Clara et al., 
2004]. Roberts and Thomas (2006) attributed this phenomenon to the suppression of the 
MS/MS detector signal due to the higher concentration of organic matter in the raw 
wastewater influent than in the treated effluent.  
 
Surface and pure water  
Diclofenac showed minimal chemical and biological degradation in the lake Greifensee water 
when incubated in a glass vessel in the dark while rapid elimination by meanes of 
photodegradation was observed [Buser et al., 1998b]. They reported half-life time less than 1 
h after exposure of diclofenac to sunlight. The same behavior was observed by Packer et al. 
(2003). They reported, in both purified and Mississippi River water, half-life time of 39 min 
after exposure of diclofenac to the sunlight in August. They additionally expected increasing 
of the half-life time to approximately 3-8 h in winter due to decrease of the sunlight light 
intensity [Packer et al., 2003]. In purified water, Andreozzi et al. (2003) reported 5 d as a    
half-life of diclofenac during the spring to summer time while, in the midsummer time, 
Schmitt-Jansen et al. (2007) reported 3.3-6.4 h. 
 
As well as laboratory experiments, efficient removal again due to photodegradation was 
observed for diclofenac in the aquatic environment. Buser et al. (1998b) reported that 90 % 
of the diclofenac entering a major tributary of Swiss Lake Greifensee is significantly 
eliminated by photolytic degradation and neither sorption nor accumulation could be found in 
the sediments of the lake. Under the environmental condition, diclofenac showed short      
half-life time ranging 4 to < 24 h [Buser et al., 1998b, Ashton et al., 2004]. However, longer    
half-life (8 days) in the Lake Greifensee over a summer period (August-October) was 
reported by Tixier et al. (2003). The metabolic rate in humans could influence the half-life 
time of diclofenac in the aquatic environment. Bendz et al. (2005) proposed that substances 
which have high metabolic rate in humans (low excretion rate as parent compound) exhibit 
short half-lifes in the aquatic environment almost less than 1-2 days and vice versa. 
Therefore, Letzel et al. (2009) were not able to detect diclofenac in almost all river samples 
collected 10 km away from the WWTP discharge site. However they assumed that locally, 
directly behind WWTP discharge points, higher amounts could occur in surface water. 
Furthermore, diclofenac has been reported to be susceptible not only to light but also to 
ozonation where extensive elimination (90-97 %) from pure water samples can be realized at 
ozone doses of 0.5 mg/L [Zwiener and Frimmel, 2000, Ternes et al., 2002, Vieno et al., 
2007].  
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Soil and sediment  
In different types of soil, the fate of 14C-diclofenac was investigated revealing higher 
biodegradability in clayey silt soil than silty sand soil where 23 and 43 %, respectively, of the 
initially applied radioactivities could be extracted after 3-d incubation interval [Kreuzig et al., 
2003]. In sandy sediment, a high persistence of diclofenac to biodegradation was suggested 
by Ternes et al. (2002) during investigation of diclofenac for 28 days under aerobic and 
anaerobic conditions, while Groning et al. (2007) reported rapid removal of diclofenac (93 % 
within 5 days) under aerobic conditions. In a biodegradation experiment, the effect of water-
sediment interaction on the elimination of diclofenac was investigated by Kunkel and Radke 
(2008) in bench scale channel applying water from the River Roter Main at different velocity. 
They observed that the fast influx of water, which maintain adequate transfer of solutes and 
oxygen to the sediment, results in rapid removal of diclofenac (DT50 3.2 d) while the slow 
influx result in slow removal rates (DT50
 
 of 8.5 d). In contrast, they reported that diclofenac 
could not be eliminated within 12 days when fortified in only river water (without sediment) 
assuming that sorption to suspended matter, microbial degradation, and hydrolysis of 
diclofenac are excluded in river water.  
Sorption and Column studies 
Sorption is considered one of the key factors controlling the input, transport, and 
transformation of chemicals in the environment. Depending on their lipophilicity, there are 
mainly two coefficients used for assessment of sorption of organic compounds based on the 
octanol/water partitioning coefficient (Kow) and on the normalized organic carbon-based 
coefficient (Koc). Since most of pharmaceuticals often contain polar functional groups (e.g. 
carboxylic, aldehyde and/or amine), these coefficients can be used only as an approximate 
guide to help in the interpretation of their sorption behavior. However, studying sorption 
behavior of pharmaceuticals, especially in sediments, is very important in predicting the 
mobility and leaching tendencies of these compounds at the bank filtration sites. Additionally, 
the sorption coefficient Kd
  
 values can be used for estimation of the particle associated 
fraction of pharmaceuticals in surface water and hence calculation of their freely dissolved 
fractions [Stein et al., 2007, Ramil et al., 2010]. Medicinally, it is observed that the drugs 
abuse has increased considerably. Therefore, sorption of pharmaceuticals onto solids, other 
than sediments, such as activated charcoal, magnesium silicate, magnesium stearate, or talc 
powder would be very helpful in treatment of acute toxicity resulting from drug overdose 
especially in case of drugs that do not have specific antidote [Tella and Owalude, 2007]. 
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Rather than lipophilicity, physico-chemical properties of the solids, humification stage of the 
solid organic matter (SOM), the level of clay and organo-clay complexes, many factors can 
affect the interaction of pharmaceuticals with special parts of organic matter or with minerals 
such as temperature, pH, ionic strength, cation bridging, cation exchange and hydrogen 
bonding [Goss and Schwarzenbach, 2001, Golet et al., 2003, Ternes et al., 2004, Chefetz et 
al., 2008, Carballa et al., 2008]. 
 
For diclofenac, no considerable sorption (based on the relative concentration C/Co) was 
observed in batch experiments using sand (taken from the underground of a groundwater 
catchment area) under natural aerobic and anoxic conditions [Ternes et al., 2002]. 
Additionally, the sorption behavior (depending on the Kd values) onto different soil types was 
studied by Kreuzig et al. (2003). They expected leaching potential of diclofenac through 
sandy soil where Kd was estimated at 4 L/kg. However, leaching experiment using two soil 
types with different organic carbon and clay contents showed strong adsorption of diclofenac 
as it could not be detected in the leachate [Drillia et al., 2003]. The published sorption 
coefficient (Koc) of diclofenac was found to be 830 L/kg [Antonic and Heath, 2007]. 
Additionally, Kd of 9 L/kg was reported by Barron et al. (2009) for diclofenac in agriculture 
soil. In more detail, the effect of organic matter on the mobility (column experiments) and 
sorption/desorption (batch experiments) behavior of diclofenac in different sterilized soil 
layers (with different solid organic matter contents) using tap water or secondary-treated 
wastewater (STWW) was studied by Chefetz et al. (2008). Upon their column experiments, 
they classified diclofenac as a slow mobile compound in high SOM containing soil while its 
mobility increases significantly in SOM poor soils. Additionally, they reported lower sorption 
of diclofenac onto the soil layers in case of using STWW (32 %) than tap water (64 %). They 
attributed these results to the formation of diclofenac complexes with the dissolved organic 
matter (DOM) or with organic and inorganic suspended materials which were found to be 
higher in the STWW solution. In contrast, in their batch experiments using soil with high SOM 
contents, diclofenac exhibited lower sorption in case of tap water (KF= 8.81) than STWW 
(KF=11.90). They assumed that co-sorption and/or cumulative sorption of diclofenac with the 
dissolved organic matter (DOM) to the soil’s solid matrix (mainly SOM) are the suitable 
explanation of these results. Opposite results were obtained when soil with low SOM was 
used (higher sorption in case of tap water than STWW). They explained these results by the 
competitive sorption between diclofenac and DOM on the few SOM sites and hence 
decreased the sorption affinity of diclofenac. Margon et al. (2009) attributed the transport of 
diclofenac through the coarse soil profile to the formation of diclofenac/humic acids micelles 
as a result of the interaction between diclofenac and the humic acids. In another laboratory 
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study, diclofenac showed negligible sorption onto sediment particles while limited sorption 
may occur at lower pH [Buser et al., 1998b]. The sorption coefficient of diclofenac was found 
to be quite low and the distribution coefficient (Kd
 
 values) was estimated between 0.55 to 
4.66 in sandy sediment [Scheytt et al., 2005a] and at 4.2 in river sediment [Krascsenits et al., 
2008]. Furthermore, the water/sludge distribution coefficient of diclofenac was found to be 
16, 66, and 105 L/kg as reported by Ternes et al., 2004, Carballa et al., 2008, and Barron et 
al., 2009, respectively, indicating that sorption tendency to sludge was relatively low. Similar 
behavior was reported by Joss et al. (2005), Bernhard et al. (2006) and Knopp et al. (2007) 
during investigation of diclofenac in presence of sludge. On the other hand, Bui and Choi 
(2009) reported high adsorption rate (88 %) for diclofenac on the synthesized mesoporous 
silica SBA-15. 
Additionally, column experiments with groundwater model systems indicated a moderate 
persistence of diclofenac. The elimination was between 60 % and 80 % in aerobic systems 
and between 40 % and 60 % in anaerobic systems [Preuss et al., 2001]. Other column 
experiments performed by Scheytt et al. (2004) and Mersmann et al. (2002) showed high 
retention factors of 2.0 and 2.6, respectively. Furthermore, sorption of 35 % [Scheytt et al., 
2006a] and 79 % [Scheytt et al., 2006b] was reported for diclofenac probably due to 
degradation under the experimental conditions. These results may indicate that diclofenac 
has low or no mobility at bank filtration sites. In Germany, complete elimination (100 %) was 
observed for diclofenac during a bank filtration study [Schmidt et al., 2003].  
 
1.1.7 Phototransformation  
Phototransformation may be caused by solar radiation. The most dangerous part of the solar 
radiation is the highest energetic of the UV region. Naturally, UV radiation passing the upper 
atmosphere has frequencies of 200-400 nm. In the upper atmosphere, the most energetic 
part of the UV radiation (200-290) is absorbed, almost by nitrogen, oxygen, carbon dioxide 
and ozone. Approximately, 10 % of the UV is able to reach the earth's surface in the range of 
290 - 320 nm. Artificially, the sunlight can be simulated using radiation sources such as Xe-
lamp, mercury arc lamps and germicidal lamps that are able to emit spectrum starting from 
290 nm [Jagger, 1985, Moore, 2002, Tixier et al., 2003, Meite and Mazellier, 2006, Mendez-
Arriaga et al., 2008]. Generally, substances with absorption spectra that have a good overlap 
with the radiation source spectrum are considered photo-reactive compounds. The published 
absorption maxima of diclofenac are 285 [Moore et al., 1990, Zilnik et al., 2007, Cavalheiro et 
al., 2008], 286 [Chefetz et al., 2008], 275 [Moore, 2002], 273 in aqueous acid and 275 nm in 
aqueous alkali [El Haj et el., 1999]. However, the absorption band which runs to 325 nm 
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(allowing complete overlap on the emission spectrum above 290 nm) is responsible for the 
well known photosensitivity phenomenon of diclofenac [Figure 7]. 
 
Figure 7: UV spectrum (λ = 220-400 nm) of diclofenac (    ) against sunlight spectrum  
(---) on the earth’s surface 
 
This phenomenon has been reported by several authors in different laboratory studies 
[Moore et al., 1990, Encinas et al., 1998b, Ravina et al., 2002, Andreozzi et al., 2003, 
Gaudiano et al., 2003, Agueera et al., 2005, Perez-Estrada et al., 2005, Schmitt-Jansen et 
al., 2007, Kim and Tanaka, 2009] as well as under environmental conditions [Buser et al., 
1998b, Poiger et al., 2001, Tixier et al., 2003, Packer et al.,2003, Bartels and von Tuempling 
Jr, 2007, Scheurell et al., 2009]. All of them observed a fast phototransformation either in 
surface and/or in pure waters when diclofenac is exposed to light.  
 
In purified artificially fresh and river waters, direct photolysis (under natural sunlight) and/or 
indirect photolysis using Fenton reagent as a source of (•OH) radicals or isopropanol as 
hydroxyl radical scavenger were frequently studied. After exposure to sunlight for almost 30 
h, Agueera et al. (2005) and Schmitt-Jansen et al. (2007) found that more than 70 and 90 %, 
respectively, of the initially applied diclofenac was degraded. Another study reported up to 75 
% decrease of diclofenac concentration within 2 h of exposure to Xe lamp [Mendez-Arriaga 
et al., 2008]. In presence of photo-Fenton reagent, complete transformation of diclofenac 
was observed in a time period ranging from few minutes [Ravina et al., 2002] to 60 min 
[Perez-Estrada et al., 2005] and totally mineralized after 50 min of exposure to a lamp 
emitting light at 254 nm [Ravina et al., 2002] or after 100 min of exposure to sunlight [Perez-
Estrada et al., 2005]. Packer et al. (2003) reported more rapid transformation for diclofenac 
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in presence of isopropanol. It has to be noticed that, the photolysis of diclofenac is 
accompained by decrease in the pH value (ranging from 6.5 to 3) due to elimination of HCl 
[Perez-Estrada et al., 2005, Mendez-Arriaga et al., 2008]. 
 
Depending on the treatment applied, different phototransformation products of diclofenac 
such as hydroxylated intermediates, C-N cleavage products [Vogna et al., 2004], quinone 
imine derivatives [Perez-Estrada et al., 2005] and carbazole derivatives have been found 
[Table 2]. Carbazole derivatives (especially 8-chlorocarbazole-1-acetic acid) are considered 
the most frequently detectable compounds formed by photolysis of diclofenac [Moore et al., 
1990, Encinas et al., 1998b, Buser et al., 1998b, Poiger et al., 2001, Agueera et al., 2005, 
Cavalheiro et al., 2008, Scheurell et al., 2009]. It was isolated (using reversed phase column 
chromatograpy) and identified by LC/MS, GC/MS (after derivatization with diazomethane), 
high resolution EI/MS and NMR [Moore et al., 1990] and by electron impact MS and NMR 
[Encinas et al., 1998b]. In comparison to diclofenac, it was characterized as more polar 
[Moore et al., 1990], photodegradable [Moore et al., 1990, Encinas et al., 1998b] and more 
photosensitive [Poiger et al., 2001]. However, due to the lack of authentic reference 
chemicals, the photochemistry of diclofenac and its phototransformation products were 
studied by Encinas et al. (1998a) using 2,6-dichlorodiphenylamine and 1-chloro-9H-
carbazole as related model compounds. The nature of the reaction including conversion of 
diphenylamine to carbazole, in presence of light, has been already published since 1963 
[Bowen and Eland, 1963]. This reaction has been reported for the first time for 
pharmaceuticals when carbazole derivatives were obtained by irradiation of meclofenamic 
acid using visible or UV light [Philip and Szulczewski, 1973]. 
 
On the other hand, the artifact [1-(2,6-dichlorophenyl) indolin-2-one] was reported as one of 
the major phototransformation products of diclofenac in pure water [Bartels and von 
Tuempling Jr., 2007] and recently in surface water [Scheurell et al., 2009]. Using of GC/MS 
in their sample analysis could be the reason for their observation, since the formation of 
artifact at high temperature may be possible. Nevertheless, phototransformation appears to 
be the most important natural elimination process for diclofenac in the aquatic environment at 
all. Therefore, several authors applied UV radiation in removal of diclofenac from polluted 
and drinking water especially in combination with of photo-Fenton, photocatalytic titanium 
dioxide, hydrogen peroxide, and/or ozone. These combinations, which are known as the 
advanced oxidation process, were found to be the best method achieving almost complete 
mineralization of diclofenac [Huber et al., 2003, Vogna et al., 2004, Mendez-Arriaga et al., 
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2008, Benotti et al., 2009, Felis et al., 2009, Felis and Miksch, 2009, Garcia-Araya et al., 
2010]. 
 
Table 2: Selected transformation products of diclofenac mainly due to photolysis 
processes 
 
Structure M.formula and M.weight Methods of identification  Reference 
N
OH
O
HCl
 
8-chloro-9H-
carbazole-1-acetic 
acid 
C14H10ClNO
259 
2 
GC/MS/CI, HPLC/MS, High 
resolution EI/MS, 1 Moore et al. (1990) HNMR 
GC/MS/EI Buser et al. (1998b) 
GC/MS/EI, HPLC/MS Encinas et al. (1998b) 
GC/MS/EI Poiger et al. (2001) 
LC/TOF/MS Agueera et al. (2005) 
GC/MS/EI Scheurell et al. (2009) 
N
OH H OH
O
 
8-hydroxy-9H-
carbazole-1-acetic 
acid 
C14H11NO
241 
3 
GC/MS/CI, HPLC/MS, High 
resolution EI/MS, 1 Moore et al. (1990) HNMR 
GC/MS/EI, HPLC/MS Encinas et al. (1998b) 
GC/MS/EI Poiger et al. (2001) 
LC/TOF/MS Agueera et al. (2005) 
N
OH
Cl H
 
8-chloro-9H-
carbazole-1-
methanol 
C13H10
231 
ClNO 
LC/MS/MS Encinas et al. (1998b) 
LC/TOF/MS Agueera et al. (2005) 
N
OH
O
H
 
C14H11NO
255 
2 
GC/MS/CI, HPLC/MS, High 
resolution EI/MS, 1 Moore et al. (1990) HNMR 
GC/MS/EI Buser et al. (1998b) 
GC/MS/EI Vogna et al. (2004) 
N
Cl
OH
H
 
C13H8
229 
ClNO 
LC/MS/MS Encinas et al. (1998b) 
LC/TOF/MS Agueera et al. (2005) 
GC/MS/EI Bartels and Von Tuempling Jr. (2007) 
N
OH H OH
O
OH  
C14H11NO
257 
4 LC/TOF/MS Agueera et al. (2005) 
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Table 2: Continued 
 
Structure M.formula and M.weight Methods of identification Reference 
N
HCl
OHO
 
C13H10ClNO
247 
2 GC/MS/EI Agueera et al. (2005) 
N
HCl
HO
OH Cl  
C13H9Cl2NO
281 
2 LC/TOF/MS Agueera et al. (2005) 
N
HCl H
O
 
C14H10
243 
ClNO GC/MS/EI Agueera et al. (2005) 
N
HCl
 
C12H8
201 
ClN GC/MS/EI Agueera et al. (2005) 
N
HCl
Cl  
C13H11Cl2
251 
N 
GC/MS/EI Agueera et al. (2005) 
GC/MS/EI Bartels and Von Tuempling Jr. (2007) 
N
HCl
Cl
OH
 
C13H9Cl2
265 
NO 
GC/MS/EI Agueera et al. (2005) 
GC/MS/EI Bartels and Von Tuempling Jr. (2007) 
N
HCl
OH
 
C13H10
231 
ClNO 
GC/MS/EI Agueera et al. (2005) 
GC/MS/EI Bartels and Von Tuempling Jr. (2007) 
N
HCl
 
C12H10
203 
ClN 
 
GC/MS/EI Agueera et al. (2005) 
N
HO
 
C13H9
195 
NO 
GC/MS/EI Bartels and Von Tuempling Jr. (2007) 
GC/MS/EI, HPLC/MS Encinas et al. (1998b) 
N
OH
 
197 
C13H11
 
NO GC/MS/EI, HPLC/MS Encinas et al. (1998b) 
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Table 2: Continued 
 
Structure M.formula and M.weight Methods of identification Reference 
N
 
181 
C13H11
 
N GC/MS/EI, HPLC/MS Encinas et al. (1998b) 
N
O
 
197 
C13H11
 
NO GC/MS/EI, HPLC/MS Encinas et al. (1998b) 
NH2
Cl
 
C6H6
127 
ClN GC/MS/EI Bartels and Von Tuempling Jr. (2007) 
NH2
Cl Cl
 
C6H5Cl2
161 
N GC/MS/EI 
Bartels and Von 
Tuempling Jr. (2007) 
GC/MS/EI Vogna et al. (2004) 
ClCl
OH
 
C6H4Cl2
162 
O GC/MS/EI Bartels and Von Tuempling Jr. (2007) 
Cl
N
Cl
O
 
C15H11Cl2
292 
NO GC/MS Pfleger et al., 1992 
Cl
N
Cl
O
O
H
 
C15H13Cl2NO
310 
2 GC/MS Pfleger et al., 1992 
Cl
N
Cl
O
O
 
C16H15Cl2NO
324 
2 GC/MS Pfleger et al., 1992 
Cl
N
Cl
O
O
O  
C16H11Cl2NO
336 
3 GC/MS Pfleger et al., 1992 
Cl
N
Cl
O
O
O
H
 
C16H15Cl2NO
340 
3 GC/MS Pfleger et al., 1992 
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1.1.8 Biotransformation  
Biotransformation is a physiological process in which chemical substances are modified or 
degraded by means of living organisms such as human, bacteria, algae, etc. As organic 
substances, the biological transformation of pharmaceuticals in the ecosystem, which mainly 
occurs due to the bacterial action, involves two metabolic pathways: First, metabolism in 
which bacteria use the compound as a primary carbon source. Second, co-metabolism in 
which bacteria can partially convert a substance by an enzyme produced during the 
metabolism of another substance without using it as primary carbon source. In a trace level, 
substances are most probably metabolized by co-metabolism. The biotransformation 
products of diclofenac detected in the environment are almost the same products excreted 
by human and animals, since bacteria and fungus (Epicoccum nigrum) were reported to 
convert diclofenac to its hydroxylated metabolites [Ibrahim et al., 1996; Webster et al., 1998]. 
The first data dealing with the biotransformation of diclofenac in mammalian excretion were 
obtained using either diclofenac [Riess et al., 1978] or 14C-diclofenac [Stierlin et al., 1979]. 
However, there was no indication for the presence of the diclofenac human metabolites in 
the environment [Buser et al., 1998b, Tixier et al., 2003]. Compared to their laboratory 
experiments, several authors excluded biotransformation of diclofenac under the 
environmental conditions not only in surface water [Buser et al., 1998b, Tixier et al., 2003, 
Kunkel and Radke, 2008] but also in presence of activated sludge [Buser et al., 1998b, 
Quintana et al., 2005, Joss et al., 2006]. However, in 2007, a major reactive metabolite (p-
benzoquinone imine of 5-hydroxydiclofenac) was detected, in a laboratory study, as a result 
of transformation of diclofenac by the indigenous microflora in river sediments under aerobic 
conditions [Groning et al., 2007]. They assigned, furthermore, abiotic adsorption to be the 
further fate for this reactive product. Additionally, in a specially designed small-scale pilot 
wastewater treatment plant, indolinone, alcoholic, and methoxy derivatives of diclofenac 
were identified by GC/MS [Kosjek et al., 2007a, b] while hydroxyl, benzoquinone imine 
derivative and nitro analogue of diclofenac were identified by means of liquid 
chromatography-quadrupole time of flight-mass spectrometry (LC/QqToF/MS) [Kosjek et al., 
2008]. Furthermore, 4'-hydroxy indolinone, 4'-hydroxy- and 5-hydroxy diclofenac were 
identified in human urine samples [Stuelten et al., 2008a] as well as, for the first time, in 
WWTP effluents [Stuelten et al., 2008b, Perez and Barcelo, 2008]. Additionally, other seven 
biotransformation products of diclofenac were detected in activated sludge flow-through 
bioreactors by Kosjek et al. (2009). Recently, Scheurell et al. (2009) detected the human 
metabolites 3'-hydroxy-, 4'-hydroxy- and 5-hydroxydiclofenac in surface water. The structure 
of some biotransformation products of diclofenac are shown in Table 3 and the others were 
previously demonstrated in Figure 5.  
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Table 3: Structures of selected biotransformation products of diclofenac  
 
Structure M.formula and M.weight 
Method of 
identification Reference 
Cl
Cl
N
OH
O
O  
C14H9Cl2NO
309 
3 
HPLC/DAD,  
LC/MS/MS/ESI, 
NMR 
Groning et al., 2007 
LC/QqToF/MS/ 
ESI Kosjek et al., 2008 
O
N
Cl
Cl  
C14H9Cl2
277 
NO 
GC/MS Kosjek et al., 2007a, b 
LC/QqToF/MS/ 
ESI Kosjek et al., 2009 
N
OH
Cl H
 
C13H10
231 
ClNO GC/MS Kosjek et al., 2007a, b 
N
Cl H
O
 
C14H12
245 
ClNO GC/MS Kosjek et al., 2007a, b 
Cl
Cl
N
H OH
O
OH 
C14H11Cl2NO
311 
3 LC/QqToF/MS/ 
ESI Kosjek et al., 2008 
Cl
Cl
N
H OH
O
NO2  
C14H10Cl2N2O
 
4 
340 
LC/QqToF/MS/ 
ESI Kosjek et al., 2008 
O
N
Cl
ClOH  
C14H9Cl2NO
293 
2 
 
LC/MS/MS/ 
ESI Stuelten et al., 2008b 
Cl
Cl
N
H
CH2
 
C13H10Cl2
249 
N LC/QqToF/MS/ 
ESI Kosjek et al., 2009 
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1.1.9 Risk assessment 
Environmental risk assessment (ERA) procedures for pharmaceuticals have been developed 
for regulatory purposes in Europe using the same principles already applied in the Europian 
Technical Guidance Documents (EUTGD) of chemicals  [Carlsson et al., 2006a, Grung et al., 
2008]. Depending on the existing environmental occurrence and toxicity data from the 
literature, risk quotient of diclofenac could be calculated according to the following equation: 
 
Risk quotient = PEC/PNEC 
where: 
PEC: Predicted environmental concentration 
PNEC: Predicted no-effect concentration 
 
There are mainly two approaches for calculation of worst case PEC of pharmaceuticals in 
surface water without considering transformation or degradation. The first depends on 
consumption rates, removal during sewage treatment, human metabolization and/or type of 
application. In the literature, this approach has been represented in different forms using 
different equations: equation 1 [EMEA, 2006, Grung et al., 2008, Carlsson et al., 2006a, Fent 
et al., 2006, Huschek et al., 2004], equation 2 [Sebastine and Wakeman, 2003, Grung et al., 
2008, Ashton et al., 2004, EMEA, 2001, Jones et al., 2002, Stuer-Lauridsen et al., 2000] and 
equation 3 [Tauxe-Wuersch et al., 2005, Johnson et al., 2007]. 
 
PEC = (M x A x 100)/ (V x D x DDD x P x 365)                mg/L         (equation 1)  
 
The bold digits and letters are called Fpen (the percentage of market penetration of 
pharmaceutical) which is equivalent to the proportion of the population being treated daily 
with a specific drug (diclofenac) and it is proposed to be 0.01 (or 1 %) [EMEA, 2006]. 
However, in Norway it is more than 1 % [Grung et al., 2008]. 
 
PEC = [A x (1-R/100)]/ (365 x P x V x D)                           mg/L         (equation 2) 
PEC = [A x (1-R/100) x (1-E/100)]/ (365 x P x V x D)        mg/L         (equation 3) 
where: 
M: Maximum daily dose consumed per inhabitant (mg/inh d); for diclofenac 150 mg/(inh.d)  
A: Predicted amount of drug consumed per year in the relevant geographic area (mg/y) 
R: Removal rate (in percentage) during sewage treatment; default value = 0  
V: Volume of wastewater produced per inhabitant per day; default value = 0.2 L/(inh.d)  
DDD: Defined daily dose values [mg/(inh.d)]; obtained from data reported by WHO (100 mg) 
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P: Number of inhabitants (population) of the geographic area under consideration (inh) 
D: Dilution factor; default value = 10  
E: Maximal excretion of the conjugated and unchanged drug in percent; default value = 0 
365: Number of days/year 
100: The conversion factor for percentage. 
 
In case of assess the worst case concentration, drug metabolism in humans and the removal 
rate during the wastewater treatment processes should be set to 0. 
On the other hand, the second approach (equation 4) depends on the specific measured 
load for each inhabitant [Letzel et al., 2009]. 
 
PEC = (SLI x 1000)/ V x D                                                mg/L        (equation 4) 
where: 
SLI: Specific load for each inhabitant (mg/inh d); obtained from real measurements.  
 
It has to be stated that the previously mentioned equations do not result in an acurrate PEC 
value as they do not consider the transformation of pharmaceuticals in surface water and 
water/sediment ecosystem, after discharging with the wastewater effluents. However, the 
first three equations can produce more realistic results in case of limited biotransformable 
pharmaceuticals. For diclofenac, equation 4 can be considered the most suitable formula 
giving more environmental relevant results for PEC due to the following reasons: 
1. The use of default values in the first three equations does not reflect realistic 
environmental concentrations in a specific investigated area. 
2. The real amount of consumed diclofenac is unknown, since considerable amount of 
diclofenac is frequently sold over the counter. 
3. The amount of diclofenac excreted without metabolization shows high variation (1 to 
25 %). 
4. The removal rate (0 to100 %) of diclofenac in WWTP shows inconsistent results.  
5. Although the dermal application results in a higher discharge of diclofenac (90 %), the 
total amount of diclofenac applied to the skin cannot be calculated.  
Therefore, it could be helpful for the rough calculation to be followed by real value 
measurements to obtain more accurate estimation.  
 
On the other hand, predicted no-effect concentration of pharmaceuticals can be calculated 
from the toxicity data provided by specific toxicity tests. Toxicity is often assessed based on 
EC50, LD50 and/or no observed effect concentrations. Predicted no-effect concentration is 
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obtained by dividing one of these values to an appropriate assessment factor (AF). 
According to the field of investigation, the AF are calculated and reported in the 
corresponding TGD. In case of diclofenac, AF estimated at 10 [EMEA, 2006]. 
 
Of course, not all pharmaceuticals have to be subjected to the ERA procedure at the same 
time, but the priority should be determined according to several factors. The physico-
chemical properties, PEC, the environmental fate (degradation, bioaccumulation, and 
sorption) are considered the main factors controlling the selection of pharmaceuticals for 
ERA [EMEA, 2006, Carlsson et al., 2006a]. 
 
For refinement, substances which have log Kow or Pow above 4.5, PEC value >0.01 μg/L in 
surface water or known to affect aquatic organisms at concentrations even below 0.01 µg/L 
should be further investigated for environmental fate and toxicity [EMEA, 2006]. Similar 
strategies exist in the US [Ankley et al., 2007]. For biodegradability, the test should be initially 
conducted in the WWTP and the substance which is not readily biodegradable (DT90 of >3 
days) should be investigated in a water/sediment study. Substance that shows significant 
shift to the sediment (≥ 10 % after or at 14 days), is expected to exhibit potential risk (unless 
the substance is readily biodegradable). Bioaccumulation can be indicated by Kow > 1000. 
Sorption in WWTP can potentially be of concern if Kd
 
 value > 10000 L/kg, unless the 
substance is readily biodegradable. Pharmaceuticals with risk quotient > 1 are expected to 
have an environmental potential risk or to cause environmental adverse effects. Therefore, 
they should be further evaluated in the aquatic environment in order to apply the necessary 
risk reduction measures [EMEA, 2006]. 
For diclofenac, the risk quotient was found to be < 1 [Woldegiorgis et al., 2007, Ashton et al., 
2004, Carlsson et al., 2006a, Huschek et al., 2004, Jones et al., 2002] especially when 
measured environmental concentrations (MECs) were used [Grung et al., 2008]. Therefore, it 
is not involved within the first ten pharmaceuticals that they could potentially be of concern in 
the environment. However, using the PECs (0.48-0.75 µg/L) and PNEC (0.1 µg/L) result in a 
risk quotient > 1 [Grung et al., 2008]. Additionally, based on PECs in wastewater used in the 
crop irrigation and PNEC of water and rats, the risk quotient of diclofenac was estimated by 
Munoz et al. (2009) in the range of 6-27 for soil ecosystem and in the range of 1-7 for 
predator foods. Furthermore, several authors reported that the PECs (0.14-2.21 µg/L) 
[Huschek and Krengel, 2002, LUA Brandenburg, 2002; Tauxe-Wuersch et al., 2005, Letzel et 
al., 2009] and the MECs [Table1] of diclofenac in surface waters exceeded the action limit 
0.01 µg/L by hundred times in some cases. Nevertheless, in addition to the fact that 
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diclofenac has a log Kow
 
 = 4.5, the ecotoxicity data are considered the most important reason 
to included diclofenac in almost all risk assessment studies of pharmaceuticals. 
1.1.10 Ecotoxicity 
For evaluation of chronic toxicity, Schwaiger et al. (2004) and Triebskorn et al. (2004) studied 
the sublethal toxic effects of diclofenac on fish, rainbow trout (Oncorhynchus mykiss), 
exposed to doses ranging from 1 µg/L to 500 µg/L over a period of 28 days. The 
histopathological examinations of exposed fishes showed adverse effects such as alterations 
in the liver, kidney and gills at lowest observed effect concentration (LOEC) of 5 µg/L 
[Schwaiger et al., 2004] and even at 1 µg/L [Triebskorn et al., 2004, 2007] probably due to 
bioaccumulation. Based on subchronical exposure studies, Hoeger et al. (2005) estimated 
the no observed effect concentration (NOEC) for brown trout at 0.5 μg/L and the PNEC value 
at 5 ng/L. Additionally, acute toxicity tests (4 days) were conducted by Hong et al. (2007) for 
determination of diclofenac toxic effect on male medaka fish (Oryzias latipes). At the 
environmentally relevant concentration of 1 µg/L, they proposed that diclofenac has the 
potential to cause cellular toxicity, genotoxicity and estrogenic effects to the exposed fishes 
as revealed from the elevation of three biomarkers cytochrome P450, p53 and vitellogenin in 
tissues. 
 
The toxicity was not limited to diclofenac only but it extended to its transformation products 
also which were found to be more toxic than diclofenac itself. It was reported that the 
phytotoxicity of diclofenac to the unicellular chlorophyte microalgae (Scenedesmus 
vacuolatus) increased sixfold after 53 h of exposure to sunlight [Schmitt-Jansen et al., 2007]. 
Photosensitization and hence photobiological adverse effects of irradiated diclofenac were 
demonstrated by Moore et al. (1990) and Quintero and Miranda (2000). Moore et al. (1990) 
prove the ability of diclofenac to form singlet 1O2 (reactive oxygen species) and free radical 
species (generated by homolysis of the photolabile carbon-halogen bond) which may react 
covalently with several biological targets (lipid, protein and/or DNA) compound leading to an 
exaggerated toxic effect (especially skin cancer). Based on reactive oxygen species and 
DNA binding assay, Onoue et al. (2009) were able to predict photogenotoxic risk of irradiated 
diclofenac. 8-chloro-9-H-carbazole acetic acid, the analogue to the phototoxic drug 
carprofen, considered the main reason of the photosensitivity responses induced by 
diclofenac through formation of free radicals [Moore et al., 1990, Encinas et al., 1998b]. Lysis 
of red blood cells (RBCs) occurs only in the presence of 8-chloro-9H-carbazole acetic acid 
indicating that chlorine substituent plays an important role in the hemolysis process of the red 
blood cells [Encinas et al., 1998b]. Furthermore, p-benzoquinone imines and the 
 
 
INTRODUCTION 
 
 
 34 
hydroxylated metabolites mainly 4'- and 5'-hydroxydiclofenac were discussed to be the prime 
reason for hepatotoxic adverse effects of diclofenac [Bort et al., 1998, Poon et al., 2001]. 
 
Additionally, diclofenac does not occur in the environment as a single contaminant, but as 
complex mixtures with other pharmaceuticals. Therefore, Cleuvers (2003) studied the 
synergistic toxicity of diclofenac on the aquatic organisms from different taxonomical classes. 
They revealed that diclofenac in combination with ibuprofen exerted a much stronger toxic 
effect than could be seen by each compound individually. Furthermore, the most frequently 
published ecotoxicological problem in different countries is the death of vulture after 
scavenging diclofenac treated livestock. Rapid decline of vulture population were reported in 
India, Pakistan, Nepal and recently Egypt [Arun and Azeez, 2004, Oaks et al., 2004, Green 
et al., 2004, 2006, Cuthbert et al., 2006, Taggart et al., 2007a, b] probably due to different 
toxicity mechanisms such as increase the production of reactive oxygen species, 
interference with uric acid transport [Naidoo and Swan, 2009], inhibition of renal 
prostaglandins [Meteyer et al., 2005], or damage to renal tubular cell [Ng et al., 2006].  
 
Based on the previously mention information, it can be concluded that diclofenac definitely 
poses a risk on the ecosystems where it is present. Therefore, diclofenac was recently 
banned on the Indian subcontinent [Naidoo and Swan, 2009] and classified environmentally 
as dangerous drug in Sweden [RSMPA, 2004, Carlsson et al., 2006a]. 
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2. Research deficiencies and objectives 
After reviewing the literature dealing with diclofenac residues in the environment, several 
important points have to be taken in consideration:  
1- Because of the information deficiency, the fate of diclofenac in water/sediment 
ecosystems is poorly understood and, up to date, no comprehensive study has been 
conducted to explain this in details. 
2- Although many experiments regarding transformation of diclofenac in wastewater 
treatment plants have been already done, their results can not readily be transferred 
to the water/sediment compartments. 
3- Although sediment compartment (with its higher density of microorganisms than 
water compartment) is considered the potential major sink of diclofenac, studies 
concerning the role of sediments in the elimination of diclofenac contaminants from 
the aquatic compartments are sparse and sometimes incomplete. Additionally, most 
of the environmental studies concern mainly with analysis of water and they do not 
pay a great attention to the sediment. Of course water analysis is important, but it 
describes the contamination levels over a narrow time window. In contrast, sediment 
analysis provides information over a wider time range of contamination since it is less 
sensitive to the environmental changes. 
4- The investigation of the environmental fate of a substance is a very complex issue 
especially under field conditions which is more realistic but in the same time relatively 
expensive, intensive, many data are difficult to interpret and the environmental 
conditions are difficult to control. In contrast, laboratory tests are considered more 
helpful for the explanation of the environmental processes (especially when the test 
substance is used as a radiolabeled material) because the results are usually 
comparable and reproducible due to the standardized conditions. 
5- Although fate studies is a part of a wide effort aimed at environmental risk 
assessment of pharmaceuticals residues in the environment, the risk assessment 
using data on transformation of the substances in water/sediment systems is not 
considered neither in the literature nor in the guidelines probably due to the lack of 
information. Therefore, making such data available is very helpful for better risk 
assessment, when it is necessary.  
6- Although several studies concerning identification of transformation products of 
diclofenac are already existed, products arising from the interaction between 
diclofenac and water/sediment compartments could not be found. The transformation 
products may have different biological effect compared to the parent compound. 
Therefore, their identification is essential not only to predict the fate, the 
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environmental impact on the ecosystem or even to provide a comprehensive risk 
assessment on drug residues under the environmental conditions, but also for 
designing improved treatment technologies for elimination of all trace contaminants. 
7- Although several identification methods have been already published, the 
identification of unknowns in complex matrices stills a difficult issue. It requires the 
application of analytical tools capable of providing the comprehensive information 
required to final structural elucidation. 
8- Using of only one method is not enough for the identification of the transformation 
products, since formation of large numbers of unknown compounds with different 
physico-chemical properties may complicate their separation. Therefore, combination 
of at least two techniques may provide complementary information that enabled the 
identification of unknowns. Additionally, absence of the transformation products as 
authentic standards is the most common problem rendering the identification process 
more complicated with lower degree of confidence than in presence of reference 
authentic standards. 
 
In this sense, three approaches were determined to be the major aims of the present work.  
 
2.1 Fate study 
In this part, laboratory tests on the fate and behavior of 14C-diclofenac in water/sediment 
systems were conducted according to the OECD guideline 308 [OECD, 2002a] not only to fill 
the information gap but also to check the applicability of this test to determine the fate and 
behavior of photosensitive pharmaceutical compounds using a special irradiation apparatus. 
The fate of 14C-diclofenac was evaluated according to the mineralization rates, the amount of 
radioactivity remained in the water phase, the extractable residues and the non-extractable 
residues in respect to the initially applied radioactivity. Especially in the trapping of 14C-
carbon dioxide released during the mineralization of 14C-diclofenac, the technical design of 
the irradiation apparatus (discontinuous gas exchange) and the biometric flask equipped with 
soda lime trap (continuous gas exchange), recommended by OECD guideline 308 for testing 
chemicals, are different. Therefore, an additional laboratory batch system that allows for 
discontinuous gas exchange to maintain aerobic conditions was applied in short- and      
long-term degradation tests using different types of sediments (sandy and sandy loam), 
different incubation conditions (dark and light), different incubation intervals (from 0 up to 100 
d), different extraction techniques (solid phase extraction, liquid–liquid extraction, and 
sequential extraction), and different analytical techniques (RTLC and HPLC) were conducted 
in order to obtain comprehensive results. Additionally, matrix characterization and 
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sorption/desorption experiments were involved. By means of this complex simulation test, 
depletion rates in water and sediment, overall disposition of 14
 
C-residues, mass balances, 
and characterization of biodegradation products are investigated [Ericson, 2007]. 
2.2 Identification of transformation products 
In this part, several analytical techniques were used for investigation of diclofenac and its 
transformation products in pure water and water/sediment systems under different laboratory 
conditions. First, HPLC/UVD and HPLC/DAD were used for screening purposes on UV 
absorbent phototransformation products of irradiated diclofenac using special irradiation 
apparatus. Second, GC/MS was applied for determination of the exact origin of the 
diclofenac artifact. Additionally, derivatized and underivatized samples of irradiated 
diclofenac were examined by GC/MS for identification of polar and non polar 
phototransformation products, respectively. Third, a new strategy using HPLC combined with 
the hybrid triple quadrupole-linear ion trap mass spectrometer system (LC/MS/MS-QTRAP) 
was applied for the first time in the identification the phototransformation products of 
diclofenac after irradiation experiments or its biotransformation products after dark 
experiments. Finally, the concentrations of diclofenac were determined for different 
irradiation experiments.  
 
2.3 Structural confirmation of the main transformation product 
In this part, the most abundant phototransformation product of diclofenac should be isolated 
by means of preparative reversed-phase column chromatography and semi-preparative 
HPLC to make it available as authentic reference standard material. Afterwards, the structure 
was confirmed using 2D 1H- and 13
 
C-NMR analysis. 
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3. Materials and Methods 
 
3.1 Sampling and storage of native water and sediment  
Natural water and sediments were taken from headwater stream at Sandbach catchment 
area near Hordorf and Schandelah, Lower Saxony, Germany. These investigation sites were 
up-stream located to the next municipal wastewater treatment plant and thus not affected by 
any effluent contamination. In order to sample mainly sediment under aerobic conditions 
[OECD, 2002a], the sampling depth was restricted to 5 cm from the upper layer of the 
sediment. The sediment was then placed in plastic container and covered with native water. 
Additionally, surface waters were collected from the same sites in separate containers. Water 
was filtrated, sediment was wet sieved to < 2 mm, homogenized, combined together in ratio 
of 3:1 and stored at 4 °C in the dark for 28 days at maximum.  
 
3.2 Matrix characterization 
Water/sediment samples were characterized at specific time intervals according to the OECD 
guideline 308 [Table 4]. Several parameter were determined in water and sediment phases 
such as pH, redox potential (Eh), oxygen content (O2
 
), water holding capacity (WHC), and 
substrate induced respiration (SIR). Additionally, the grain size analysis was performed by 
the Institute of Geoecology, TU Braunschweig.  
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Table 4: Characterization of water/sediment samples [OECD, 2002a] 
 
Parameter 
Stage of test procedure 
After 
sampling 
Before 
equilibration 
At the start 
the of test During test 
At the end 
of the test 
Water      
Source X --- --- --- --- 
pH X X X X X 
Eh X X X X X 
O X 2 X X X X 
TOC --- X X --- X 
Sediment      
Source X --- --- --- --- 
Depth X --- --- --- --- 
pH X X X X X 
Eh X X X X X 
TOC --- X X --- X 
Microbial activity --- X X --- X 
X = performed, --- = not determined, Eh = redox potential, O2
 
 = oxygen content, TOC = total 
organic carbon 
3.2.1 Determination of water holding capacity 
Each sediment type (3 g) was transferred to an aluminum dish, homogenized and equally 
distributed by a spatula or spoon. The dish was then positioned into an infrared heater with 
analytical balance (Ultra-X 210, Gronert, Germany). Afterwards, the water was completely 
evaporated using the infrared heater to constant dry mass. The difference between the 
weight of the sediment before and after drying was listed. The percentage of water holding 
capacity (WHC) and the dry substance (ds) were calculated according to the following 
formulas: 
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WHC (%) = [(Wi – Wf)/Wi
ds (%)      = 100 - WHC (%) 
]x 100 
where: 
Wi
W
: initial weight of the sediment before drying 
f
The test was performed directly after sampling to avoid water losses and repeated four times 
for each sediment type. 
: final weight of the sediment after drying  
 
3.2.2 Determination of pH and redox potential 
The pH and redox potential values were measured in the water phase by means of pH and 
redox meter pH Multical 535 GLP equipped with pH-glass electrode and redox-electrode 
(WTW, Weilheim, Germany). Afterwards, they were measured directly in the wet sediments 
after decantation of the water phases. The pH meter was calibrated before each 
measurement using three different buffer solutions (pH 4, 7, 9.2). These solutions were 
freshly prepared every month. The reading was recorded after getting stable for 5 min. In 
case of the Eh, the voltage was measured by silver/silver chloride electrode so that the 
obtained value was added to + 211 mV to be related to the voltage of standard hydrogen 
electrode and the results were expressed as redox potential Eh. By the same way as the pH, 
the redox electrode was checked prior each series of measurements by determining their 
response in the redox buffer solution. The reading was recorded after 30 min from the 
beginning of measurement.  
 
3.2.3 Determination of the dissolved oxygen content 
Oxygen content was measured only in water phase by oxygen-meter Oxi 340i with OxiCell 
325 oxygen-electrode (WTW, Weilheim, Germany). The electrode of the instrument was 
immersed directly in the samples before filtration. After reaching a stable value, the reading 
was recorded and the oxygen content was expressed in mg/L. 
 
3.2.4 Determination of the total organic carbon  
Total organic carbon (TOC) was determined by means of the organic carbon analyser C-
Analyzer Dohrmann DC-90 (Dohrmann, Santa Clara, CA, USA). For this purpose, known 
weight sediment samples were combusted in an oxygen stream at 900 ºC and the released 
carbon dioxide was subsequently detected by a non-dispersive infrared detector. Preliminary, 
the sediment samples were treated with an excess of hydrochloric acid (4 M) to remove 
carbonates and homogenized by gentle shaking. Afterwards, samples were heated on a hot 
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plate at 100 ºC to remove the excess HCl. Samples were then dried in drying oven at 105 º C 
overnight. After cooling, samples were ground in a mortar by a pestle for TOC analysis. The 
TOC amount was calculated on the basis of an external standardization. The standard 
curves (20 to 150 µg carbon range) were constructed using mixture of oxalic acid dehydrate 
and aluminum oxide in a ratio (1:9). Finally, the results were expressed in % of dry substance 
according to the following formula: 
 
TOC (%)  =  (Wb/Wa
where: 
) x 100 
Wa
W
: initial weight (µg) 
b
 
: amount of carbon (µg) 
In each water sample, on the other hand, TOC was measured after decantation. Prior to the 
measurements few drops of concentrated HCl were added to each sample to remove 
carbonate bound carbon. The obtained results were expressed in mg/L. 
 
3.2.5 Determination of the microbial activity 
Using OxiTop® OC 110 control system with OxiTop®-C measuring head (WTW, Weilheim, 
Germany), the microbial activity of the sediments was determined as a function of pressure 
decrease due to the microbial respiration process initiated by a certain substance. This 
process is known as substrate induced respiration (SIR). For this purpose, 0.4 g of glucose 
was added to 50 g (ds) of sediment into each 1 L glass vessel. Afterwards, KOH pellets were 
put using pincers into rubber quivers and hanged in the vessels in order to adsorb the 
released carbon dioxide due to the respiration process. Finally, the measuring heads were 
screwed tightly and the vessels were incubated in the dark at 20 ± 1 ºC for 5 days. The 
negative pressure developed due to the consumption of the oxygen was recorded and the 
microbial activity was expressed in mg O2
 
/(100 g h) [ISO, 1997]. Data regarding 
characterization of water and sediments directly after sampling are given in Table 5. 
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Table 5: Characteristics of water and sediments directly after sampling 
 
 Water Sediment 
  S1 S2 S3 
Sediment type ---- sand sandy loam sandy loam 
Sand [%] ---- 90 53 45 
Silt [%] ---- 1.5 20 31 
Clay [%] ---- 8.5 30 27 
TOC 49.3-67.4 mg/L 0.2 % ds 0.4 % ds 0.5 % ds 
WHC [%] --- 20 30 40 
pH 8.3 7.4 7.3 7.2 
Eh [mV] 430 210 220 240 
O2 7.8  [mg/L] --- --- --- 
SIR [mg O2 ---- /100 g h] 1.85 1.90 --- 
--- = not determined, TOC = total organic carbon, WHC = water holdig capacity, Eh = redox 
potential, SIR = substrate induced respiration, ds= dry substance 
 
3.3 Reference standards 
3.3.1 14
The stock standard solution (6037 Bq/µL) and the working standard solutions (1483 Bq/µL 
and 925 Bq/µL) of phenylacetic acid ring-U-
C-diclofenac standards 
14C-diclofenac, specific radioactivity 2260 MBq/ 
mmol (Amersham Pharmaceutical Biosciences, Little Chalfont, and Buckinghamshire, UK) 
were prepared in methanol. The structure and labelling position of 14
 
C-diclofenac are shown 
in Figure 8. 
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Figure 8: Chemical structure of 14
 
C-diclofenac sodium showing the labeling position 
The radiochemical purity (85 %) was checked by means of radio-thin layer chromatography 
(RTLC) as described for the screening of transformation products (cf. chapter 2.7.8). Only 
limited amount of 14
 
C-diclofenac standard solution was available for the fate monitoring 
study. Therefore, an additional clean up procedure could not be conducted. 
3.3.2 Diclofenac standards  
In 10 mL volumetric flasks, diclofenac (Sigma-Aldrich, Deisenhofen, Germany) stock 
standard solutions at concentration of 1 µg/µL were prepared in methanol, acetone, and pure 
water and at concentration of 0.1 µg/µL in ethyl acetate (after ultrasonication for 15 min) 
while working standard solutions were prepared at concentration of 15 ng/µL in acetone, and 
10 ng/µL in methanol and pure water. All prepared standard solutions were stored at – 20 °C 
except that were prepared in pure water (stored at 4 °C). 
 
3.4 Determination of sorption, desorption and isotherms 
By means of sorption or distribution coefficients (Kd), the affinity of 14C-diclofenac to the 
water or the sediment phase can be asseseed. The Kd was determined according to the 
OECD guideline 106 [OECD, 2002b]. For this purpose, sediment S3 was air dried and then 
sieved to particle sizes <2 mm. A 0.01 M CaCl2 aqueous solution was used as a solvent 
phase. Afterwards, the sediment (20 g) and the CaCl2 solution (60 mL) were mixed, in a 
PTFE capped centrifugation tubes, in the ratio of 1:3. This ratio was preliminary selected to 
simulate the same ratio used during the fate study. The mixtures were then equilibrated 
under constant agitation on a horizontal shaker at 230 rpm for 24 h. Afterwards, different 
volumes (concentrations) of working standard solution of 14C-diclofenac in methanol (1828 
Bq/µL) were spiked directly into the aqueous phase (the volumes of methanol were less than 
0.1 % (v/v) of total solution volume). The number of replicates for each concentration was 
four. After shaking the mixtures for 24 h, the aqueous phases were separated by 
centrifugation (Centrifuge; Megafuge 1.0, Heraeus GMbH, Germany) at 3000 rpm for 5 min 
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to remove particles with a diameter greater than 0.2 µm from aqueous phase. The amounts 
of 14C-diclofenac sorbed onto the sediment were calculated as the difference between the 
amount 14C-diclofenac initially applied in the solution and the amount remained at the end of 
the agitation period (indirect method). Preliminary, centrifugation tubes containing only CaCl2 
solution spiked with 14C-diclofenac showed no considerable losses during the experiments. 
For comparison purpose, surface water was used as a solvent phase instead of CaCl2 to 
determine the Kd
Finally, the K
 value at single concentration level. A blank for each concentration was 
made as specified by OECD guideline 106 [OECD, 2002b]. 
d was determined according to equation number 1. It describes the ratio 
between the mass concentration of the 14C-diclofenac in the sediment phase and the mass 
concentration of the 14
 
C-diclofenac in the aqueous solution, under the test conditions, when 
sorption equilibrium is reached.  
Kd = Cs/Cw = (ms x vo)/(mw x msed
where: 
)                                (1) 
Cs: content of the 14
C
C-diclofenac adsorbed on the sediment at sorption equilibrium (μg/kg). 
w: mass concentration of 14
m
C-diclofenac in the aqueous phase at sorption equilibrium 
(μg/L). 
s: mass of the 14
m
C-diclofenac adsorbed on the sediment at sorption equilibrium (μg). 
w: mass of the 14
m
C-diclofenac in the solution at sorption equilibrium (μg). 
sed
v
: quantity of the sediment phase, expressed in dry mass of sediment (kg). 
o
 
: initial volume of the aqueous phase in contact with the sediment (L). 
Furthermore, the influence of concentration on the sorption process was tested by the 
determination of Freundlich and Langmuir sorption isotherms. Six different concentrations of 
14C-diclofenac ranging from 0.06 to 0.6 Bq/L were applied. The sorption data were found to 
be fitted to the Freundlich equation which relates the amount of the 14C-diclofenac sorbed 
onto the sediment to the concentration of the 14
 
C-diclofenac in solution at equilibrium 
(equation 2). This equation was used in its logarithmic or linear form (equation 3). 
Cs = KF x Cw  
where: 
                                                                 (2) 
Cs: content of 14
C
C-diclofenac sorbed on the sediment at sorption equilibrium (μg/kg). 
w: mass concentration of 14
K
C-diclofenac in the aqueous phase at sorption equilibrium 
(μg/L). 
F: Freundlich sorption coefficient (µg1-1/n L1/n
1/n 
/kg). 
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1/n: Freundlich exponent, Freundlich sorption capacity parameter, Freundlich affinity 
      constant or Freundlich regression constant.  
 
Logarithmic form: logCs = logKF + 1/n logCw
 
                (3) 
Freundlich sorption coefficient KF (µg1-1/n L1/n/kg) is the amount of 14C-diclofenac (µg) 
adsorbed per one kg sediment after the equilibrium had been established. It can be 
calculated from the intercept value of the Freundlich isotherm. The Freundlich exponent 
(Freundlich sorption capacity parameter) 1/n is unitless [Scheytt et al., 2005a], sometimes 
also n is used [Ramil et al., 2010, Barron et al., 2009, Chefetz et al., 2008]. It is equal the 
slop of the Freundlich isotherm. 1/n describes the affinity of 14
 
C-diclofenac to the sediment 
(the higher 1/n the higher affinity to the sediment). 
Since desorption process also plays an important role in the behavior of a chemical in the 
environment, desorption experiments were preformed by replacing the CaCl2 solutions with 
fresh solutions. The new mixtures were agitated for 24 h. Afterwards, the amount of 14C-
diclofenac desorbed from the sediment was determined in the aqueous phase. Desorption 
was calculated as the percentage of the amount of 14C-diclofenac which is desorbed related 
to the amount of diclofenac previously adsorbed. The purpose of this experiment is to 
investigate whether diclofenac is reversibly or irreversibly adsorbed on sediment. Desorption 
is considered reversible when the amount desorbed is more than 75 % of the amount 
adsorbed [OECD, 2002b]. The desorption coefficient (Kdes) was determined according to 
equation number 4. It describes the ratio between the amount of 14C-diclofenac remained in 
the sediment phase and the amount of 14
 
C-diclofenac desorbed in the aqueous solution, 
when desorption equilibrium is reached.  
Kdes = [(ms - mw) x vo]/ mw x msed
where: 
                                     (4) 
ms: mass of the 14
m
C-diclofenac adsorbed on the sediment at sorption equilibrium (μg) 
w: mass of the 14
m
C-diclofenac desorbed from the sediment at desorption equilibrium (μg) 
sed
        desorption experiment (kg) 
: quantity of the sediment phase, expressed in dry mass of sediment during the 
vo
     experiment (L). 
: total volume of the aqueous phase in contact with the sediment during the desorption 
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Furthermore, Freundlich desorption isotherm (KF-des) was calculated according to equation 
number (5). The Freundlich desorption isotherms equation relates the amount of 14C-
diclofenac remaining adsorbed on the sediment to the amount of 14
 
C-diclofenac in solution. 
Desorption data were found to be fitted to the logarithmic form of the Freundlich desorption 
equation (equation 6). 
Cs = KF-des x Cw 
C
                                                               (5) 
s: amount of 14
     (μg/kg); 
C-diclofenac remaining sorbed on the sediment at the desorption equilibrium  
Cw
 
: amount of diclofenac in the aqueous phase at the desorption equilibrium (μg/L) 
Logarithmic form: logCs = logKF-des + 1/n logCw
 
            (6) 
3.5 Water/sediment tests in the dark  
For the biotransformation tests of 14C-diclofenac, 300-mL Erlenmeyer flasks filled with 50 g 
(ds) sediments (S1 or S2) and 150 mL surface waters were prepared. The water sediment 
systems were then equilibrated, without stoppers, at 20 ± 2 ºC for 7 days to reach reasonable 
stability of the system. After the equilibration period, aliquots (50 µL each) of 14C-diclofenac 
were spiked directly into the water phase of the test systems using water-miscible organic 
solvent, e.g., methanol. The concentration of the organic solvent in the overlying water did 
not exceed 0.5 %. The spiking level of the 14C-diclofenac was 0.07 MBq giving a 
concentration of 200 µg/kg sediment or 70 µg/L water. The adjustment of the applied amount 
of the radiotracers focused on the diclofenac relative environmental concentration as well as 
on the analytical feasibility mainly defined by the specific radioactivity. After fortification, the 
flasks were then gently shaken (manually) disturbing the sediment as little as possible. 
Flasks regarding each type of the sediment were then divided into two main groups in order 
to differentiate between mineralization (MIN), 14
 
C-diclofenac residues in the aqueous phase 
(AP), in the extractable fraction (ER) and non-extractable fraction (NER) using two different 
biodegradation systems. 
First, the laboratory-batch system [Figure 9] in which the flasks were equipped with an inlet 
and an outlet valve allowing for discontinuous gas exchange [Kreuzig et al., 2003] was 
applied. Additionally, it is equipped with an internal trap filled with 8 mL 0.1 M potassium 
hydroxide solution to absorb 14
 
C-carbon dioxide, potentially released by mineralization. 
1/n 
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Second, the biometric flask system [Figure 10] was applied. It was equipped with a tube 
filled with 20 g granulated soda lime (Merck, Darmstadt, Germany). The tube was coupled 
with the flask to absorb 14
 
C-carbon dioxide that might be released by mineralization. This 
system allows for continuous gas exchange. Therefore, aerobic condition was maintained all 
the time.  
1: inlet valve, 2: outlet valve with activated charcoal filter, 3: internal 14
 
C-carbon dioxide 
absorption trap (8 mL 0.1 M potassium hydroxide solution), 4,5: water/sediment sample  
Figure 9: Laboratory-batch system (discontinuous gas exchange system) for 
biotransformation tests of 14
 
C-diclofenac in water/sediment systems 
 
1, 3: glass wool, 2: soda lime, 4,5: water/sediment sample 
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Figure 10: Biometric flask system equipped with soda lime trap (continuous gas 
exchange) for aerobic biotransformation tests of 14
Afterwards, the test systems of each sediment type were incubated in the dark at 20 ± 2 ºC 
for different intervals (0, 1, 3, 7, 14, 28, 56, 100 d) and (3, 56, 100 d) in case of both 
laboratory test systems, respectively. Additionally, in the batch systems, the potassium 
hydroxide trap and the air above the water phase were exchanged every 4 days to improve 
the trapping capacity of the alkaline solution and to save aerobic conditions.  
C-diclofenac in 
water/sediment systems  
 
For matrix characterization during the test period, water/sediment samples were prepared as 
mentioned before. These samples were fortified with non-labeled diclofenac (200 µg/kg 
sediment or 70 µg/L water). To achieve comparability, the samples were incubated parallel to 
the 14C-diclofenac tests. Both laboratory test systems were equipped with the corresponding 
14C-carbon dioxide traps, although they would not allow for determination of mineralization. 
Additionally, blank water/sediment samples before equilibration, after equilibration, and at the 
termination of the experiment were conducted as control samples. In order to test the effect 
of methanol (in which 14
 
C-diclofenac was dissolved) on the microbial activity of the 
sediments, moreover, water/sediment samples (solvent control) were spiked with 50 µL, 
each, of pure methanol were prepared as mentioned before. Approximately, 120 
water/sediment tests were performed during this investigation. 
3.6 Irradiation experiments  
To examine the photoinduced effect on diclofenac in water/sediment system, a special 
irradiation apparatus [Figure 11] was used [Kreuzig, 1998, Höllrigl-Rosta et al., 1999, 
Kreuzig et al., 2003, Kreuzig and Höltge, 2005]. It consisted of a sample container provided 
by a cooling system and a glass tube with inlet and outlet valves, containing the mercury 
medium-pressure lamp (Schott, Mainz, Germany). The lampe is surrounded by Pyrex®
 
 
cooling jacket defining the cut off at λ = 290 nm. The power supply is connected to a timer 
clock to get the required irradiation periods. 
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1, 2: inlet-/ outlet valve with activated charcoal filter 3: cooling device, 4: mercury medium 
pressure lamp with Pyrex® cooling jacket (cut off: λ = 290 nm), 5: 14
 
C-carbon dioxide 
absorption trap, 6: sediment 7: exchangeable sample container, 8,9: water cooling device, 
10: water  
Figure 11: Irradiation apparatus for testing on photoinduced transformation 
 
3.6.1 Water/sediment tests 
For each sediment type, the water/sediment samples were prepared and equilibrated as 
mentioned under the biotransformation test (cf. chapter 3.5). In contrast to the 
biotransformation test, the content of the flask was carefully transferred after the equilibration 
time into the sample container of the irradiation apparatus and left for a certain period to 
obtain clear water phase as much as possible. Then, 50 µL 14C-diclofenac were spiked 
directly into the water phase of the test system. An internal potassium hydroxide trap was 
used to absorb 14
 
C-carbon dioxide. After fixing the sample container tightly into the irradiation 
apparatus, the incubation was started at 20 ± 2 °C under 10 h-light/14 h-dark for the 3-day 
incubation period.  
Furthermore, in order to differentiate between biotic and abiotic transformation processes, 
additional experiments using pure water/quartz sand instead of real water/sediment samples 
were performed [Kunkel and Radke, 2008]. The quartz sand was preliminary tested for 
microbial activity by means of SIR method (cf. chapter 3.2.5) within 3 days incubation period. 
The results showed no sign of any respiration process indicating that the samples were 
sterile enough. Other methods for sterilization such as autoclavation, addition of sodium 
azide, mercuric chloride or formalin were excluded because they may lead to structural 
alteration and may influence the sorption properties of the natural sediment [OECD 2002a, 
Lotrario et al., 1995, Ramil et al., 2010]. 
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3.6.2 Water tests 
In order to estimate the role of the sediment in the removal of the transformation products of 
diclofenac, irradiation tests were additionally conducted using native water and 
demineralized water separately without sediment. For this purpose, 150-mL water samples 
were fortified with 50 µL 14
 
C-diclofenac each and incubated under the same irradiation 
conditions (cf. chapter 3.6.1). The obtained results were then compared with the irradiation 
experiments performed in water/sediment system. 
For quality assurance, all water/sediment samples prepared during the whole experiments 
were conducted in duplicate. Additionally, the radioactivities were measured in the extracts 
applying different volumes at different extraction steps. Finally, the mass balances were 
conducted allowing for a comparison of the quantity of radioactivity present in the each 
compartment against the quantity initially applied into the test system. The results were 
accepted when the recovery rates were in the range of 90 % to 110 % and the standard 
deviations did not exceed 10 %. In all presented figures, the error bars show the mean 
standard deviation between the two tests, their lower and their upper ends refer directly to 
the individual measurement values.  
 
3.7 Radiotracer analysis 
At the termination of each incubation interval, the materials (potassium hydroxide solution or 
the soda lime granules) for 14
 
C-carbon dioxide trapping were removed. Then, the 
water/sediment systems were separated for analytical purposes. If necessary, sediment and 
water samples were stored at -20 or 4 °C, respectively, until analysis.  
3.7.1 Determination of mineralization rates 
Du to the mineralization processes, the released 14C-carbon dioxide can be measured in 
different ways according to the type of 14C-carbon dioxide trap. In the laboratory-batch 
system, the alkaline absorption solution was removed by means of a syringe with a long 
needle and transferred into a vial containing 10 mL Quicksafe A (Zinsser, Frankfurt, 
Germany). In the biometric flask system, the 14C-carbon dioxide sorbed to the soda lime had 
to be transferred quantitatively into the liquid phase for measurement. For this reason, the 
soda lime granules were mixed with 60 mL of hydrochloric acid and stirred until complete 
dissolution. Nitrogen was introduced gently through the soda lime/hydrochloric acid mixture. 
The 14C-carbon dioxide in the resulting gas flow was sequentially trapped in 3 successive 
vials containing 15 mL of Oxysolve-C400 each (Zinsser, Frankfurt, Germany). In both cases, 
the vials were then analyzed by the liquid scintillation counter (LSC; Wallac 1409, Turku, 
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Finland) for 30 min using background correction. Later on, the mineralization percentage was 
calculated according to the following equation: 
 
MIN = A1 x 100/A2 
where: 
A1:   Radioactivity in the analyzed absorption solution (Bq). 
A2:   Initially applied radioactivity (Bq). 
100: Conversion factor to percent. 
 
Principles of liquid scintillation counting 
The liquid scintillation counter is a very precise, simple, and fast instrument for measuring 
radioactivity in liquid samples. It is mainly composed of a dark chamber with 2 photomultiplier 
tubes and a pulse counter. Hence, this instrument is designed to measure light energy in the 
dark. Therefore, the radioactive emissions should be converted to photons of light in order to 
be detected by the photomultiplier tube. The radioactive emissions include alpha particles 
(α), beta particles (β), and gamma rays (γ). Radiocarbon atoms of the 14C-labeled 
substances are characterized by neutron rich nucleoli that decay with a half-life of 5730 
years. During the decaying processes, neutrons are converted to a protons resulting in 
emission of β particles and neutrinos. The latter are almost impossible to detect by LSC as 
they do not interact significantly with matter. The process of beta decay of 14
 
C-substances 
can be demonstrated by the following reaction: 
 
C                             N + e-
 
 (β particles) + neutrino 
In comparison with gamma rays, beta particles have low penetration power and can not be 
directly detected by the instrument. For this purposes, the radioactive samples is placed in a 
vial containing a relatively dense scintillation cocktail either for aqueous solvents (Quicksafe 
A) or for organic solvents (Quicksafe N). Both cocktails consisted of solvent and fluor 
(scintillator compound that fluoresces when it is bombarded with β particles). The role of 
solvent is to efficiently absorb the bulk of the radiation energy produced by beta particles 
before all of its kinetic energy is dissipated by some other mechanisms (heat or ionization). 
Because of their high electron density, aromatic compounds (benzene derivatives) such as 
toluene and xylene and the less toxic phenyl xylylethane were found to be the best solvents 
for LSC. Up on absorption of beta energy, the solvent molecules are converted to the exited 
state. However, these compounds have little tendency to emit light and hence could not be 
detected. In order to return to the ground state, alternatively, the exited solvent molecules 
14 
6 
14 
7 
decay 
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transfer the captured energy to other solvent molecules which are the fluors. The later are 
broadly divided into primary, e.g. 2,5-diphenyloxazole, and secondary, e.g. p-bis-(o-
methylstyryl) benzene, scintillators. The role of the primary scintillator is to receive the energy 
of the solvent molecules and to emit it in the form of light flashes at a wavelength that could 
be detected by the photomultiplier tubes. However, the early photomultiplier tubes were 
found to be not sensitive in the region of fluorescence emission of the primary scintillators as 
most of them were found to emit light below 408 nm. Therefore, the secondary scintillators or 
the wavelength shifters were introduced to capture the flashes of the excited primary 
scintillators and emit it at longer wavelength region that more suitable to the photomultiplier 
tubes. The latter convert the flashes of light into countable electrical pulses and record them 
as counts per minute (cpm). Since the scintillation counter is not 100 % efficient, the cpm 
should be converted to disintegrations per minute (dpm) in order to get the number of decay 
which actually occurred. The dpm is then converted to the systematic international unit of 
radiation, becquerel (Bq), which corresponds to 60 dpm.  
 
On the other hand, the energy emitted by beta particles or photons during the energy transfer 
process is not only absorbed by the scintillation cocktail but also by sample components 
leading to losses of energy. This process is known as quenching which can easily decrease 
the fluorescence intensity and hence reduce the pulses below the detection limit of the 
counter, thus reducing the overall counting efficiency. Three types of quenching are mainly 
known, physical, chemical and colour. For quench correction, the external artificial gamma 
emission source Europium-152 (152
 
Eu), radioactivity of 0.74 MBq, was applied next to the 
sample vial and after the initial counting, the sample is counted again. Gamma rays result in 
emission of Compton electrons which show the same quench effects as the sample 
spectrum. For determination of the extent of quenching, therefore, the measured energy 
spectrum of the Compton electrons is compared with their theoretical energy spectrum. 
3.7.2 Determination of 14
At the termination of each incubation interval, the water/sediment systems were separated by 
decantation and filtration, with minimal disturbance to the sediment as it was described by 
Ericson (2007), Löffler et al. (2005), OECD (2002a). By means of graduated measuring 
cylinder, the total water volume was then determined. Afterwards, 3 different aliquots (50, 
100 and 500 µL) were mixed individually with Quicksafe A (10 mL in a vial) and the 
radioactivities were measured by LSC for 30 min using background correction. 
C-diclofenac residues in water phases 
 
 
 
MATERIALS AND METHODS 
 
 
 53 
It was the objective not to disturb the water/sediment interface assumed to be the most 
important layer for transformation process [Craven et al., 1986]. Therefore, any rinsing of the 
sediment samples was avoided durig the test period considering that the concentration of 
14
 
C-diclofenac in the pore water is the same as in the water phase. Therefore, the 
radioactivity amount of the pore waters was added to the extractable fraction (cf. 3.7.4). 
However, additional experiments were performed to estimate the radioactivity amount that 
could be retained in the pore waters. For this purpose, laboratory-bach water/sediment 
systems were prepared as mentioned before (cf. 3.5) and incubated in the dark for 7 days. 
After separation of water/sediment system as mentioned here, some of the sediment 
samples were rinsed with 3 x 50 mL fresh water to exchange the pore water. Afterwards, the 
radioactivity in the total volume of the pooled water was measured. On the other hand, the 
other sediment samples were extracted directly with ethyl acetate (cf. 3.7.4). Finally, the 
results of both extraction methods were compared for determination of the effect of pore 
water. The radioactivity % in the aqueous phase (AP) was calculated according to the 
following equation: 
 
AP = A1 x V2 x 100/A2 x V1 
where:  
A1:   Radioactivity in the analyzed aliquot (Bq). 
A2:   Initially applied radioactivity (Bq). 
V1:   Volume of the analyzed aliquot (mL). 
V2:   Total volume of the measured water phase (mL). 
100:  Conversion factor to percent. 
 
3.7.3 Determination of DT50 and DT90
The dissipation time DT
 in water phases 
50 and DT90 are the times at which the initial concentration of 14C-
diclofenac is reduced from the water phase to 50 and 90 %, respectively. Based on the 
residual radiotracer amounts in the water phase, the dissipation times DT50 and DT90 were 
calculated using the ModelMaker (2007) statistical software [Moenickes, 2010]. The 
regression curves were calculated from first order kinetics depending on best fit of at least 5 
points. DT50 and DT90 can be calculated also using the elimination rate constant (kelim
 
) 
according to the following equations: 
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DT50 = ln 2/kelim
DT
                 (1) 
90 = ln 10/kelim
 
               (2) 
3.7.4 Determination of 14
After separation of the water/sediment systems, the sediments were extracted individually 
with 150 mL of ethyl acetate using a horizontal shaker at 200 rpm overnight for determination 
of the extractable residues (ER). The suspensions were then decanted through folded filters 
and the sediment was rinsed three times with 50 mL of ethyl acetate. The total volume of the 
pooled ethyl acetate was measured and the radioactivities in 2 (50 and 100 µL) aliquots were 
determined, after mixing with Quicksafe N (10 mL), by LSC for 15 min using background 
correction. Afterwards, the ethyl acetate extracts were evaporated by means of rotary 
evaporator to 5 mL. The radioactivity in 10 µL of the concentrated extracts was then 
determined. Afterwards, the extracts were stored in brown glass vials at 4 ºC until screening 
analysis.  
C-diclofenac residues in extractable fractions 
The radioactivity % in the ER was calculated according to the following equation: 
 
ER = A1 x V2 x 100/A2 x V1 
where:  
A1:   Radioactivity in the analyzed aliquot (Bq). 
A2:   Initially applied radioactivity (Bq). 
V1:   Volume of the analyzed aliquot (mL). 
V2:   Total volume of the organic solvent (mL). 
100:  Conversion factor to percent. 
 
For quality assurance, the extraction efficiency of ethyl acetate against acetone, acetonitrile 
and methanol was preliminary tested. For this reason, in 300-mL Erlenmeyer flasks, 50 g 
(ds) wet sediment (S3) was applied and spiked with 14
 
C-diclofenac at approximately 1.7 
MBq/kg each. Afterwards, sediments were extracted individually with the corresponding 
solvent as mentioned before for ethyl acetate. Furthermore, 50 g sediment samples (dry 
substance content) were spiked with aqueous diclofenac standard at 1 or 2 mg/kg. The 
diclofenac was then extracted by means of ethyl acetate as mentioned above and analyzed 
using HPLC/UVD. The recoveries of diclofenac were found to be 98 ± 5 %. 
3.7.5 Determination of 14
For the determination of non-extractable residues (NER), the extracted sediments were 
transferred onto evaporating dishs and left for drying. The sediments were then 
C-diclofenac residues in non-extractable fractions 
 
 
MATERIALS AND METHODS 
 
 
 55 
homogenized with mortar and pestle. To minimize the variability, 4 aliquots (150-200 mg 
sediment) of each sediment sample were mixed with 10 mg cellulose (Merck, Darmstadt, 
Germany) in the sample boats and burned for 4 min in the oxygen stream (350-380 mL/min) 
at 900 ºC of the biological oxidizer (OX-500, Harvey Instruments Hillsdale, NJ, USA). The 
resulting 14
 
C-carbon dioxide was trapped in vials containing Oxysolve-C400 (15 mL). The 
radioactivity was then determined by LSC for 10 min without background correction. Later 
on, the sediments were stored in brown bottles at - 20 ºC.  
To control the performance of the instrument, recovery rates of the sample oxidizer were 
determined before starting, during and at the end of the measurements. For this reason, 3 
blank sediment samples were prepared as mentioned above and spiked with a defined 
amount of the reference standard 14C-LU-111995 ((+)-exo-{2-[6-(4-fluorophenyl)-3-aza-
bicyclo[3.2.0] heptane-3-yl]ethyl}-1,3H-chinazoline-2,4-doin-fumerate; Knoll, Ludwigshafen, 
Germany) and combusted directly after the preheating time. After burning of each spiked 
sample, blank sediment was burned in order to avoid memory effects. Furthermore, after 
each set of sample replicates one blank, one standard and another blank were combusted. 
Additionally, a 14
The radioactivity % in the NER was calculated according to the following equation: 
C-standard paper with radioactivity 5000 dpm was burned at the end.  
 
NER = A1 x M2 x 100/A2 x M1 
where:  
A1:   Radioactivity in the analyzed aliquot (Bq). 
A2:   Initially applied radioactivity (Bq). 
M1:  Weight of the analyzed aliquot (g). 
M2:  Total weight of the dried sediment sample (g). 
100: Conversion factor to percent. 
 
3.7.6 Chemical characterization of non-extractable residues 
At the termination of both dark and irradiation water/sediment experiments, the matrix affinity 
of non-extractable residues to the sediment was tested sequentially by second and third 
extraction steps. The first step was performed according to Heise et al. (2006). For this 
purpose, 150 mL methanol and 600 µL of hydrochloric acid were added to 20 g of dried, ethyl 
acetate extracted, sediments in 300-mL Erlenmeyer flasks. The flasks were then shaken on 
a horizontal shaker at 220 rpm overnight. The extracts obtained after filtration were rotary 
evaporated to 5 mL. Aliquots were taking before and after evaporation, mixed with Quicksafe 
N (10 mL) each, and subsequently scintillation counted. After drying, the radioactivities in the 
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methanol/hydrochloric acid extracted sediments were analyzed for the non-extractable 
residue as mentioned under 3.7.4. As a third step of the sequential extraction procedure, a 
silylation technique, for derivatization of humic substances using silylation reagents at room 
temperature, was applied [Haider et al., 1992, Klaus et al., 1998 Oesterreich et al., 1999]. 
For this purpose, 15 g of the dried, methanol/hydrochloric acid extracted, sediments were 
filled into centrifuge tubes and treated with 40 mL N-dimethylformamide and 5 mL 
chlorotrimethylsilane. After shaking overnight at 220 rpm, the suspensions were centrifuged 
(Megafuge 1.0, Heraeus GMbH, Hanau, Germany) at 3000 rpm for 5 min and the organic 
supernatants were then filtered, the moist sediment retreated with 10 mL N-
dimethylformamide, centrifuged for 5 min at 3000 rpm and filtered again. The pooled extracts 
were scintillation counted and the non-extractable residues were determined in the 
sediments after drying as mentioned under 3.7.4. During the application of this extraction 
technique, the mass balance was set up after every extraction step. 
 
3.7.7 Solid phase extraction  
Method description  
For the RTLC screening of the water samples, diclofenac and its transformation products had 
to be concentrated. For this purpose, solid phase extraction (SPE) was used as a clean up 
and enrichment step using strata-X cartridge (StrataTM-X 33u µm cartridge, polymeric 
sorbent, reversed phase, Phenomenex, Aschaffenburg, Germany). Prior loading of water 
samples, the cartridges were conditioned with 5 mL of acetone, 5 mL of methanol, and 5 mL 
of demineralized water (pH 2). Afterwards, the aqueous phase was adjusted at pH 2.5 with 
diluted HCl, to prevent diclofenac from taking its ionic form [Kot-Wasik et al., 2006]. After 
loading the samples, at a flow rate of 3 mL/min, the cartridges were dried under gentle 
stream of nitrogen. Afterwards, diclofenac and its transformation products were eluted with 5 
x 1 mL methanol. The radioactivities in 2 aliquots (50 and 100 µL) of the methanol eluent, 
after mixing with 10 mL Quicksafe N (Zinsser, Frankfurt, Germany), were measured by LSC 
to ensure complete elution of the radioactivity. Additionally, the radioactivities in 2 aliquots of 
the percolates were measured by LSC for determination of break through of the diclofenac 
and its transformation products. Finally, the methanol eluent was stored in brown glass vials 
at 4 ºC until RTLC analysis and the cartridges were stored at - 20 ºC until the setup of the 
mass balances. For quality assurance, the extraction efficiency of Strata-X material was 
preliminarily tested by spiking of 14C-diclofenac in 50 mL water samples at a radioactivity 
level of 0.14 MBq/L each. The water was then extracted as mentoned above. The recoveries 
were found to be 93 % ± 3 [Appendix, Table A1]. Additionally, the difference between the 
radioactivity determined in the water phase and in the percolate were determined for 
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calculation of losses occurred during the SPE. The radioactivity % in the eluent was 
calculated according to the following equation: 
 
Eluent = A1 x V2 x 100/A2 x V1 
where: 
A1:   Radioactivity in the analyzed aliquot (Bq). 
A2:   Initially applied radioactivity (Bq). 
V1:   Volume of the analyzed aliquot (mL). 
V2:   5 mL. 
100: Conversion factor to percent. 
 
Strata-X sorbent material 
Since the concentrations of 14C-diclofenac in the water phases are relatively low, enrichment 
steps are needed especially when it occurs together with its transformation products which 
are expected at lower concentration than 14
 
C-diclofenac. Although several extraction 
methods have been published, SPE remains the most widely used method for extraction and 
clean up of diclofenac from water samples either alone or in combination with the other 
methods [Ahrer et al., 2001, Bartels and von Tuempling Jr, 2007, Antonic and Heath, 2007]. 
In the literature, different types of SPE cartridges were reported to be suitable for extraction 
of environmental samples containing diclofenac and/or it transformation products such as 
Strata-X [Hilton et al., 2003, Kosjek et al., 2005, Drover and Bottaro, 2008], Oasis HLB [Tixier 
et al., 2003, Bueno et al., 2007, Chefetz et al., 2008, Chen et al., 2008, Kosjek et al., 2008, 
Terzic et al., 2008, Bui et al., 2009], BakerBond PolarPlus [Stuelten et al., 2008a, b], Isolute 
ENV+ [Groning et al., 2007] and Oasis MAX in combination with Oasis HLB [Agueera et al., 
2005, Bartels and von Tümpling Jr, 2007]. In the present study, the polymeric sorbents, 
Strata-X (polydivinylbenzene resin containing 2-pyrrolidinone groups) was selected for 
extraction of diclofenac and its transformation products from water samples due to its sorbent 
material which improve the retention of acidic, basic and neutral compounds. This may be 
attributed to its modified polymeric surface of this material that has hydrophilic, lipophilic, and 
π-π retention interaction mechanisms [Figure 12]. Therefore, Strata-X has been used 
simultaneously in the analysis of multi-class pharmaceuticals in water samples [Hilton and 
Thomas, 2003, Roberts and Thomas, 2006]. 
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Figure 12: Structure of Strata-X sorbent material showing different retention 
mechanisms 
 
3.7.8 Screening of 14
Method description 
C-diclofenac and its transformation products 
In all extracts, the composition of the radioactivity was investigated using radio thin layer 
chromatography (RTLC) either Tracemaster 20 Automatic TLC-linear analyzer B 284, 
(Berthold, Muenchen, Germany) or the Rita Star TLC-Scanner (Ray Test, Straubenhardt, 
Germany). The substances were separated on silica gel plates, 60 F254, 20 x 20 cm2 (Merck, 
Darmstadt, Germany). The plates were divided into several tracks, one of which was 
reserved for 14C-diclofenac reference standard for Rf comparison purpose. Extracts and 
standards were spotted by means of disposal micro-pipettes in the pre-concentration zone (2 
x 20 cm2) from each other and from the edges of the plate. The volumes applied onto the 
plates were depended on the radioactivity amounts of the analytical solutions. After the 
evaporation of the solvents in a fume hood, the plates were placed into the development 
chamber filled with approximately 100 mL of the developing solvent. Using normal phase 
TLC plates, two different solvent systems were used for detection of diclofenac and its 
transformation products. First solvent consisted of n-hexane/ethyl acetate/acetic acid 
(50:50:1 v/v/v) while the second was dichloromethane/methanol/25 % ammonia (85:14:1 
v/v/v). For comparison purposes, the extracts of some irradiation experiments were 
additionally developed on reversed phase (RP-18) silica gel plates (Merck, Darmstadt, 
Germany), 60 F254s (20 x 20 cm2
 
) using acetonitrile/water/formic acid (90:10:0.02). This ratio 
was preliminary determined after testing different solvent ratios starting from (50:50:0.02). All 
plates were developed to a distance of 18.5 cm in a closed development chamber and were 
then dried in a fume hood. Then, the TLC plates were scanned for certain time, according to 
the radioactivity amount in each spot, at an amplifier voltage of 900 V. A mixture of argon 
and methane (90:10) was used as a purge gas. The software Chroma 2D or Gina star were 
used to evaluate the autoradiographic data and the peaks were integrated manually after 
smoothing. The percentage of diclofenac detected as a parent compound was calculated 
from the following equation:  
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Substance (%) = A x ROI/100 
where:  
A:     Radioactivity percentage in the applied extract. 
ROI: Percentage of region of interested (computed by the soft ware after manual integration).  
100: Conversion factor to percent. 
 
For quality assurance, the radiochemical purity of 14
 
C-diclofenac was checked before starting 
each set of experiments. 
Principles of RTLC 
In contrast to LSC, RTLC is designed to detect alpha and beta radiation emitted by 
radioactive substances which exist in the solid state. These substances were previously 
spotted as analytical solutions onto TLC plates and left for drying. The measurement is 
occurred by means of a sensitive movable proportional counter tube (detector). Additionally, 
RTLC instrument detects not only presence of, for example, beta particles and measure the 
resulting pulse, but also determine the position or the distribution of separated radioactive 
substances on a developed TLC plate. RTLC mainly comprises of ionization tube in which a 
positively charged counting wire (anode) and a ground wire (cathode) are involved. For 
amplification of the signals, a sufficiently high voltage is applied between the electrodes (900-
1800 V). Additionally, insulating counting gas consisting of 10 % methane and 90 % argon is 
allowed to flow constantly through the tube as a purge gas. This mixture is preferred because 
it is nearly non-flammable and allows the counter to operate at lower voltage than with 
methane alone (3000 V). In the standby mode, the potential difference between the 
electrodes is considered to be constant and hence stable base line is obtained. On the other 
hand, when a 14C-radioactive substance, present on a TLC plate, is placed parallel to the 
counter tube, the gas molecules are bombarded with beta particles leading to ionization of 
their atoms. As a result, free electrons and positive ions are formed. This process is known 
as a primary ionization process. According to their polarity, the charged particles are 
accelerated towards the anode and the cathode. In their way towards the anode, the 
electrons move with increasing speed and gain more and more energy. These electrons 
cause further ionization to the other gas atoms leading to formation of further electrons and 
positive ions. This process is known as a secondary ionization process. The latter continuous 
resulting in generation of charge cascade (charge multiplication process) from the point of 
primary ionization to the anode wire. The generated charge is proportional to the ionization 
energy of the emitted beta particles. Additionally, the charge existed in the anode wire 
generates an induced charge in the cathode which is subsequently discharged in two 
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directions causing two different delay times in the normal current. The time is then passed 
through a time to digital converter and the difference between the digits determines the start 
and the stop margin (position) of the signal on the TLC plate. Afterwards, the Rf value of a 
certain radioactive substance is automatically determined. Furthermore, the intensity of 
radioactivity is given in impulses without referring to the time unit, because the time of the 
measurement depends on the amount of radioactivity spotted on the plate. The identification 
of substances is made through the comparison of their Rf
 
 values with reference standards 
developed on the same plate.  
3.8 GC/MS experiments 
3.8.1 Detection of diclofenac after derivatization 
Due to low vapor pressures and polarity, the carboxylic group of diclofenac should be 
converted to the ester derivate in order to improve its volatility and the thermal stability for 
more sensitive GC/MS detection [El Haj et al., 1999, Antonic and Heath, 2007]. Although 
diazomethane was frequently used in derivatization of diclofenac, it was excluded in the 
present study due to its high toxicity and low stability. Alternatively, pentafluorobenzyl 
bromide (PFBBr; obtained from Sigma-Aldrich, Deisenhofen, Germany) was used. The 
derivatization process was applied according to Moeder et al. (2007). After addition of 50 µL 
of 10 % anhydrous K2CO3
 
 to 1 mL diclofenac standard in acetone (15 ng/µL), 20 µL of 5 % 
PFBBr were added and the reaction mixture was heated for 4 h at 60 °C. After cooling, the 
reaction mixture was evaporated up to dryness. The residues containing diclofenac 
pentafluorobenzyl ester were then dissolved in 5 mL of n-hexane. The excess of the reagent 
was removed by addition of 10 mL of pure water and shaken at least for 1 min. Afterwards, 
the organic layer was separated, dried with anhydrous sodium sulphate, decanted, reduced 
to 1 mL and stored at -20 °C until GC/MS analysis. 
3.8.2 Detection of diclofenac without derivatization 
Different concentrations (1-10 ng/µL) of diclofenac standard solutions were prepared in 
acetone or ethyl acetate and then directly injected into GC/MS to check the thermal behavior 
of diclofenac. 
 
3.8.3 Detection of phototransformation products of diclofenac  
In order to determine the structure of the phototransformation products of diclofenac in water, 
500 mL of pure water were placed in the sample container of the irradiation apparatus and 
fortified with 5 mL of aqueous diclofenac standard solution (10 ng/µL). The container was 
then incubated under the irradiation apparatus at 20 ± 2 °C for 5 h. A-100 mL water sample 
was taken every hour, liquid-liquid extracted (cf. 3.8.4) and then analyzed for diclofenac and 
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its phototransformation products. The same procedure was repeated for three days (10 
light/14 dark) using 300 mL pure water and 3 mL of aqueous diclofenac standard solution (10 
ng/µL). A 100-mL water sample was taken every day and analyzed before and after 
derivatization, by means of GC/MS. The samples were collected in such intervals because 
the transformation rate of diclofenac was unknown. 
 
3.8.4 Liquid-liquid extraction  
After transferring water samples into a separating funnels, diclofenac and its 
phototransformation products were extracted five times with 30 mL ethyl acetate each. Prior 
extraction, 2 g sodium chloride were added to improve phase separation. Subsequently, the 
extracts were pooled. Samples analyzed by GC/MS were filtrated and dried over 25 g 
anhydrous sodium sulphate [Bartels and von Tuempling Jr., 2007]. The filtrated extracts were 
evaporated to 1 mL. The extracts were then stored in brown glass vials and stored at -20 °C 
until analysis.  
 
For quality assurance, the liquid-liquid extraction procedure was preliminarily tested by 
different techniques. For radiotracer analysis, 14
 
C-diclofenac was spiked in 100 mL water at a 
radioactivity level of 0.35 MBq/L. For GC/MS and LC/MS/MS, 100 mL water samples were 
fortified with diclofenac at the concentration level of 0.1 mg/L. For HPLC/UVD, 100 mL water 
samples were spiked at the concentration level of 1 mg/L. The recoveries calculated after 
radiotracer, GC/MS, HPLC/UVD and LC/MS/MS analysis were 94 ± 2 %, 89 ± 1 %, 92 ± 2 % 
and 89 ± 1 %, respectively [Appendix, Table A2-A5].  
3.8.5 GC/MS Instrumentation 
GC/MS operation system 
GC/MS determination was performed using a Shimadzu (GC-17A) gas chromatograph 
equipped with Shimadzu AOC-20i programmable auto injector. The gas chromatograph was 
coupled to a Shimadzu QP 5050A (Shimadzu, Kyoto, Japan) mass selective detector (MSD). 
The ionization was done in electron impact mode (EI) with electron energy of 70 eV. In case 
of identification purposes, the mass spectrometer was operated in full scan mode at the 
mass of range 60 - 600 amu and, in case of quantitation of diclofenac and diclofenac 
pentafluorobenzyl ester it was operated in a single ion monitoring mode (SIM). The 1-μL 
aliquots were injected into the split/splitless injector port (250-280 °C). A DB-5 MS fused 
silica capillary column with 30 m length, 0.25 μm film thickness and 0.25 mm inner diameter 
was used (J&W Scientific, Folsom, CA, USA). The GC oven temperature program started at 
60 °C, held for 2 min and was then increased to 300 °C with a rate of 10 °C/min. This final 
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temperature was held for 20 min. The transfer line temperature was maintained at 300 °C 
and the carrier gas flow rate of helium was 1 mL/min.  
GC/MS principles  
GC/MS is an instrument that combines the advantages of gas chromatography and mass 
spectrometry. It is a powerful widely used tool for the separation, identification and/or 
quantitation of a mixture of substances. GC/MS is generally consists of an injection port, 
column and a MS detector. It is designed to measure the substances when they are in the 
gas phase. Therefore, a solvent containing mixture of substances is introduced, by means of 
micro syringe, to a very hot chamber known as the injection port. As a result, flash 
evaporation occurs transferring the substances from the liquid into the gas phase. During this 
process, however, the substances undergo thermal stress. Hence, GC is preferably used for 
the analysis of less polar and thermal stable analytes. Afterwards, by means of inert carrier 
gas (mobile phase) such as helium, the vaporized substances are introduced to a very long, 
narrow and temperature controlled column known as the capillary column. The inner wall of 
the column is covered with a thin film known as the stationary phase. According to their 
polarity and boiling point, the substances are separated depending on their affinity to the 
mobile or the stationary phase. As the separated substances emerge from the column 
opening, they enter into the MS unit through the transfer line. There, the substance is ionized 
and the generated ions are separated according to their mass to charge ratio. Among 
ionization techniques, electron impact ionization is considered the most common and 
perhaps the standard form of ionization. The large amount of structural information is yielded 
by the full scan mass spectra obtained under electron impact (EI) ionization and the 
possibility of using commercial libraries, making screening and identification of unknowns 
feasible, are the most two important advantages of GC/MS technique. 
 
3.9 HPLC experiments 
3.9.1 14
Because the irradiation period mentioned under 3.7.2 was found to be too long to detect any 
phototransformation products of diclofenac, additional irradiation experiments were 
conducted to get an idea about their nature. Additionally, labeled and unlabeled diclofenac 
were mixed together in order to enhance the concentration of labeled diclofenac. Therefore, 
irradiated samples can be also analyzed by means of HPLC. For this purpose, 500 mL of 
pure water was fortified with 500 µL unlabeled aqueous diclofenac standard solution (1 
µg/µL) and 150 µL of labeled diclofenac (925 Bq/µL) in the sample container of the irradiation 
apparatus. The container was then fixed tightly into the irradiation apparatus and kept at 20 ± 
2 °C for different irradiation intervals (1-5 h).  
C-diclofenac irradiation tests 
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During the incubation time, a 100-mL water sample was removed every hour for HPLC/UVD 
and radiotracer analysis. Afterwards, the water phases were liquid-liquid extracted by means 
of ethyl acetate (cf. 3.8.4). For the setup of mass balances, the radioactivity was then 
measured in the water phases remained after liquid-liquid extraction and in the ethyl acetate 
extracts before and after rotary evaporation. Additionally, the evaporated extracts were 
screened for diclofenac and its transformation products (cf. 3.7.8). The partitioning behavior 
for diclofenac and its phototransformation products were indicated by the determination of 
the extraction efficiency of ethyl acetate for the radiotracer residue after each irradiation 
interval. For HPLC analysis, the ethyl acetate extracts were reconstituted in 1 mL methanol 
to be suitable for the HPLC system. For quality assurance, the solvent exchange step from 
ethyl acetate to methanol was preliminary tested by means of HPLC/UVD. The recoveries 
were found to be 100 ± 2 % [Appendix, Table A6]. As a second extraction step, the water 
remained after liquid-liquid extraction process was subjected to SPE (cf. 3.7.7). Afterwards, 
the eluted analytes were screened by the HPLC for presence of phototransformation 
products of higher polarity that could not be extracted by means of ethyl acetate. 
 
3.9.2 Unlabeled diclofenac irradiation tests 
The unlabeled test was performed almost the same as the radiotracer test (cf. 3.9.1). In 
contrast, the whole irradiation time was prolonged to be 10 h instead of 5 h aiming to 
transform diclofenac completely, sampling was performed every 2 h instead of 1 h. 
 
3.9.3 HPLC Instrumentation 
The HPLC analysis was performed using Hewlett Packard 1050 Series HPLC-system 
(Hewlett Packard, Waldbronn, Germany) which consisted of injector, pump and variable 
wavelength UV detector. Diclofenac and its phototransformation products were separated in 
a 250 mm x 4 mm LIChrospher®
 
 100 RP-18 column (5 µm) (Agilent Technologies GmbH; 
Waldbronn, Germany). As a confirmative step, two different isocratic mobile phases, 
degassed by helium, were used. The first consisted of methanol/water/phosphoric acid 
(70:30:0.1 v/v/v) and the second consisted of acetonitrile/water/formic acid (50:50:0.1 v/v/v). 
The flow rate was 1 mL/min. An injection volume of 25 µL was used for all samples. Column 
temperature was 28 °C. The quantitation of diclofenac was performed at λ = 280 nm, while 
the phototransformation products were detected at λ = 254 nm. 
Later on, the absorption spectrum of diclofenac and its phototransformation products were 
obtained using HPLC/DAD. For this purpose, an Agilent 1100 series HPLC-system (Agilent 
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Technologies, Waldbronn, Germany) equipped with a binary pump, column thermostat, 
thermostated autosampler and DAD detector was used. The mobile phase consisted of 
acetonitrile/water/formic acid (50:50:0.1 v/v/v) was used at a constant flow of 1.0 mL/min. 
The previously mentioned column was kept at a constant temperature of 20 °C. The volume 
of injection was adjusted at 20 μL and the vials were kept at 10 °C in the autosampler. The 
absorption spectra were recorded in a wavelength ranging from 200 to 400 nm. 
 
HPLC principles  
High performance liquid chromatography (HPLC) is an analytical technique used for 
separation of mixture, identification and/or quantitation of organic and inorganic compounds. 
The instrument comprises of mobile phase reservoirs, pump, injector loop or autosampler, 
sample valve, column, detector and data analysis system. Analytes to be analyzed should be 
dissolved in HPLC compatible solvents. By means of the injector, a small volume of this 
solvent is introduced to the stream of mobile phase. The latter is forced under high pressure 
by the action of the pump into the stationary phase of the column. As they travel through the 
column, the analytes are interacted with the stationary phase and separated according to 
their number of interactions or their affinity for partitioning between the mobile and the 
stationary phase. Afterwards, the separated analytes reach to the detector to be recorded at 
certain time known as retention time. The retention time under particular conditions is 
considered a unique identifying characteristic of a given analyte. 
 
3.10 LC/MS/MS experiments 
3.10.1 Pure water tests 
For structural identification of phototransformation products of diclofenac an additional 
irradiation experiment was preformed in which the samples were prepared exactly as 
mentioned under 3.9.2 with an exception that they were diluted before analysis by LC/MS 
water in ratios of 50:50 (v/v). 
 
3.10.2 Water/sediment tests 
Irradiation experiments 
For structural elucidation of phototransformation products of diclofenac in water/sediment 
systems, an additional irradiation experiment was preformed in which the system was 
equilibrated and, extracted as mentioned under 3.6.1 with the following exceptions. Only one 
sediment type was used (S3), the fortification level of diclofenac was 500 µL (1 µg/µL), the 
irradiation period was 5 h instead of 3 days, the water phase was extracted by means of 
liquid-liquid extraction instead of SPE, and the14C-carbon dioxide trap was not analyzed for 
determination of mineralization rate. The other exception was the handling of the ethyl 
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acetate extracts of both water and sediment compartments. These extracts have to be 
carefully cleaned before LC/MS/MS analysis. For this purpose, the extracts of water and 
sediment samples were evaporated to 1 mL, then dried under a gentle nitrogen stream and 
reconstituted in a final volume of 5 mL by adding ethyl acetate/cyclohexane (50:50 v/v). If 
necessary, the extracts were then stored at - 20 °C until the clean up steps. 
 
Dark experiments 
For structural elucidation of biotransformation products of diclofenac in water/sediment 
systems, another dark experiment was conducted by the same way as mentioned for the 
irradiation experiments with only one exception that the flasks were stoppered and incubated 
in the dark at 20 ± 2 ºC for 7 days. The air above the water phase was exchanged after 4 
days to maintain aerobic conditions. 
 
3.10.3 GPC clean up 
The Gilson GPC unit (Middleton, UAS) consisted of isocratic HPLC-pump model 302, auto-
sampler injector model 231, dilutor model 401, fraction collector model 201, and glass 
chromatographic column filled with 38-39 cm of bio-beads S-X8 (dimensions: 59 cm length, 
2.9 cm inner diameter). The eluent was a mixture of ethyl acetate and cyclohexane (50:50 % 
v/v). The flow rate was set at 5.0 mL/min and the injection volume was 4.0 mL. The elution 
was programmed as 23 min waste, then 12 min analyte fraction containing diclofenac and its 
phototransformation products, and finally 10 min rinsing. Prior GPC clean up, the extract was 
micro-filtered using PTFE syringe filter. The 4-mL aliquots were injected into the GPC 
apparatus. The fractions were separated as 0-115 mL, 115-175 mL and 175-225 mL for the 
forerun, analyte, and tailing fractions, respectively. The analyte fractions were rotary 
evaporated to 1 mL then to dryness under a gentle nitrogen stream. Afterwards, the residues 
were recomposed to a final volume of 2 mL in methanol. The extracts were stored in amber 
vials and stored at - 20 °C until chromatographic analyses. Before LC/MS/MS analysis, the 
extracts were diluted 10 times with LC/MS water/methanol (50:50 v/v) to avoid saturation of 
the quadrupole and to meat the calibration curve. For quality assurance, the clean up 
procedure was preliminary tested by means of HPLC/UVD. The recoveries were found to be 
97 ± 5 % [Appendix, Table A7]. 
 
3.10.4 Alumina column clean up 
Preliminary, a second clean up step was tested aiming to get cleaner sediment extracts. For 
this reason, another irradiation experiment was conducted and after the GPC clean up step, 
the extracts were still coloured green. Therefore, alumina column for clean up of polar 
compounds was tried according to Batarseh (2003). A chromatographic column (2 cm i.d. x 
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30 cm) was plugged with a piece of glass wool, and packed with 10 g alumina (90 neutral, 
70-230 mesh; Merck, Darmstadt, Germany) previously activated at 220 °C over night, 
deactivated with 12.5 % water and shaken for at least 4 hours using a horizontal shaker. The 
sediment extracts were transferred to the alumina column and then eluted with 5 mL ethyl 
acetate followed by 100 mL of methanol/ammonia mixture (99:1 v/v). The eluent was then 
rotary evaporated to 2 mL and then analyzed. 
 
3.10.5 LC/MS/MS Instrumentation 
LC/MS/MS principles 
 
The identification and structural elucidation of unknowns are a challenging task. Therefore, 
LC/MS/MS/ESI QTRAP was selected for identification of the phototransformation products of 
diclofenac. It mainly comprises of HPLC, ion source, mass analyzer and detector [Figure 
13].  
 
 
 
Figure 13:  LC/MS/MS/ESI QTRAP (AB Sciex, Ontario, Canada)  instrument showing 
the mechanism by which ions are formed in the Turbo VTM
 
 ESI ion 
source before entring the MS/MS region 
Ion source 
Among the atmospheric pressure ionization (API) techniques, in which the formation of ions 
occur at the atmospheric pressure, electrospray ionization (ESI) and atmospheric chemical 
ionization (APCI) are considered the most commonly used in LC/MS/MS analyses. Both are 
sensitive and soft ionization modes that produce positive or negative ions from polar 
substances introduced as a stream of the HPLC eluent through a needle. In case of ESI, the 
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ionization occurs in the liquid phase by the application of high electric fields to the needle. 
From the liquid phase, spray of charged droplets is then formed by the aid of a nebulizer gas. 
As the solvent evaporates by means of a vaporizer gas, the droplets shrink and the repulsion 
forces between the charged ions increase. Subsequently, the droplets become unstable and 
hence dissociate into smaller droplets. This process is repeated several times resulting in 
separation of the ions from the surface (due to the high repulsion force) or explosion of the 
droplets. In both cases, gas phase ions are produced. In case of APCI, gas phase molecules 
are produced by means of heater at the LC/MS/MS interface. Afterwards, the chemical 
ionization occurs in plasma created by corona needle discharge. Due to the volatilization 
before ionization, APCI is limited to smaller molecules than ESI which is more sensitive, 
softer, and applicable for a wide range of substances especially the thermolabile ones. 
However, APCI has the advantage of being less influenced by sample matrix effects. 
Alternatively, atmospheric pressure photoionization in which ionization occurs by a xenon 
lamp instead of a corona discharge needle is considered the third type of API but less 
applicable.  
 
Mass Analyzer 
The vacuum region of the mass spectrometer is separated from the spray by a capillary 
orifice. Via this orifice [Figure 13], precursor ions enter into Q0  region in presence of the 
curtain gas which is responsible for the declustering of the ions and protection of the curtain 
plate from striking by these ions. At Q0 region, fragmentation can be induced and controlled 
by the declustering potential. Additionally, ions can be accumulated in Q0 region in order to 
enhance their concentration before entring Q1 region to be scanned. Afterwards, ions can be 
introduced to Q2 region (collision cell). There, it can be additionally fragmented by means of 
an inert gas (collision gas) in order to produce characteristic fragment ions (product ions). 
The degree of fragmentation is directly proportional to the pressure of the collision gas and 
the collision energy. After fragmentation, product ions enter Q3 region to be scanned. Before 
scanning, Q3
 
 can optionally be used as a linear ion trap (LIT) mass spectrometer in order to 
enhance the sensitivity by the trapping of ions. 
In the literature, several advantages have been reported for LC/MS/MS to be widely 
accepted as a main tool in the structural elucidation purposes [Abdel-Hamid et al., 2001, 
Ahrer et al. 2001, Jansen et al., 2005, Fatta et al., 2007, Chen et al., 2008]: 
1- In contrast to GC/MS, it has high capability for analyzing very polar, less volatile, 
thermolabile compounds in shorter run time without a need for derivatization using 
highly toxic and carcinogenic derivatization reagents such as diazomethane.  
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2- In comparison with single MS, tandem MS provides more selectivity and sensitivity in 
complicated matrices because it is associated with higher and more stable signal to 
noise ratios as a result of the specific fragmentations of the isolated precursor ions 
and the elimination selectivity of the background noise. Additionally, complete 
chromatographic resolution of analytes, with the same molecular mass, is not a real 
problem as long as the overlapping analytes have different product ions.  
3- Hybrid QTRAP mass analyzers combine both high selective triple quadrupole (QqQ) 
scan functions and high sensitive LIT scan functions in a single instrument. In the 
past, a sample had to be analyzed with two different instruments (QqQ and a 3D ion 
trap) to obtain similar information. Additionally, the trapping capacity and the ion path 
length of the LIT systems are 70 and 30 times, respectively, higher than the 3D 
systems leading to much higher sensitivity.  
4- Compared to LC/TOF/MS, QqQ is more applicable in quantitative purposes as it 
provides a higher effective linear dynamic range. 
5- Several scans can be performed in the QqQ mode such as:  
a)   Q1 or Q3 scan: A single full MS scan in which the first (Q1) or the third (Q3) 
quadrupole search in a particular mass range for all ions.  
      b)   Product ion scan (PI): An MS/MS full scan in which the Q1 is fixed to transmit a 
certain precursor (mother) ion and, after fragmentation in Q2, the Q3 searches in a 
particular mass range for all product (daughter) ions generated by the precursor ion. 
      c)   Precursor ion scan (Prec): An MS/MS full scan in which the Q3 is fixed to detect a 
certain product ion after fragmentation in Q2, and the Q1 searches in a particular 
mass range for all precursor ions generating the specified product ion. 
      d)   Multiple reactions monitoring (MRM) scan: An MS/MS full scan in which Q1 is 
fixed to transmit a certain precursor ion and, after fragmentation in Q2, Q3 is fixed to 
detect a certain product ion generated from the precursor ion.  
6- LIT offers some extra scans such as: 
a)   Enhanced MS (EMS): A single full MS scan in which ions are transferred directly 
to Q3, trapped for a certain time to enhance the concentration and finally scanned in 
a particular mass range for all ions.  
      b)   Enhanced product ion scan (EPI): An MS/MS full scan in which the Q1 is fixed to 
transmit a certain precursor ion and, after fragmentation in Q2, the product ions are 
trapped for a certain time in Q3 to enhance the concentration and finally scanned in 
a particular mass range for all ions generated by the precursor ion. 
7- Presence of the built-in information dependent acquisition (IDA) software allows 
combinations of two different scans, i.e. EMS and EPI, in the same run providing 
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maximum information by fewest numbers of injections. Hence, rapid identification and 
confirmation of unknowns could be obtained. In the IDA, the first and the second scan 
are known as survey and dependent scan, respectively. The instrument is allowed to 
switch to the dependent scan when the predefined criteria (such as ion intensities or 
threshold) are acquired during the survey scan. Finally, after a short time, the 
instrument is switched back to the initial conditions. 
The selected scan modes used in the present study and their applications are shown in 
Table 6.  
 
Table 6: Scan modes selected for the present study 
 
 Q1 function 
Q2 
function 
Q3 
function 
Scan 
type Application 
 
------ ------ 
Trap&Scan 
all ions 
EMS 
Confirm 
presence of 
known ions 
 
Fixed ion 
Fragmen-
tation 
Trap&Scan 
all ions 
EPI 
Identification 
of fragments Unknown 
ion 
IDA EMS-EPI 
 
Scan 
all ions 
Fragmen-
tation Fixed ion Prec 
Identification 
of precursors 
 
Fixed ion Fragmen-tation Fixed ion  MRM 
Quantifcation 
of analytes  
 
On the other hand some disadvantages have been reported for LC/MS/MS [King et al., 2000, 
Buchberger, 2007] 
1- In the form of signal suppression, the ionization modes used in LC/MS/MS such as 
ESI are more influenced by the matrix components, eluting at the same time with the 
analytes, than the ionization modes used in GC/MS such as EI or CI. However, this 
problem was avoided in the present study by means of dilution. Gomez et al. (2006) 
reported signal suppression of 62 % and 7 % for diclofenac in spiked hospital effluent 
wastewater before and after dilution (1:2), respectively. 
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2- The mass accuracy of QqQ is lower than TOF mass analyzer. 
3- In comparison to 3D, multiple ion transitions MSn
 
 is not possible in case of          
QTRAP mass analyzer. 
Method description 
The 4000 QTRAP LC/MS/MS system consisted of an Agilent 1200 series liquid 
chromatograph including a vacuum degasser, a binary pump, and an high performance 
autosampler (Agilent Technologies, Waldbronn, Germany) coupled to an Applied 
Biosystems/MSD SCIEX 4000 QTRAP tandem mass spectrometer equipped with an 
electrospray ionization interface, Turbo VTM
 
 source, (Applied Biosystems GmbH, Darmstadt, 
Germany). The LC/MS/MS system was controlled by Analyst software (version 1.4.2 Applied 
Biosystems) with a built-in information depending acquisition scan function. 
The electrospray ionization interface operated in negative ion mode [M-H]-. Diclofenac and its 
phototransformation products were separated on a Gemini 110A C18
 
 reversed-phase column 
(150 mm × 3 mm i.d., 5 µm particle size; Phenomenex, Aschaffenburg, Germany). 
Acetonitrile/0.5 % formic acid (aq.) [50:50 (v/v)] was used as the mobile phase in the isocratic 
mode. The flow rate was 0.3 mL/min. The injection volume was 20 µL.  
The compound dependent (ion optics) parameters were automatically optimized by infusion 
method (continuous injection of diclofenac standard solution into the MS/MS directly) using 
an external pump. The optimal values for the declustering potential (DP), entrance potential 
(EP), collision cell energy (CE), and collision cell exit potential (CXP) were - 40, - 10, - 16, 
and - 11 V, respectively. The collision affected dissociation gas (CAD) was adjusted at high 
pressure. On the other hand, the ion source parameters were automatically optimized by flow 
injection analysis (FIA) method. Nitrogen was used as curtain gas (CUR), nebulizer gas 
(Gas1), vaporizer or auxiliary gas (Gas 2), at 20.7 x 104, 34.5 x 104, 34.5 x 104
 
 Pa, 
respectively. The ion spray voltage (IS) was - 4 kV. The interface heater (ihe) was 100 °C 
and the turbo gas temperature (TEM) was optimized manually at vaporization temperature of 
200 °C.  
The parameters were optimized using diclofenac standard solution for [M-H]- (294 m/z) since 
the other phototransformation products are not available as standard solutions. The 
identification of the unknown phototransformation products of diclofenac was carried out 
using information depending acquisition (IDA) experiments which allow combination of two 
different scan types in the same run. Therefore, enhanced full mass scan (EMS) was used 
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as a survey scan (mass range m/z 100–500, scan time 0.4 s, scan rate 1000 amu/s, trap 
time 20 ms) and the enhanced product ion scan (EPI) was used as dependent scan. The IDA 
was established to record the most abundant product ion of the ions that exceed 15 x 104
 
 
counts in the scan range of m/z 100–500. Precursor ion scan (Prec) was applied after that for 
identification of the precursor ions of m/z 250, 214, 196 and 185 (mass range m/z 150–400, 
scan time 3 s, scan rate 83 amu/s). Quantitation for diclofenac was performed by multiple 
reaction monitoring mode (MRM) for the deprotonated precursor ion (m/z 294) and its related 
product ion (m/z 250) using the external standard method. Quadrupoles Q1 and Q3 were set 
at unit resolution. 
For quality assurance, blanks were carried out to check for interference and contamination 
during the GC/MS, HPLC and LC/MS/MS experiments. Most of the samples were prepared 
in duplicate and the measurements were performed two times. Linear regression analysis 
was used in the quantitation of the diclofenac. The quantitation was based on direct peak 
area measurements that were automatically computed using external calibration standards. 
The external calibration curves were prepared by plotting the total peak areas of diclofenac 
versus the concentrations. The linearity was accepted when the regression coefficients were 
≥ 0.995 and the slopes were consistent with the measured peak areas. The complete 
calibration curve parameters are listed in Appendix, Table A8. However, due to the lack of 
authentic reference standards, concentrations of transformation products were expressed as 
peak areas. Additionally, the stability of the diclofenac under the storage conditions was 
continuously checked by comparing previously used calibration series with freshly prepared 
ones. 
 
3.11 NMR experiments 
For structural confirmation and quantitation purposes, large amount of the most abundant 
phototransformation product of diclofenac, namely 8-chloro-9H-carbazole-1-acetic acid, was 
tried to be obtained in pure form through chromatographic isolation.  
 
3.11.1 Sample preparation 
Diclofenac (1 g) was dissolved in 200 mL water and then irradiated for 5 h. Longer irradiation 
time was avoided because phototransformation products may be as photosensitive as 
diclofenac. The water phase was then liquid-liquid extracted as mentioned before using ethyl 
acetate 20 x 50 mL. Afterwards, the extract was rotary evaporated to dryness at 40 °C and 
the residues were then dissolved in 20 mL methanol. Preliminary, the effect of irradiation 
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time and the amount of diclofenac initially applied on the transformation processes were 
tested.  
 
3.11.2 Isolation by column chromatography 
For fractionation, the methanolic solution was transferred to a preparative reversed-phase 
chromatographic column (35 cm length, 4 cm inner diameter, Lichroprep C18
 
, particle size 
40-63 μm; Merck, Darmstadt, Germany). Acetonitrile/water/formic acid (50:50:0.1 v/v/v) was 
used as a mobile phase under low pressure. Previously, the column was conditioned with 1 L 
of the same mobile phase. The eluent was then collected in several fractions: 2 x 75 mL 
flasks and 70 x 20 mL tubes. During fractionation, rapid tests by means of reversed -phase 
thin layer chromatography were carried out to check for the separation capacity. Fractions 
containing mainly the target compound were combined, rotary evaporated to dryness under 
reduced pressure at 40 °C and the residues were then dissolved in 5 mL methanol for 
additional purification. 
3.11.3 Purification by semi-preparative HPLC 
For further separation, a semi-preparative HPLC (Merck, Darmstadt, Germany) was used. It 
consists a of Merck-Hitachi L-6200 intelligent pump equipped with Merck-Hitachi L-4200 
UV/VIS detector set to λ = 254 nm, 0.1 mL injection loop and Luna C18 column (250 mm x 
10 mm, 5 μm particles; Phenomenex, Aschaffenburg, Germany). The solvent system was A: 
water with 0.1 % formic acid and B: acetonitrile/water/formic acid (50:50:0.1, v/v/v). The 
gradient was programmed as shown in Table 7. The flow rate was 4.6 mL/min. Within the 5-
min post-run period, the initial conditions were adjusted again. A 0.1-mL volume of the last 
methanolic solution was injected successively into the semi-preparative HPLC system. 
Phototransformation product 1 was collected manually during numerous runs. The purity of 
the isolated phototransformation product 1 solutions was determined by analytical HPLC as 
described before. After removal of the pooled mobile phase by rotary evaporation under 
reduced pressure at 40 °C, the residue was dissolved in deuterated methanol (CD3OD) for 
1H- and 13
 
C-NMR analysis. 
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Table 7: HPLC gradient for purification of 8-chloro-9H-carbazole-1-acetic acid  
 
Time (min) 
A % 
Acetonitrile/water/formic acid 
(50:50:0.1, v/v/v) 
B % 
0.1 formic acid aqu. 
C% 
Acetonitrile 
0 40 60 0 
20 100 0 0 
30 100 0 0 
30.1 0 0 100 
35 0 0 100 
40 40 60 0 
 
 
3.11.4 NMR instrumentation 
NMR spectra were recorded by means of a Bruker Avance II 600 spectrometer equipped 
with a CP-TCI-z cryoprobe (Bruker BioSpin, Rheinstetten, Germany) at 600 MHz (1H) and 
150 MHz (13C). The solvent used was deuterated methanol (CD3OD). Internal chemical shift 
references were tetramethylsilane (TMS) for the 1H spectra (δ = 0.00 ppm) and the solvent 
peak for the 13C spectra (δ = 77.01 ppm). Two-dimensional H,C-hsqc and H,C-hmbc spectra 
were recorded using standard Bruker pulse programs. Sweep widths and pulse delays were 
optimized for the sample under investigation. The 1
 
H-NMR spectrum was simulated by using 
Bruker’s WinDAISY program [Ernst, 2009]. 
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4. Results and discussion 
In this chapter, the results of the experiments are displayed, explained and compared with 
other published data, if found. These experiments were focused mainly on sorption and 
desorption behavior of diclofenac at different concentration levels, biotransformation and 
phototransformation fate of diclofenac in water/sediment systems with different experimental 
design, identification of phototransformation products of diclofenac and isolation of the most 
abundant one. 
 
4.1 Sorption/desorption behavior of diclofenac in sandy loam sediment 
In order to describe the affinity of diclofenac to sediments, sorption and desorption 
experiments were performed. By means of these experiments, mobility, leaching tendency 
and remobilization of diclofenac can be estimated. Based on the concentration decrease in 
the aqueous phase (indirect method), sorption coefficients (Kd) of diclofenac onto sandy 
loam sediment (S3) were calculated. The results showed Kd of 5.5 ± 0.8 [Table 8]. The 
complete data set are listed in Appendix, Table A9. The accuracy of the results was tested 
by multiplying the Kd values with the sediment/solution ratio which were found to be > 0.3 
L/kg. Therefore, the estimated Kd values based on the current indirect method were 
considered to be accurate and there was no need to analyze the sediment phase. The latter 
is recommended to be analyzed as well, when the Kd
 
 value or the result of its multiplication 
with the sediment/solution ratio is < 0.3 L/kg [OECD, 2002b]. 
The estimated Kd value revealed that diclofenac could be considered as a slightly mobile 
pharmaceutical compound. Only pharmaceuticals with Kd ≤  1 L/kg are considered to be 
quantitatively mobile. Therefore, leaching tendency of diclofenac could be expected to some 
extend through the sediment under investigation. Since concrete leaching potential 
standards of pharmaceuticals in sediments have not been set yet, alternatively, the leaching 
potential criteria of pesticides through the soil can be temporarily used for predicting the 
transport of diclofenac. Enhanced leaching potential of pesticides in soil were defined by Kd 
< 5,  Koc
 
 < 300, water solubility >30 mg/L, half life in soil >14 days, and half life in water >175 
days [Fichter and Holden, 1992]. 
Additionally, it is well known that the texture of the sorbent material extremely affects the 
sorption process. In batch experiments using sandy sediment, the Kd values of diclofenac 
reported by Scheytt et al. (2005a) were in the range of 0.6 to 4.7 L/kg. In silty sand and 
clayey silt soil, Kreuzig et al. (2003) reported Kd values of 4 and 10 L/kg, respectively. In soil 
leaching experiment, Drillia et al. (2003) observed no recovery of diclofenac in the leachate 
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due to the strong sorption of diclofenac onto the soil. However, depending on other 
conducted laboratory soil column experiments [Mersmann et al., 2002, Scheytt et al., 2004] 
higher mobility of diclofenac under natural aquifer conditions than calculated from 
octanol/water partition coefficients was expected. In any case, the present experiments 
indicate that even for the sediments with low organic carbon sorption of negatively charged 
substances (polar) is considered a relevant process. 
 
Table 8: Distribution coefficient Kd
 
 and Freundlich parameters 
 Kd K (L/kg) F (µg1-1/n L1/n 1/n /kg) R2 
Sorption   5.5 ± 0.8   7.5 ± 1.0 0.92 0.99 
Desorption 13.3 ± 3.0 15.8 ± 1.0 0.90 0.90 
 
 
In order to study the sorption behavior of diclofenac in more depth, sorption isotherm was 
constructed at constant temperature. There are mainly two common models describing the 
sorption processes i.e., Freundlich isotherms which originally derived for describing the 
adsorption of gas molecules on the solid surface and Langmuir isotherms which originally 
derived for describing the adsorption of gas molecules forming monolayer on the surface of 
solid. These models are traditionally and successfully used for describing the adsorption of 
pharmaceutical from aqueous solutions onto solids as well [Ternes et al., 2002, Scheytt et 
al., 2005a, Hajare and Pishawikar, 2006, Tella and Owalude, 2007, Ramil et al., 2010].  
 
The sorption data of diclofenac showed that the isotherms were concentration dependent 
and best fitted to the Freundlich isotherm model. The relationship of logCs against logCw is 
shown in Figure 14. From which, the Freundlich affinity constant (KF) and the exponent (1/n) 
were calculated from the intercept and slope of the generated isotherm, respectively. The 
entire Freundlich parameters are represented in Table 8. The Freundlich exponent 1/n was 
found to be close to 1.0 indicating that the sorption isotherm of 14C-diclofenac are almost 
linear which means increasing sorption affinities with increasing aqueous phase 
concentrations of 14C-diclofenac. The KF value of 7.5 ± 1 was slightly higher compared to the 
Kd values. This variation is mostly due to the value of 1/n (0.92) which is not exactly equal 
the unity. The Freundlich isotherm becomes linear when 1/n = 1. This is the simplest case of 
the Freundlich isotherm and is named the Nernst partitioning (Kd). In this case, the 
Freundlich adsorption coefficient (KF) will be equal to the distribution coefficient (Kd). 
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The KF value presented in this study differs from previous sorption experiments made by 
Ternes et al. (2002) and Scheytt et al. (2005a). For elimination of diclofenac from drinking 
water, Ternes et al. (2002) used granular activated carbon as a solid phase showing higher 
KF values ranging from 36 to 141. Compared to KF
 
 presented in the current study, lower 
values (0.57-0.81) were calculated by Scheytt et al. (2005a). Again the reason may be the 
difference in the texture of the sediments where sandy sediment was used during those 
experiments while sandy loam sediment was used in the present study. Sorption properties 
of the sediments are influenced mainly by TOC, clay, and silt content. However, substances 
not only partition into the organic matter but also a certain fraction of their molecules “sorbs” 
to the internal microvoids or holes [Stein et al., 2007]. Furthermore, sorption can be attributed 
to several different mechanisms, namely adsorption or absorption to the natural organic 
matter, interactions with mineral surfaces, bonding to several different kinds of surface 
moieties, and interactions of charged species with solids [Scheytt et al., 2005a, 
Schwarzenbach et al., 2003]. 
Since desorption processes also play an important role in the behavior of chemicals in the 
environment, the desorption coefficient (Kdes) was calculated [Table 8] and the Freundlich 
desorption isotherm was constructed [Figure 15]. The results showed that the Kdes was 13.3 
± 3 which was found to be much higher than the sorption coefficient (Kd). The complete data 
set are listed in Appendix, Table A10. The results reflected higher apparent affinity of 
diclofenac to the sediment in the desorption direction than in the sorption direction. 
Additionally, desorption percentage was found to be 20 ± 3 % indicating that 14C-diclofenac 
was irreversibly sorbed onto the sediment. Low desorption values could further limit 
diclofenac migration or mobilization in surface waters. Desorption is considered reversible 
when the amount desorbed is more than 75 % of the amount sorbed [OECD, 2002b]. The 
Freundlich desorption isotherm of diclofenac was slightly linear (1/n = 0.9) and the KF-des
 
 was 
15.8 ± 1.  
For the purposes of comparison, additionally, surface water was used as a solvent phase 
instead of CaCl2 solution. The Kd and Kdes of surface water were found to be 4.4 ± 0.6 and 
15.8 ± 1.7, respectively. These results reveal no considerable difference between CaCl2 and 
surface water as aqueous solvent phases. On the other hand, Koc
 
 (organic carbon 
normalized adsorption coefficient) was not calculated in the present study because it is only 
to some extent applicable to polar substances and not applicable with sediment of low 
organic matters content [Fränzle et al., 1987, Calvet, 1989, OECD 2002b]. 
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Figure 14: Freundlich sorption isotherms of diclofenac onto sandy loam 
sediment (S3). Cs and Cw 
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Figure 15: Freundlich desorption isotherms of diclofenac from sandy loam 
sediment (S3). Cs and Cw 
 
are the remaining adsorbed and 
desorbed aqueous concentrations, respectively 
 
 
RESULTS AND DISCUSSION 
 
 
 78 
4.2 Fate monitoring of radiotracer diclofenac in dark water/sediment systems 
In the dark, the microbial activity is considered the major cause of the disappearance of 
diclofenac from the water/sediment systems. The reason could be the biotransformation 
processes which expected to occur at the interface between water and sediment [Craven et 
al., 1986]. However, sorption onto the sediment and diffusion controlled transport could be 
other reasons. Therefore, for a better understanding, the disappearance of diclofenac can be 
differentiated into mineralization, formation of transformation products either in the aqueous 
phase or in the extractable residues (ER) and formation of non-extractable (NER) or bound 
residues. The boundary conditions, in which the degradation processes occurred, were 
obtained through characterization of the used water and sediments matrices at the 
termination of each incubation interval. 
 
4.2.1 Matrix characterization 
In both sediments (S1 and S2) as well as in both laboratory test systems, i.e., batch system 
and the biometric flask equipped with soda lime trap system, the physico-chemical 
parameters such as pH and the redox potential of water and sediments, the oxygen 
concentration in the water phase and TOC in the sediments generally displayed no 
considerable variations at the beginning and at the end of the study [Table 9, 10]. Directly 
after sampling, both water and sediments were found to be slightly alkaline. The pH values of 
the water, S1 and S2 were 8.3, 7.4, and 7.3, respectively. These values remained nearly 
constant until the end of the dark experiment. During the study period, aerobic conditions 
were indicated by the Eh and O2 content values which were almost higher than 150 mV and 
2 mg/L, respectively. However, Eh < 150 mV were observed at the end of some incubation 
intervals. This observation could be caused by interferences of the electrode measurement in 
suspended matter [Kreuzig et al., 2007]. Particularly for the biometric flasks with soda lime, 
applied under continuous gas exchange, Eh < 150 mV is not realistic. Additionally, the TOC 
values of both sediments were found to be relatively low. The sediments were found to be 
microbially active as indicated by their SIR values that were between 1.0-1.9 mg O2/100 g h 
and 1.2-3.4 mg O2
 
/100 g h for S1 and S2, respectively, during the course of the experiments. 
As shown from the control samples, the organic solvent used in the fortification of the test 
substance had no effect on the microbial activity of both sediments within the study period. 
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Table 9: Physico-chemical parameters of water/sediment WS1 systems used in 
transformation test of diclofenac in the dark 
 
 Water Sediment 
 pH Eh [mV] 
O2 TOC  
[mg/L] [mg/L] pH 
Eh 
[mV] 
SIR  
[mg O2
TOC 
/100 g h] [% ds] 
AS  8.3 430 7.8 49.3 7.4 210 1.9 0.2 
BE 8.2 410 6.1 70.1 7.6 310 1.0 0.2 
d0 BS 8.3 410 4.7 --- 7.5 380 --- --- 
d1 BS 8.0 430 2.8 --- 7.6 230 --- --- 
d3 BS 7.9 420 2.4 --- 7.6 10 --- --- 
d7 BS 7.6 380 2.4 --- 7.5 30 --- --- 
d14 BS 7.7 380 3.2 --- 7.5 -30 --- --- 
d28 BS 7.6 430 3.9 --- 7.3 90 --- --- 
d56 BS 7.8 430 4.4 --- 7.1 170 --- --- 
d100 BS 7.7 420 5.1 155.5 7.2 100 1.5 0.3 
d100 BS 
Control  7.7 430 5.1 107.7 7.1 150 1.2 0.2 
d3 SLT 8.0 390 1.9 --- 7.6 -20 --- --- 
d56 SLT 8.3 400 4.4 --- 7.3 110 --- --- 
d100 SLT 8.5 440 5.1 172.2 7.8 130 1.6 0.3 
d100 SLT 
Control  8.2 470 5 114.3 7.5 200 1.3 0.2 
AS = after sampling, BE = before equilibration, BS = batch systems, SLT = flasks equipped 
with soda lime trap systems, d = day(s), ds = dry substance, --- = not determined 
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Table 10: Physico-chemical parameters of water/sediment WS2 systems used in 
transformation test of diclofenac in the dark 
 
 Water Sediment 
 pH Eh [mV] 
O
[mg/L] 
2 TOC 
[mg/L] pH 
Eh  
[mV] 
SIR  
[mg O2
TOC  
/100 g h] [%.ds] 
AS  8.3 430 7.4 67.4 7.3 220 1.9 0.4 
BE 7.8 370 6.0 90.5 7.1 270 1.2 0.4 
d0 BS 7.5 440 2.1 --- 7.1 130 --- --- 
d1 BS 7.7 420 2.2 --- 7.4 330 --- --- 
d3 BS 7.4 400 2 --- 7.1 50 --- --- 
d7 BS 7.5 390 1.7 --- 7.2 80 --- --- 
d14 BS 7.7 420 3 --- 7.1 10 --- --- 
d28 BS 7.6 420 4.3 --- 7.3 20 --- --- 
d56 BS 7.8 440 4.7 --- 7.4 170 --- --- 
d100 BS 7.8 440 5.2 240.8 7.5 200 2.1 0.5 
d100 BS 
Control  7.8 440 5.2 133.2 7.3 210 3.3 0.4 
d3 SLT 7.4 430 2.3 --- 7.2 60 --- --- 
d56 SLT 8.3 430 5.1 --- 7.6 200 --- --- 
d100 SLT 8.5 410 5.2 230.1 7.8 210 3.4 0.5 
d100 SLT 
Control  8.5 410 5.1 140.3 7.9 200 3.4 0.4 
AS = after sampling, BE = before equilibration, BS = batch systems, SLT = biometric flasks 
equipped with soda lime trap systems, d= day(s), ds = dry substance, --- = not determined 
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4.2.2 Mineralization rates 
The most efficient elimination process for every organic compound in the environment is 
complete mineralization (MIN) by microorganisms to carbon dioxide and water. In the present 
study, diclofenac showed mineralization rates of 13 ± 0.2 % and 13 ± 0.1 % of the initially 
applied radioactivity amount in case of WS1 and WS2, respectively, after 100 d incubation 
period in the batch system. Within the incubation period in the biometric flask system, 
diclofenac was mineralized to 13 ± 3.5 and 13 ± 1.8 % of the initially applied radioactivity 
amount in case of WS1 and WS2, respectively. These results indicated that mineralization of 
diclofenac to carbon dioxide and water occurred at lower amounts. 
 
It has to be noticed that the biometric flask system had an obvious disadvantage where the 
analysis of the radioactivity amounts trapped by the soda lime granules was laborious. In 
contrast, the analysis of potassium hydroxide trap solution of the batch system was much 
easier.  
 
4.2.3 Disappearance of 14
The investigation of aqueous phase (AP) of water/sediment systems is very important for 
estimation of the behavior of diclofenac. In the batch system, it was observed that the 
radioactivity disappeared out of the aqueous phase during the study period. For the WS1, the 
radioactivity decreased from 106 ± 0.5 % to 10 ± 0.6 % of the initially applied radioactivity 
amount within an incubation period of 100 days [Figure 16]. By the same way, the 
radioactivity in the water phase of WS2 decreased from 106 ± 1.5 % to 9 ± 0.2 % of the 
initially applied radioactivity amount within an incubation period of 100 days [Figure 17]. 
C-diclofenac from the aqueous phases 
 
As shown by RTLC, the biotransformation of diclofenac was started, probably at the 
water/sediment interface, without any lag period and almost completely disappeared after 28 
d and 56 d in WS1 and WS2 [Figure 18], where 1.3 % and 5.2 % could be detected as 
diclofenac, respectively. During these periods, the first solvent (n-hexane/ethyl acetate/acetic 
acid; 50:50:1 v/v/v) and the second solvent (dichloromethane/methanol/25 % ammonia; 
85:14:1 v/v/v) showed formation of several unknown biotransformation products. An example 
is given in Figure 19. The numbers of the unknowns differed according to the incubation 
interval of each sediment type [Appendix, Table A11-A14]. On the other hand, mainly one 
of these biotransformation products could be detected at the termination of the experiments 
suggesting further transformation for those products. The elimination rate constants of 
diclofenac from the water phase were calculated to be 0.07 and 0.05 per day resulting in 
DT50 of 10 and 13 d and DT90 of 34 and 42 d for WS1 and WS2, respectively.  
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It has to be noted that, the radioactivity amount regarding diclofenac in the water phase of 
WS1 (44 %) and WS2 (36 %) exhibited no change in the test samples of 7 d and 14 d as 
shown by RTLC. This observation could be an indication on the ecotoxicity of the 
biotransformation products of diclofenac due to the susceptibility of the biomass against 
these biotransformation products. As a result, the microorganisms utilizing diclofenac as the 
energy source could be inhibited. On this basis, stopping of the biotransformation process 
might be expected and after a recovery period the biotransformation process could be 
continued. Additionally, the radioactivity amounts detected in all compartments, in the WS1, 
within the incubation period of 7 d and 14 d, were found to be almost the same. The previous 
observation may refer to the close relationship between the biotransformation process and 
the formation of the non-extractable residues. The same observation has been reported by 
Kreuzig et al. (2003). They confirmed that the formation of non-extractable residues during 
the investigation of diclofenac in soil is directly depending on the microbial activity. 
 
Despite the microbial activity at the end of the experiment was found to be relatively higher in 
the WS2 sediment (2.1 and 3.4 mg O2/100 g h for batch and biometric flask systems, 
respectively) than in the WS1 (1.5 and 1.6 mg O2
 
/100 g h for batch and biometric flask 
systems, respectively), the disappearance of diclofenac from the water phase of the WS1 
was found to be faster than in the water phase of WS2 [Figure 18]. It was found that, after 
28 d 1 and 21 % of the initially applied radioactivity could be identified as diclofenac in the 
WS1 and WS2, respectively. These results showed that there was no relation between the 
total microbial activity and the biotransformation rate of diclofenac, i.e., the degradation of 
diclofenac was found to independent on the total microbial population. This observation 
might indicate that biotransformation of diclofenac is restricted to specific group(s) of 
microorganisms, an assumption which is supported by observations of Paje et al. (2002) and 
Groening et al. (2007), or it is restricted to a specific enzyme produced by certain 
microorganisms during the metabolism of another compound which might support the idea of 
the co-metabolic nature of diclofenac [Groening et al., 2007]. The latter observed that 
presence of Gram-negative bacteria, especially those belonging to the Cytophaga-
Flavobacterium group and the γ-Proteobacteria, cause an increase of diclofenac 
biotransformation. 
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Figure 16: Balances of the biotransformation test series of 14
 
C-diclofenac in 
water/sediment WS1 system using laboratory batch systems 
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Figure 17: Balances of the biotransformation test series of 14
 
C-diclofenac in 
water/sediment WS2 system using laboratory batch systems 
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Figure 18: Disappearance of 14
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Figure 19: RTLC chromatogram of 14C-diclofenac (DCF) in the water phase of the 
laboratory batch system WS1 incubated in the dark for different intervals, 
extracted by SPE and developed by first solvent (n-hexane/ethyl 
acetate/acetic acid, 50:50:1 v/v/v) 
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4.2.4 Extractable residues  
The extractable residues (ER) represent the fractions of diclofenac and/or its 
biotransformation products that could be extracted by means of an organic solvent. 
According to their polarity and eluotropic series against silica gel, methanol, acetonitrile and 
acetone are classified as polar organic solvents with elution strength of 0.73, 0.50, and 0.47, 
respectively. They are miscible with water in all ratios. In contrast, the miscibility of ethyl 
acetate (elution strength = 0.38), as a less polar organic solvent, with water is only 8.7 % 
(w/w). Basically, water miscible organic solvents are expected to exhibit higher extraction 
capacity for diclofenac from wet sediments than solvents partially miscible with water. 
However, the test of extraction efficiency showed that ethyl acetate had the highest 
extraction power (90 ± 3.5) in comparison to acetone (69 ± 4.7), acetonitrile (69 ± 3.6) and 
methanol (57 ± 2.9) as shown in Figure 20. The complete data set are listed in Appendix, 
Table A15. Additionally, ethyl acetate provides minimal disturbance for the water/sediment 
interface which considered the most important layer for biotransformation processes [Craven 
et al., 1986]. Among the tested solvents, moreover, ethyl acetate was found to be the easiest 
organic solvent in handling. Therefore, ethyl acetate was chosen as the most suitable solvent 
for the extraction process.  
 
Sorption or weakly interaction of diclofenac and its biotransformation products with the 
sediments, probably by van der Waals forces, could be the cause of the extractable fraction. 
Additionally, pore water of wet sediment could be also involved as a reason of formation of 
the extractable residues. As shown in Figure 21, two different extraction methods for 
water/sediment samples were compared for calculation of the radioactivity amounts that 
could be remained in the pore water. After separation of the water/sediment system, 
therefore, sediments were either extracted directly by ethyl acetate or rinsed with fresh water 
three times (50 mL each) before ethyl acetate extraction step. The difference between the 
radioactivity amounts detected in the ER of both methods (10 %) was equivalent to the effect 
of pore water [Appendix, Table A16]. It is obvious that during the rinsing process the 
sediment surface is completely disturbed. Such disturbance is not recommended either by 
guideline 308 [OECD, 2002a], or by Löffler et al. (2005) or Ericson, (2007). Therefore, the 
radioactivity amounts of the pore waters were added to the extractable fractions within the 
present study.  
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Figure 20: Extraction efficiency tests for 14
 
C-diclofenac in wet sediment (S3) using 
different solvents 
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Figure 21: Tests on remaining radioactivity of 14C-diclofenac in pore water after 
direct solvent extraction 
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According to the time of contact, abundance of the biotransformation products and the affinity 
of diclofenac and its biotransformation products for sorption onto the sediments, the 
radioactivity amounts that could be extracted with ethyl acetate were determined. Ethyl 
acetate extracts were found to contain traces of the initially applied radioactivity at the 
beginning (0.7 ± 0.1 and 0.8 ± 0.1 % for WS1 and WS2 sediments, respectively), and at the 
termination of the experiments (0.2 ± 0.1 and 0.8 ± 0.1 % for WS1 and WS2 sediments, 
respectively) [Figure 16, 17]. These results may indicate that, at the beginning of incubation 
intervals, the time of contact either between diclofenac which has already moderate sorption 
properties or its biotransformation products which may have higher sorption properties than 
diclofenac and the sediments which have already low organic matter content was not enough 
for strong interaction between them. Therefore, the sediments were not able to keep high 
amounts of radiotracer substances and hence low radioactivity amounts were detected in the 
extractable residues. On the other hand, at the termination of the incubation intervals, 
diclofenac was completely transformed biologically to other products as shown by RTLC. 
These products had enough time to interact strongly, probably by sorption, with the 
sediments. As a result of this strong sorption process, ethyl acetate was not able to extract 
these biotransformation products from the sediments. Therefore, low radioactivity amounts 
were detected in the extractable residues. Between the beginning and the end of the 
incubation intervals, diclofenac might be weakly sorbed onto the sediment and hence the 
extractable residues increased as the time of contact increased up to 14 d. After this time, 
the extractable resides continuously decreased as the amounts of diclofenac decreased due 
to the biotransformation process.  
 
This finding clarified that only biotransformation products of diclofenac had the capability to 
interact strongly with the sediments. This assumption was supported by the results of the 7-d 
and 14-d incubation intervals in which the extractable residues contained almost 16 and 22 
% from the initially applied radioactivity for WS1 and WS2, respectively. Most of these 
amounts, 10 and 14 % as shown by the first solvent and the second solvent, respectively, in 
case of WS1 and 15 and 20 % as shown by the first solvent and the second solvent, 
respectively, in case of WS2, were identified by means of RTLC as the parent compound 
[Appendix, Table A17-A20]. Finding of mainly diclofenac in the extractable residues might 
be attributed to a moderate sorption process onto the sediments. 
 
Sorption of diclofenac to the sediments can not be explained mainly by its lipophilicity (Pow 
4.51) because under the pH conditions in sediment (pH 7.4) and water (pH 8.3) diclofenac 
(pKa 4.16) was relatively present in its negatively dissociated form due to the presence of an 
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ionizable carboxyl group. Therefore, the occurrence of diclofenac in the sediment can be 
expected to be caused mainly by ionic interactions [Scheytt et al., 2005a]. The ionic sorption 
could occur on positively charged sediments minerals. Hydroxy-iron and -aluminum 
compounds exhibit a high sorption capacity for acids. This could be attributed to the large 
chemical reactivity of these positively charged minerals toward the negatively charged 
carboxyl and hydroxyl groups of the acid compounds. Additionally, sediment organic 
functional groups have considerable role in the interaction processes [Spadotto and Hornsby, 
2003, Huang et al., 1977]. On the other hand, Chefetz et al. (2008) proved that the organic 
matter have a considerable effect in the sorption process of diclofenac onto soil. The 
presence of diphenyl moiety in the structure of diclofenac may play an important role in the 
interaction of diclofenac with the solid organic matter.  
 
In the present study, sorption unlikely be attributed to the organic matter where the TOC 
content was found to be relatively low in both sediments (0.2 and 0.4 % in the S1 and S2 
sediments, respectively) [Table 9, 10]. The clay content of both sediments could play a role 
in the sorption process where the extractable residues were found to be higher in the WS2 
than in the WS1 [Figure 16, 17]. The reason could be due to the higher percentage of the 
clay content in case of S2 sediment (30 %) than in case of the S1 sediment (8.5 %) [Table 
5]. However, because of the major amount of diclofenac has been detected in the water 
phase, the microbial transformation expected to represent the most dominant sink for 
diclofenac in the dark.  
 
In contrast to other incubation intervals, the RTLC of the concentrated ethyl acetate extracts 
of 56 d and 100 d incubation intervals in both sediments were found to be difficult for 
integration, using both solvents, due to the low radioactivity amounts, at maximum 5 % of the 
initially applied radioactivity for both sediments.  
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4.2.5 Non-extractable residues 
The amounts of the radioactivity remained after the ethyl acetate extractions in both 
sediments were considered as non-extractable residue (NER). It was found, that the non-
extractable residues increased from 2 ± 0.1 to 83 % and from 2 ± 0.4 to 82 ± 0.1 % for S1 
and S2, respectively, within an incubation period of 100 days [Figure 16, 17]. Strong 
sorption or binding to the sediments by different types of mechanisms such as hydrogen 
bonds, charge transfer complexes and covalent bonds could be the reason for formation of 
the NER [Haider et al., 1992, Northcott and Jones, 2000, Gevao et al., 2000]. Additionally, 
trapping of molecules in a molecular sieve formed by humic materials could be also another 
possible reason [Haider et al., 1992]. These mechanisms are usually results in strong 
irreversible interaction that could be attributed to the formation of highly reactive intermediate 
biotransformation products which interacts strongly with the sediments.  
 
Additionally, formation of volatile biotransformation products was relatively excluded as the 
radioactivity recovered was entirely complete at all incubation intervals with a median mass 
balance of 106 ± 2. The complete data sets are represented in Appendix, Table A21, A22. 
 
Briefly,  the fate of diclofenac in water/sediment systems almost resulted in mineralization 
rate of 13 %, DT50 in the water phase of 13 d, and formation of 82 % non-extractable 
residues within of 100-d incubation period. By means of such data, the persistence criteria of 
diclofenac in water/sediment systems can be estimated in different ways. According to the 
European Union for the pesticide registration procedure, persistence can be achieved by 
mineralization < 5 %, DT50 > 120 d, and formation of non-extractable residues > 70 % 
[Federal Biological Research Center for Agriculture and Forestry, 1998, European 
Commission, 2006]. On this basis, diclofenac can be considered as a moderately persistent 
organic compound. According to the environmental classification of OECD guideline 308 
[OECD 2002a], on the other hand, diclofenac can be classified as a non-persistence 
pharmaceutical compound where pharmaceuticals that have DT50 < 16 d, 16 < DT50 < 40 d, 
and DT50
 
 > 40 d are classified as non-persistent, moderately persistent, and potentially 
persistent compounds, respectively.  
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
 
 
 90 
4.2.6 Comparison between the batch system and the biometric flask system  
In order to evaluate the applicability of the batch system, the discontinuous gas exchange 
system, a comparison with the biometric flask system, the continuous gas exchange system, 
was performed for both sediment types. Three incubation intervals, i.e., 3 d, 56 d, and 100 d 
of the experiments, were selected to be compared with each other. This comparison was 
estimated depending on the redox potential, oxygen content, radioactivity amounts detected 
in each compartment, the dissipation behavior of diclofenac as detected by RTLC, and the 
mass balances obtained at the termination of the incubation intervals of both water/sediment 
systems. In all water/sediment samples, the redox potential in the water phase was found to 
be ≥ 390 mV. At the termination of the experiments, additionally, the oxygen concentrations 
were ≥ 5 mg/L. Theses results indicated that, the biotransformation processes of diclofenac 
in both systems were performed under aerobic conditions. Especially for 56 d and 100 d 
incubation intervals, furthermore, the detected total radioactivity amounts in all 
compartments, the mass balances [Figure 22, 23] and the radioactivity amount detected as 
diclofenac in the water phase [Table 11], especially for WS1, were found to be close to each 
other. The complete data set are listed in Appendix, Table A23, A24. 
 
Table 11: Percentage of radioactivity remained as diclofenac in the water phase of 
the applied water/sediment systems 
 
 Water phase 
 WS1 WS2 
 1st 2 solvent nd 1 solvent st 2 solvent nd solvent 
 BS SLT BS SLT BS SLT BS SLT 
3 d 63.0 61.0 66.0 69.0 38.0 55.0 38.0 67.8 
56 d   2.0   2.0 nd nd   5.2   5.0   9.0 10.0 
100 d   0.5   0.9 nd nd   0.7   2.0   2.0   2.0 
1st solvent = n-hexane/ethyl acetate/acetic acid (50:50:1 v/v/v), 2nd
 
 solvent = 
dichloromethane/methanol/25 % ammonia (85:14:1 v/v/v), nd = not determined 
Moreover, the RTLC of the extractable residues showed almost identical results within 3 d 
incubation interval. For WS1, diclofenac was disappeared to 9 %, when developed by the 
first solvent, and up to 12 %, when developed by the second solvent, for the batch and the 
biometric flask systems, respectively. For WS2, disappearance up to 14 % was detected for 
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diclofenac by the first solvent and up to 16 % by the second solvent for the batch and the 
biometric flask systems, respectively. In all cases, on the other hand, the RTLC of the 
concentrated ethyl acetate extracts of 56 d and 100 d incubation intervals were found to be 
difficult for integration due to the low radioactivity amounts, i.e., 5 % of the initially applied 
radioactivity for both sediments. This comparison clearly showed that both laboratory test 
systems lead to equivalent results on fate of 14
 
C-diclofenac in water/sediment systems.  
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Figure 22: Balances of the biotransformation tests of 14
 
C-diclofenac in water/ 
sediment WS1 after incubation in the dark for different intervals using (a) 
laboratory batch system and (b) biometric flask system 
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Figure 23: Balances of the biotransformation tests of 14
 
C-diclofenac in water/ 
sediment WS2 after incubation in the dark for different intervals using (a) 
laboratory batch system and (b) biometric flask system 
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4.3. Fate monitoring of 14
Under the influence of light the behavior of diclofenac, as a photosensitive compound, in 
water/sediment system was completely unknown. Therefore, irradiation experiments were 
conducted using two different types of sediments in order to simulate the effect of natural 
light on diclofenac in water/sediment systems. After 10 h/d irradiation of diclofenac for 3 
consecutive days, the radioactivity amounts detected as non-extractable residues in both 
sediments showed unexpected high amounts. From the initially applied radioactivity, 65 ± 1.8 
and 70 ± 0.1 % were localized as non-extractable radioactivity in the sediments of WS1 and 
WS2, respectively [Figure 24]. This could be due to the formation of high reactive 
intermediate products during the irradiation time [Agueera et al., 2005] as a result of removal 
of the chlorine atom from the phenyl ring of diclofenac. These intermediate products might 
interact strongly with the sediment leading to formation of highly stable complexes that could 
not be extracted by means of ethyl acetate. Mineralization was only observed to minor extent 
of 1 ± 0.2 % for both WS systems. The radioactivity amounts in the water phases were 35 ± 4 
and 26 ± 4 % for WS1 and WS2, respectively, from which about 2 % for both WS systems 
could be identified as diclofenac and the remaining radioactivities were mainly detected at 
the spot of application as a very large peak (29 and 16 % for WS1 and WS2, respectively) 
[Figure 25]. It could be a mixture of different highly polar primary or secondary 
phototransformation products.  
C-diclofenac after irradiation in water/sediment systems  
 
The previous results are consistent with the photosensitivity phenomena of diclofenac 
considering the photolysis as the main fate of diclofenac in presence of light. Furthermore, 
the mass balance showed that the radioactivity was recovered in an acceptable level (104 ± 
3 and 107 ± 5 for WS1 and WS2 sediments, respectively). In contrast, irradiation of 
diclofenac in pure water/quartz sand (QS) sediment system showed formation of 19 % as 
non-extractable residues while the major amount (66 %) of the initially applied radioactivity 
was detected in water phase. The mass balance was found to be 96 % from which 7 % could 
be detected in the water phase as 14
 
C-diclofenac, as shown by RTLC. The complete data set 
are listed in Appendix, Table A25, A26. In all cases, the extractable residues were found to 
be difficult for integration by RTLC due to the low radioactivity amounts (10 % at maximum). 
These results revealed that the difference between the water/quartz sand system and the 
other water/sediment systems affected the distribution behavior of diclofenac in their 
compartments. On the other hand, the microbial activity had negligible effect on the 
transformation of diclofenac in presence of light 
 
 
 
RESULTS AND DISCUSSION 
 
 
 94 
0
20
40
60
80
W/S1 W/S2 W/QS
Type of sediment
R
ad
io
ac
tiv
ity
 (%
)
MIN AP ER NER
 
 
Figure 24: Balances of the transformation tests of 14
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Figure 25: RTLC chromatogram after irradiation of 14
 
C-diclofenac in the water phase 
of WS1 for 3 days, extracted by SPE and developed by first solvent (n-
hexane/ethyl acetate/acetic acid; 50:50:1 v/v/v) 
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4.4 Chemical characterization of non-extractable residues  
In the irradiation experiment, the rapid disappearance of diclofenac in both sediments under 
the laboratory conditions was mainly attributed to its photosensitivity resulting in the 
formation of several unknown highly reactive intermediate products which were assumed to 
be the reason of the formation of high amounts of the non-extractable residues. In case of 
WS1 sediment 65 ± 2 % was defined as non-extractable residues by the ethyl acetate 
extraction step. To check the extraction efficiency of this step, the extraction power was 
enhanced using methanol/hydrochloric acid. Only 7 ± 0.7 % were additionally extracted while 
51 ± 5 % remained again non-extractable. For derivatization of the functional groups of the 
sediment identified as a sink for non-extractable residues [Heise et al., 2006, Haider et 
al.,1992], silylation technique was applied as a third step of the sequential extraction 
procedure. After silylation, 26 ± 0.2 % were then released while 26 ± 1 % remained as non-
extractable residue [Figure 26]. The complete data set are listed in Appendix, Table A28. 
 
Since radioactivity could be sequentially extracted, the bioavailability of these unknown 
transformation products onto the sediment could be also expected. In this case, sediments 
could not only play an important role as a sink of the transformation products but also as 
source due to the remobilization process. During the sequential extraction processes, 
furthermore, the extracts obtained after each step were screened for diclofenac by RTLC. 
Additionally, the ethyl acetate extracted sediments obtained after incubation for 100 d in the 
dark were extracted sequentially and screened by the same way. As shown by RTLC, 
diclofenac could not be detected in any extracts indicating that only its transformation 
products were able to interact strongly with the sediments.  
 
4.5 Role of sediment in elimination of phototransformation of diclofenac 
It is obvious that the role of sediment as a sink for the transformation products of diclofenac 
can not be neglected. In contrast to water/sediment systems, therefore, irradiation 
experiments were performed using native and demineralized water, without sediments, for 
estimation of this role. After 3 days irradiation period, the radioactivity amounts recovered 
were 92 and 107 % for native and demineralized water, respectively. In comparison with the 
radioactivity amounts recovered from the water phase of WS1 (almost 35 %), the sediment 
eliminated more than 55 % and 70 % of the phototransformation products formed in the 
water phases of native and demineralized water, respectively. At maximum, 3.5 % of the 
initially applied radioactivity could be detected by RTLC as 14
 
C-diclofenac in the water phase 
at the termination of the experiments. 
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DMF = dimethylformamide, CTMS = chlorotrimethylsilane, HCl = Hydrochloric acid 
 
Figure 26: Chemical characterization of the non-extractable residues of sediment 
WS1 by means of sequential extraction technique after the 3-d irradiation 
experiment  
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4.6 GC/MS analysis 
4.6.1 Fate of diclofenac after irradiation in pure water 
GC/MS is one of the most frequently used tools for identifying transformation products. Two 
important advantages of GC/MS methods are known. First, the large amount of structural 
information that can be yield by the full scan mass spectra obtained under electron impact 
(EI) ionization. Second, the possibility of using commercial libraries makes the identification 
of unknowns feasible. However, GC/MS has important drawbacks because of its limited 
capability for analyzing very polar, less volatile, thermolabile compounds in addition to the 
long run times and the sample preparation time in case of derivatization of polar compounds. 
As a polar compound, diclofenac has to be derivatized before GC/MS analysis for more 
sensitive detection. Several methods have been described in the literature for derivatization 
of diclofenac. In the present study, diclofenac was derivatized according to Moeder et al. 
(2007) who described the derivatization procedure using pentafluorobenzyl bromide in 
aqueous potassium carbonate solution. After heating the reaction mixture for 1 h at 60 °C, 
they extracted the derivatized compound with n-hexane which was finally concentrated to 
200 µL before GC/MS analysis in negative chemical ionization mode.  
 
As a result of following this derivatization method, three peaks were observed in the total ion 
current chromatogram of the present study. By the interpretation of the mass spectra, these 
peaks could be identified as the intramolecular cyclization product of diclofenac [1-(2,6-
dichlorophenyl)indolin-2-one] (m/z 277) which known as diclofenac artifact, diclofenac-
pentafluorobenzylester (m/z 475), and, the derivatized diclofenac artifact, 1-(2,6-
dichlorophenyl)indolin-2-one-pentafluorobenzyl ester (m/z 456) [Figure 27]. The latter one 
was found to be the most abundant substance which could be formed as a result of loss of 
water and an additional proton abstraction from the intact diclofenac-pentafluorobenzylester 
derivative. The occurrence of these compounds together in the same run could be only 
explained by an incomplete derivatization reaction or contamination of the diclofenac 
standard solution. However, the latter was excluded by means of HPLC/UVD purity test 
detecting no signal for presence of impurities where the standard solution of diclofenac was 
detected as a definite single signal [Figure 28].  
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Figure 27: Total ion current chromatogram of derivatized standard solution of 
diclofenac detected by GC/MS in full scan (EI) mode before optimization 
of the derivatization conditions 
 
 
 
 
Figure 28: Purity test of diclofenac by means of HPLC 
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For quantitation purposes, therefore, different factors affecting the derivatization reaction 
were examined to optimize the derivatization conditions in order to obtain single derivatized 
compound such as volumes of pentafluorobenzyl bromide, reaction mixture, n-hexane and 
water as well as the heating time. As neutralizing agents, triethylamine or potassium 
carbonate were tested. The latter was additionally applied as a solution or as a powder. 
Under the optimized reaction conditions, only the pentafluorobenzylester of 1-(2,6-dichloro-
phenyl)indolin-2-one with the molecular ion of m/z 456 was detected [Figure 29]. The reason 
of the disappearance of diclofenac-pentafluorobenzylester (m/z 475) and presence of 
derivatized diclofenac artifact instead is unknown. However, one of the most important 
advantages of the optimized derivatization was the evaporation of the reaction mixture up to 
dryness in order to remove any trace of water. Hence, to omit this important step may give 
the chance to the external water molecules to interact with the derivatized compound leading 
to the formation of both ions m/z 475 and m/z 456. On the other hand Moeder et al. (2007) 
proposed that, under the boundary conditions of the negative chemical ionization technique, 
this artifact formation was caused by a cyclization process under the intramolecular 
elimination of water followed by a proton abstraction from the diclofenac-
pentafluorobenzylester resulting in the loss of 19 amu. This reason can be absolutely 
excluded since the present study was performed using the electron impact ionization 
technique.  
 
Since the derivatized compound is not commercially available as standards, it was not 
possible to calculate the derivatization efficiency. However, since no by-product of 
derivatization were found to be present during the analysis, derivatization assumed to be 
complete. The stability of the derivative was checked for 3 days using its calibration curves. 
In this case the GC/MS was operated in the SIM mode for the molecular ion m/z 456. The 
results showed that even under the storage conditions at - 20 °C in the dark the derivative 
was not stable [Figure 30]. Therefore, derivatization was excluded for further investigation of 
diclofenac. In order to check for the photoinduced disappearance of diclofenac by GC/MS, 
the ethyl acetate extracts of the irradiated water samples were screened directly (without 
derivatization) for the cyclization product m/z 277 (artifact) as an indicator for the presence of 
diclofenac. The results showed that diclofenac was gradually transformed in the first five 
hours [Figure 31] and completely disappeared after one day irradiation period. The complete 
data set are listed in Appendix, Table A29. 
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Figure 29: (a) Total ion current chromatogram of the derivatized standard of 
diclofenac recorded by GC/MS applying electron impact ionization in full 
scan mode after optimization of the pentafluorobenzylation and (b) its 
corresponding mass spectrum 
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Figure 30: Calibration curves of 1-(2,6-dichlorophenyl)indolin-2-one pentafluoroben-
zylester measured up to 3 days by GC/MS 
 
 
RESULTS AND DISCUSSION 
 
 
 101 
0
2
4
6
8
10
0 1 2 3 4 5 6
Time (h)
C
on
c 
(n
g/
µL
)
 
 
Figure 31: Dissipation of diclofenac after exposure to the light of the irradiation 
apparatus for different intervals in pure water detected by GC/MS 
 
4.6.2 Origin of diclofenac artifact formation 
Because of the loss of water, diclofenac can undergo an intramolecular cyclization resulting 
in formation of 1-(2,6-dichlorophenyl)indolin-2-one (molecular formula: C14H9Cl2
O
N
Cl
Cl
NO, 
molecular weight: 277) which is known as the artifact of diclofenac. The structure of this 
compound is shown in Figure 32.  
 
 
Figure 32: Structure of the artifact of diclofenac, 1-(2,6-dichlorophenyl)indolin-2-one  
 
Numerous contradictory data have been published regarding the reason of the artifact 
formation during the GC/MS analysis of diclofenac. In the present study, therefore, a 
diclofenac standard solution in acetone was directly injected into the split/splitless injector of 
the GC/MS system at 280 °C in order to determine the exact origin of this indolinone cyclic 
amide structure. The characteristic full scan spectrum [Figure 33] depicting the molecular 
ion m/z 277 definitely confirmed that 1-(2,6-dichlorophenyl)-indoline-2-one was formed as a 
thermal artifact.  
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Figure 33: (a) Total ion current chromatogram and (b) mass spectrum of the artifact 
of diclofenac as detected by GC-MS in full scan (EI) mode 
 
This reason was in agreement with some authors while others attributed the formation of 
artifact to different reasons such as acidic treatment, alkylation in alkaline media, MS 
conditions, sonolysis, or exposure to light. Others have identified the artifact of diclofenac as 
one of its bio- or phototransformation products. Under acidic conditions using 0.5 % sulphuric 
acid in 2.2.2-trifluoroethanol, Geiger et al. (1975) converted diclofenac into its artifact in order 
to be able to determine it in the biological fluids by GC/ECD. During biotransformation study 
of diclofenac in animal and man, Stierlin et al. (1979) detected several indolinone derivatives 
assuming that some of them were formed due to the acidic treatment of the urine samples 
and the others were formed pyrolytically at 180 °C in the ion source during the MS analysis 
as a result of thermal decomposition. Using GC/MS, Schneider and Degen, (1981) have 
published several indolinone derivatives formed after extractive alkylation of diclofenac under 
alkaline conditions. Although Palomo et al. (1999) excluded the acidic condition to be the 
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reason of the artifact formation as confirmed by IR analysis of acidified diclofenac solution 
(0.2 M HCl, pH 1.3), Reddersen and Heberer (2003) pointed to the SPE under acidic as the 
reason for artifact formation.  
 
Furthermore, the behavior of diclofenac, in different solvent without derivatization, toward the 
temperature conditions used in the GC/MS was studied by El Haj et al. (1999). They found 
that, in methanol, diclofenac could be detected as methyl ester (stable major product) and 
indolinone cyclic structure (minor product). However, only the indolinone cyclic structure 
could be detected when diclofenac was dissolved in ethyl acetate. The high temperature of 
the GC injection port and/or the column is expected to be the reason of the esterification and 
cyclization which occur in the vapor state. Cyclization upon heating of γ and δ amino acids to 
give stable five or six membered ring has been already puplished [El Haj et al., 1999, 
Morrison and Boyd, 1987]. Additionally, the formation of the indolinone cyclic structure, after 
heating of diclofenac in acidified water at 100 °C for 90 min, was identified by GC/MS 
spectrum as a single peak and by TLC as a single spot (El Haj et al., 1999). They 
differentiated between diclofenac and the indolinone cyclic structure by measuring their UV 
absorption spectra. The latter UV spectra showed absorption maxima at 244 nm in aqueous 
acid and 275 and 303 nm in aqueous alkaline solution. Zajac et al. (1998) reported the 
formation of artifact as a result of heating process of diclofenac. Tudja et al. (2001) studied 
the thermal behavior of diclofenac sodium. They suggested the occurrence of an 
intramolecular cyclization reaction between amino and carboxylic group in solid diclofenac 
samples heated up to 270 °C resulting in the formation of the artifact. Additionally, 
sterilization (at 123 °C) of diclofenac by means of autoclaving was noted to form the artifact 
[Roy et al., 2001]. The mechanism of this reaction is shown in Figure 34. 
 
 
 
 
Figure 34: Formation of the indolinone artifact from diclofenac sodium [Roy et al., 
2001] 
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Comparing diclofenac control samples analyzed by GC or LC, Kosjek et al. (2009) confirmed 
that the formation of the artifact was due to the thermal decomposition process. Sonolysis of 
a diclofenac solution has been reported as another reason for its formation [Hartmann et al., 
2008]. Using LC/MS/MS/ESI, Giordano et al. (2003) identified the artifact when diclofenac 
either exposed to high temperature (160 °C) or exposed to light (60 W tungsten lamp) in 
presence of oxidant mixture (ferrous sulphate and ascorbic acid) due to the existence of free 
OH radicals. It was also detected by LC/MS/MS/ESI as one of the degradation products of 
diclofenac in ophthalmic solutions stored for 9 weeks at 60 °C [Galmier et al., 2005] or as 
degradation product in topical emulgel after long storage [Hajkova et al., 2002]. Additionally, 
it has been described by Kosjek et al. (2007a, b) as a one of the biotransformation products 
of diclofenac identified by means of GC/MS in a pilot wastewater treatment plant model 
study, by Bartels and von Tuempling Jr. (2007) as one of the major biotransformation 
products of diclofenac identified by means of GC/MS operating in electron impact ionization 
mode, by Moeder et al. (2007) due to the operation of GC/MS in negative chemical ionization 
mode and by Scheurell et al. (2009) as a phototransformation product formed in surface 
water. Furthermore, the 4'-hydroxy derivatives of the artifact was detected by means of 
LC/MS/MS in human urine samples as well as in WWTP effluent as a biotransformation 
product of diclofenac [Stuelten et al., 2008b]. Finally, according to European Pharmacopoeia 
(2005), the artifact can be formed as an intermediate impurity during the synthesis of 
diclofenac.  
 
4.6.3 Detection of phototransformation products of diclofenac 
For the identification of phototransformation products, the irradiated water samples were 
analyzed in two different ways by means of GC/MS in full scan mode. Hence, the extracts 
were either analyzed without derivatization for detection of possibly formed non-polar 
phototransformation products or after derivatization (as previously mentioned for diclofenac) 
for detection of possibly formed polar phototransformation products. 
 
The results showed that phototransformation products could not be detected by GC/MS 
during those phototransformation tests. Despite pentafluorobenzylation, further signals could 
not be found after the 3-d incubation interval indicating that the initially applied parent 
compound and possibly formed phototransformation products were completely transformed 
under irradiation. 
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4.7 HPLC analysis 
4.7.1 Detection and characterization of phototransformation products of diclofenac 
In order to avoid any thermal stress during the flash evaporation in a GC split/splitless 
injector HPLC was applied. For this purpose, irradiation experiments were conducted for 5 h 
using a combined mixture of labeled and non-labeled diclofenac. During this time, samples 
were taken after an irradiation interval of 1 h. The sample extract of each interval were then 
screened by means of RTLC and additionally reversed-phase HPLC/UVD and HPLC/DAD 
for UV detectable phototransformation products (PTP) probably formed besides diclofenac. 
 
To obtain detailed information about the phototransformation products during the experiment, 
the total radioactivity was measured in the different compartments through the liquid-liquid 
extraction procedure. The results were then used to setup the mass balances at the end of 
extraction step, to calculate the extraction efficiency of ethyl acetate after each interval. By 
means of this method, an idea about the chemical nature (polarity) of the 
phototransformation products could be obtained. The recovery and the percentage of the 
radioactivity in each compartment related to the initially applied radioactivity are listed in 
Table 12. It was found that the total radioactivity extracted by means of ethyl acetate 
gradually decreased from 93 to 56 % within 5 h irradiation period. Conversely, the total 
radioactivity remained in the water phase gradually increased from 12 to 41 % within the 
same irradiation period. In another way, the extraction efficiency of the ethyl acetate 
decreased from 86 to 53 % as the irradiation time increased from 1 to 5 h. The formation of 
more polar phototransformation products that could not be extracted by ethyl acetate during 
the irradiation experiment was the most suitable interpretation for these results.  
 
Additionally, the extracts developed on normal phase TLC plates and screened by RTLC 
referred to presence of at least three phototransformation products beside the parent 
compound [Figure 35]. As it was expected, the radioactivity amount identified as diclofenac 
decreased from 72 to 26 % within the irradiation period. The elimination constant (Kelim) was 
found to be 0.2 per hour resulting in DT50
 
 of 3 h. Furthermore, 3 obvious UV absorbent 
phototransformation products could be detected beside diclofenac by means of HPLC/UVD 
and HPLC/DAD at reasonable retention times [Figure 36, 37]. On the other hand, RTLC 
screened extracts developed on reversed phase TLC plates, did not show the same 
separation pattern obtained by HPLC. This might be attributed to the low separation 
performance of TLC when compared to HPLC. 
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Table 12: Balances of transformation tests of 14
 
C-diclofenac in pure water after 
irradiation for different intervals during the liquid-liquid extraction steps 
Irradiation interval (h) (a) (b) (c) (d) (e) 
1 108 12 93 86 105 
2 108 13 86 80 99 
3 108 25 77 71 102 
4 108 38 64 60 102 
5 106 41 56 53 97 
(a) Recovery percentage of the radioactivity in the 100 mL water sample directly before the 
liquid-liquid extraction.  
(b) Recovery percentage of the radioactivity remained in the 100 mL water sample after the 
liquid-liquid extraction.  
(c) Recovery percentage of the radioactivity extracted by ethyl acetate after the liquid-liquid 
extraction.  
(d) Extraction efficiency percentage of ethyl acetate (C/A x 100) 
(e) Mass balance percentage of the radioactivity in the water phases and in the ethyl acetate 
extracts (B+C) 
 
4.7.2 Dissipation behavior of diclofenac and its phototransformation products 
Aiming to obtain complete transformation of diclofenac, the irradiation intervals were 
expanded up to 10 h. The concentrated extracts were screened by HPLC/UVD. It was 
obvious that the peak areas of diclofenac and PTP1 decreased the longer the irradiation time 
was while the peak areas of PTP2 and PTP3 remained nearly constant [Figure 38]. The 
concentration of diclofenac dropped rapidly from 100 ng/μL to 33 ng/μL within the first 2 h 
and then to 4 ng/μL after 10 h of irradiation. The complete data set are listed in Appendix, 
Table A30. Furthermore, the direct HPLC/UVD analysis of the aqueous aliquots taken before 
the liquid/liquid extraction step confirmed that neither diclofenac nor related PTPs remained 
in the water samples after extraction procedure. To exclude dilution effect as a reason for 
this observation, the water remained after liquid/liquid extraction was further extracted by 
means of SPE confirming the previous results. However, in the previous radiotracer test, 
considerable radioactivity amount could be detected in the water phase after liquid/liquid 
extraction process. Therefore, it can be assumed that not only diclofenac but also its 
phototransformation products were photosensitive and hence further transformation for the 
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detected phototransformation products might be expected. This assumption was confirmed 
from their absorption spectra in which the peak tail of the detected phototransformation 
products expanded over 300 nm [Figure 39]. Thus, the last part of their absorption bands 
overlap with the beginning of the wavelengths emitted by the radiation source (cut off 290 
nm) used in the present study. 
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Figure 35: RTLC chromatogram of a transformation test of 14
 
C-diclofenac in pure 
water after irradiation for 5 h, extracted by liquid/liquid extraction and 
developed using n-hexane/ethyl acetate/acetic acid (50:50:1 v/v/v) on 
normal phase TLC plate 
 
 
Figure 36: Chromatogram of a transformation test of diclofenac after irradiation for  
5 h in pure water as detected by HPLC/UVD at λ = 280 using 
methanol/water/ phosphoric acid (70: 30: 0.1, v/v/v) as mobile phase 
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Figure 37: Chromatogram of a transformation test of diclofenac after irradiation for 5 
h in pure water as detected by HPLC/DAD at λ = 242 nm using 
acetonitrile/water/formic acid (50: 50: 0.1, v/v/v) as mobile phase 
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Figure 38: Peak areas of diclofenac and its PTPs after exposure of diclofenac to 
irradiation in pure water for different intervals as detected by HPLC/UVD 
at λ = 254 nm using acetonitrile/water/formic acid (50: 50: 0.1, v/v/v) as 
mobile phase 
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PTP = phototransformation product  
 
Figure 39: UV absorption spectra of diclofenac and its PTPs detected by HPLC/DAD 
after irradiation of diclofenac in pure water for 5 h 
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4.8 LC/MS/MS analysis 
4.8.1 Method optimization 
Preliminary, several parameters had to be optimized in order to find the best boundary 
conditions for LC/MS/MS analysis. These parameters were optimized for diclofenac, since its 
phototransformation products (PTPs) were not available as reference standards. Basically, 
there are two types of parameters, i.e., compound dependent parameters and flow 
dependent parameters that can be adjusted manually or automatically. In the present study, 
these parameters were adjusted automatically [Figure 40]. 
                              
 
 
 
Figure 40: (a) Flow dependent parameters and (b) compound dependent parameters 
and their optimum values for diclofenac 
 
Other parameter such as mode of operation and scan type had to be adjusted manually. For 
this purpose, 10 ng/μL of diclofenac were tested for the compound dependent parameters in 
both positive and negative operation mode using [M+H]+ (m/z 296) and [M–H]− (m/z 294), 
respectively. The [M–H]− ion recorded was of definite higher intensity than the [M+H]+ ion 
was. Therefore, the negative mode was selected for the further study. Additionally, different 
scan types were applied in order to obtain appropriate structure-specific information without 
interfering noise peaks. For this purpose, full scan using the first quadrupole (Q1 scan), the 
third quadrupole in the linear ion trap mode (EMS scan) to increase the sensitivity by EMS or 
a combination between EMS and EPI scan types using IDA method were tried. The latter 
was found to be the most appropriate one because the gained mass specific information that 
could be used for selection of the product ion with the most abundant mass to charge ratio 
for further LC/MS/MS experiments. Furthermore, different gradient and isocratic organic 
mobile phases were tested [Table 13a, b, c] in order to achieve better resolution, higher 
separation quality and proper 
(a) 
peak shapes for diclofenac and its PTPs. The results showed 
(b) 
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that the highest resolution was achieved by the isocratic mobile phase consisting of 
acetonitrile/ 0.5 % formic acid [50:50 (v/v)]. 
 
Table13: Mobile phases used in method optimization of diclofenac 
 
(A) 
Total time 
(min) 
Flow rate 
(µL/min) 
Eluent A %  
0.1 % acetic acid in LC/MS water 
Eluent B % 
0.1 % acetic acid in methanol 
0.00 300 35.0 65.0 
10.00 300 28.0 72.0 
15.00 300 0.0 100 
16.00 300 0.0 100 
21.00 300 35.0 65.0 
30.00 300 35.0 65.0 
 
 
(B) 
Total time 
(min) 
Flow rate 
(µL/min) 
Eluent A % 
0.5 % formic acid in LC/MS water 
Eluent B  % 
Acetonitrile 
0.00 300 90.0 10.0 
15.00 300 10.0 90.0 
20.00 300 10.0 90.0 
21.00 300 90.0 10.0 
26.00 300 90.0 10.0 
 
 
(C) 
Total time 
(min) 
Flow rate 
(µL/min) 
Eluent A % 
0.5 % formic acid in LC/MS water 
Eluent B % 
Acetonitrile 
0.00 300 50 50 
30 300 50 50 
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4.8.2 Identification of phototransformation products of diclofenac in water samples 
After standard application, diclofenac was firstly irradiated in pure water instead of real water 
samples or water/sediments samples to avoid interference, contamination, signal 
suppression and falls positive finding that could hinder the identification of its 
phototransformation products due to matrix effects. For the identification purpose, the total 
ion current chromatograms obtained by LC/MS/MS analysis of irradiated diclofenac samples 
were comprehensively investigated for every peak like shape. As a result, only four peaks 
could be identified as diclofenac and its phototransformation products due to their specific 
mass spectra at certain retention times.  
 
As an example, the total ion current chromatogram for the 2-h irradiation interval is given in 
Figure 41 in which peaks regarding diclofenac and its phototransformation products, i.e., 
PTP1, 2 and 3 were pointed by means of arrows. Furthermore, EMS and EPI mass spectra 
of diclofenac and PTP1, 2 and 3 referred to the most abundant product ions of 250, 214, 196 
and 185 m/z, respectively [Figure 42-45]. In order to find the precursor ions that were 
generating these product ions, the latter were individually subjected to the precursor ion scan 
mode. In each case, only one peak was observed in the total ion current chromatogram of 
this scan mode. Hence, each product ion was generated by means of only one precursor ion. 
As additionally shown by their related mass spectra m/z 294, 258, 240, and 229 were 
detected to be the precursors of diclofenac and PTP1, 2 and 3, respectively [Figure 46-49]. 
It was obvious that the precursor ions [M-H]− of diclofenac, PTP1, and PTP2 were 
characterized by the loss of 44 amu which exactly corresponding to the loss of [-COO]−. 
Therefore, it can be concluded that the structures of these transformation products include 
presence of carboxylic groups. On the other hand, the ion at m/z 229 [M-2H]2- was 
characterized by the loss of 26 amu (C2H4) which is common for the fragmentation of the 
aromatic compounds followed by 18 amu (H2
 
O) which is common for the fragmentation of 
the alcoholic compounds.  
As a diphenylamine compound, diclofenac is almost converted to carbazole derivatives when 
exposed to light [Bowen and Eland, 1963]. According to the m/z and the fragmentation 
pattern of the precursor ions, three carbazole derivatives could be identified as possible 
phototransformation products for diclofenac. These carbazole derivatives are 8-chloro-9H-
carbazole-1- acetic acid (PTP1), 8-hydroxy-9H-carbazole-1- acetic acid (PTP2) and 8-chloro-
9H-carbazole-1-methanol (PTP3). The structure of diclofenac and its phototransformation 
products are listed in Table 14. On the other hand, the other peaks investigated in the total 
ion current chromatogram of all intervals had nearly the same MS spectra as the base line 
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indicating that these peaks can be considered as noise peaks [Figure 50]. Therefore, the 
most relevant diclofenac phototransformation process is the photocyclization to the 
corresponding monochlorinated carbazole PTP1 and PTP3. Furthermore, the substitution of 
the chlorine atom by the hydroxyl group led to the formation of PTP2. Those 
phototransformation products were also described by Agueera et al. (2005) and Moore et al. 
(1990) by the interpretation of LC/TOF-MS and 1
 
H-NMR spectra, respectively. Within the 
present study, however, a dimer formation was not observed. The concentration of 
diclofenac was determined in MRM mode using the transition of m/z 294 to 250. It was 
observed that the amount of diclofenac dropped to 34 % and 4 % after 2 and 10 h of 
exposure to the light, respectively [Figure 51]. The complete data set are listed in Appendix, 
Table A31. 
 
 
 
Figure 41: Total ion current chromatogram of pure water sample after 2-h irradiation 
showing the presence of 3 phototransformation products besides 
diclofenac as detected by LC/MS/MS 
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Figure 42: Mass spectra of diclofenac detected by LC/MS/MS using information 
depending acquisition method: (a) Enhanced full mass scan (EMS) and 
(b) enhanced product ion scan (EPI) 
 
 
 
 
 
Figure 43: Mass spectra of 8-chloro-9H-carbazole-1-acetic acid detected by 
LC/MS/MS using information depending acquisition method: (a) 
Enhanced full mass scan (EMS) and (b) enhanced product ion scan (EPI) 
 
 
 
RESULTS AND DISCUSSION 
 
 
 116 
 
 
 
Figure 44: Mass spectra of 8-hydroxy-9H-carbazole-1-acetic acid detected by 
LC/MS/MS using information depending acquisition method: (a) 
Enhanced full mass scan (EMS) and (b) enhanced product ion scan (EPI) 
 
 
 
 
 
Figure 45: Mass spectra of 8-chloro-9H-carbazole-1-methanol detected by LC/MS/MS 
using information depending acquisition method: (a) Enhanced full mass 
scan (EMS) and (b) enhanced product ion scan (EPI) 
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Figure 46: (a) Precursor total ion current chromatogram of product ion 250 m/z 
detected by LC/MS/MS and (b) its corresponding MS spectrum identifying 
diclofenac (m/z 294) as the precursor ion 
 
 
Figure 47: (a) Precursor total ion current chromatogram of product ion 214 m/z 
detected by LC/MS/MS and (b) its corresponding MS spectrum identifying 
8-chloro-9H-carbazole-1-acetic acid ( m/z 258) as the precursor ion. 
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Figure 48: (a) Precursor total ion current chromatogram of product ion m/z 196 
detected by LC/MS/MS and (b) its corresponding MS spectrum identifying 
8-hydroxy-9H-carbazole-1- acetic acid (m/z 240) as the precursor ion 
 
 
Figure 49: (a) Precursor total ion current chromatogram of product ion m/z 185 
detected by LC/MS/MS and (b) its corresponding MS spectrum identifying 
8-chloro-9H-carbazole-1-methanol (m/z 229) as the precursor ion 
 
 
RESULTS AND DISCUSSION 
 
 
 119 
 
 
 
Figure 50: EMS spectra of the other peaks found in Figure 38 at retention times (a) 
8.7, (b) 4.7 and (c) 2.2 min. The same MS spectrum was observed 
indicating that no further PTPs could be detected 
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Figure 51: Dissipation of diclofenac after irradiation in pure water for different 
intervals as detected by LC/MS/MS using the transition (m/z 294/250) in 
MRM mode 
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Table 14: Diclofenac and its expected phototransformation products detected by LC/MS/MS 
 
Structure CAS Molecular formula 
Molecular 
mass 
Precursor 
ion 
Product 
ion 
Retention time 
(min) 
   
Cl
Cl
N
H OH
O
 
2-[(2,6-Dichlorophenyl)amino] benzene acetic acid  
 
 
 
 
15307-86-5 
 
 
 
 
 
C14H11Cl2NO
 
2 
 
 
 
295 
 
 
 
 
 
294 
 
 
 
 
 
250 
 
 
 
 
15.3 
 
   
N
OH
O
HCl
 
8-Chloro-9H-carbazole-1-acetic acid  
 
 
 
131023-44-4 
 
 
 
C14H10ClNO
 
2 
 
 
259 
 
 
 
 
258 
 
 
 
 
214 
 
 
 
11.1 
 
   
N
OH H OH
O
 
8-Hydroxy-9H-carbazole-1-acetic acid  
 
 
 
131023-45-5 
 
 
 
 
C14H11NO
 
3 
 
 
241 
 
 
 
 
240 
 
 
 
196 
 
 
 
5.2 
   
N
OH
Cl H
 
8-Chloro-9H-carbazole-1-methanol  
 
 
 
212850-69-6 
 
 
 
C13H10
 
ClNO 
 
 
231 
 
 
 
 
229 
 
 
 
185 
 
 
 
3.1 
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4.8.3 Identification of transformation products of diclofenac in water/sediment         
systems 
For identification of phototransformation products, diclofenac was irradiated in the 
water/sediment systems WS3 for 5 h. In contrast to the irradiation tests in pure water, here, 
only PTP1 could be detected besides diclofenac either in the water phases [Figure 52] or in 
the sediment extracts while PTP2 and 3 could not be detected. In the sediment extracts, 
however, diclofenac was found at much lower amounts (2 ± 0.2 %) than in the water phases 
(39 ± 2 %). The complete data set are listed in Appendix, Table A32. These results may 
reveal to PTP2 and 3 as the main reason for the formation of the non-extractable residues 
confirming the important role of sediment in the ecosystem. Therefore, sediments should not 
be disregarded when fate and behavior of polar compounds are to be monitored in aquatic 
compartments.  
 
 
Figure 52: Smoothed total ion current chromatogram of blank (---), diclofenac (DCF) 
and 8-chloro-9H-carbazole-1-acetic acid (PTP1) (ـــــ) detected by 
LC/MS/MS using information depending acquisition method in the water 
phase of water/sediment WS3 after a 5 h irradiation period 
 
On the other hand, water/sediment systems incubated for 7 days in the dark showed no 
indication for formation of biotransformation products under the experimental conditions. The 
reason might be attributed to the concentration of diclofenac which used in this experiment at 
higher level (3.3 mg/L) than in case of the radiotracer experiments (70 µg/L) where several 
unknowns were found to be formed as shown by RTLC. The transformation rate of diclofenac 
in sediment under aerobic condition was reported by Groning et al. (2007) to be inversely 
proportional to the concentration levels indicating a toxic effect of this drug or its resulting 
metabolites. The residual amounts of diclofenac were 59 ± 2 % and 19 ± 0.4 % for water 
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phase and sediment extracts, respectively, [Appendix, Table A33]. Losses of diclofenac 
within those tests may be also attributed to sorption processes in the sediment. 
 
4.9 Structure confirmation of 8-chloro-9H-carbazole-1-acetic acid by 2D 1H and 13
In contrast to LC/MS/MS, NMR has higher limits of detection and analyses are to be carried 
out for single compounds or less complex mixtures. Therefore, an irradiation experiment at 
relatively high concentration of diclofenac was performed. As shown by reversed-phase thin 
layer chromatography and analytical HPLC/UVD, it was possible to enrich 8-chloro-9H-
carbazole-1-acetic acid approximately to the 30-mg range to meet NMR’s limits of detection. 
However, at such high concentration, diclofenac could not be completely separated and 
NMR analysis was performed for analytical solution containing diclofenac and 8-chloro-9H-
carbazole-1-acetic acid. In contrast, at low concentration level of diclofenac, 8-chloro-9H-
carbazole-1-acetic acid was completely separated (almost 100 % purity) as shown by 
HPLC/DAD [Figure 53]. Nevertheless, both compounds could be differentiated because the 
C 
NMR 
1H-NMR spectrum of 8-chloro-9H-carbazole-1-acetic acid differs from that of diclofenac 
mainly in two respects. First, the symmetrical aromatic three-spin system A2X spin system of 
the dichloroaniline moiety has turned into an unsymmetrical AMX spin system. Second, the 
four-spin system of the aminophenylacetic acid part has changed into a three-spin system 
[Ernst, 2009]. The chemical shifts of two most deshielded protons at δ = 7.95 and 7.98 ppm 
are compatible with those of H4 and H5 of a carbazole unit [Figure 54]. Structure of 8-
chloro-9H-carbazole-1-acetic acid was thus proved by analysis of the 1HNMR spectrum and 
by inspection of two-dimensional 1H, 13
 
C hsqc and hmbc spectra [Table 15].  
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Figure 53: UV chromatogram of PTP1 after isolation as detected by HPLC/DAD at      
λ = 242 nm using acetonitrile/water/formic acid (50: 50: 0.1, v/v/v) as 
mobile phase 
 
 
 
 
 
Figure 54: Experimental (bottom) and simulated (top) 600 MHz 1H-NMR spectra of 
PTP1 (aromatic region), solvent: CD3
 
OD. Signals marked with x are due to 
diclofenac 
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Table 15: 1H- and 13C-NMR data of 8-chloro-9H-carbazole-1-acetic acid (PTP1), 
solvent: CD3
 
OD 
Position δH δa hmbcC b of 13C with 
1 --- 121.2 CH2 
2 7.33 128.6 H4, CH2 
3 7.17 120.9 --- 
4 7.95 119.9 H2 
4a --- 124.8 H3, H5 
4b --- 126.6 H4, H6 
5 7.98 119.7 H7 
6 7.13 120.8 --- 
7 7.38 125.9 H5 
8 --- 117.3 H6 
8a --- 138.5 H5, H7 
9a --- 140.8 H2, H4, CH2 
CH 3.94 2 41.1 H2 
COO  178.7 CH2 
a Coupling constants: J23 = 7.2, J24 = 1.0, J34 = 7.8, J56 = 7.8, J57 = 0.9, J67 = 7.7 Hz 
b
 
 Only strongest crosspeaks given 
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5. Conclusions 
Presence of pharmaceuticals in the environment is considered one of the hot topics recently 
acquired attention of many ecologists in different countries. Among the environmental issues, 
fate and behavior studies of several pharmaceuticals in water/sediment systems are poorly 
understood due to the lack of information. Pharmaceuticals could be potentially of concern in 
the aquatic environment due to their pharmacological actions and/or probably their 
transformation to perhaps more ecotoxic compounds. Therefore, fate studies are essential 
for estimation of various aspects such as persistence, occurrence, accumulation and 
estimation of the environmental risk assessment of pharmaceuticals.  
 
In addition to application of radiotracer techniques, investigation of pharmaceuticals under 
different environmental conditions is very helpful in order to obtain comprehensive 
information and hence to find suitable methods for reducing their environmental risks. Mainly 
two conditions are essential to be tested when the fate of pharmaceuticals are to be 
investigated in the water/sediment system. First is the fate of pharmaceuticals in the upper 
layers of the water bodies and shallows which are mainly exposed to the natural sunlight. 
This can be simulated by laboratory irradiation experiments using simulated sunlight. Second 
is the fate of pharmaceuticals in the deep water layers and river bed which are mainly 
exposed to the sediment biomass. This can be simulated by dark experiments. Although fate 
study under anaerobic conditions is important, aerobic condition is more important in case of 
water/sediment systems simulating the real situation especially at the water sediment 
interface which represents the most relevance place for biotransformation.  
 
Additionally, the relevance of the fate study is extremely increased when accompanied by 
other studies such as sorption/desorption experiments, identification and isolation of the 
unknown transformation products. Such combined studies are very helpful for better 
understanding of the results as well as for convincing data interpretations. Practically, several 
studies in different directions for many pharmaceuticals need a long time up to years and 
perhaps decades. In case of limited time, therefore, investigation of one pharmaceutical 
compound in depth is more realistic than to investigate several pharmaceutical compounds 
superficially leaving many open questions behind.  
 
Data regarding fate of some pharmaceuticals in water/sediment system are available but not 
including diclofenac. Therefore, the investigation of diclofenac in water/sediment systems 
was necessary to estimate several aspects: 
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1- The fate of 14
2- So far biotransformation is also accompanied by phototransformation, advanced 
laboratory test systems have to be applied to complete environmental risk 
assessment of photosensitive substances. 
C-diclofenac in aquatic ecosystems can be partly simulated by the 
standard water/sediment test.  
3- Even in the sediments with low organic matter contents, sorption and remobilization 
of diclofenac in water/sediment systems are occurred to a moderate extent. 
4- The sorption of diclofenac is a concentration dependent process and best fitted to the 
Freundlich isotherm model. 
5- Water immiscible solvents could be the best solvents for determination of the ER 
during fate studies in water/sediment systems. 
6- The fate of diclofenac in water/sediment system is greatly influenced by the 
environmental conditions especially presence and absence of light.  
7- In the dark water/sediment system, biotransformation and to moderate extend 
sorption were found to be the concentration determining process for diclofenac.  
8- Complete transformation of diclofenac to carbon dioxide and water occurs at 
relatively low amounts. 
9- The concentration is the rate determining step of the biotransformation process of 
diclofenac while sediment characteristics, texture, total microbial activity, and type of 
incubation system were found to have no considerable impact. 
10- The same persistence character for diclofenac could not be obtained by application of 
different persistence parameters.  
11- In presence of light, the most significant phototransformation process of diclofenac is 
the photocyclization to the corresponding monochlorinated carbazole and 
monohydroxy carbazole. 
12- The phototransformation process, which is mainly controlled by the irradiation time, is 
the concentration determining process for diclofenac in water/sediment systems as 
well as in pure and native water. 
13- The transformation products of diclofenac display a higher potential for accumulation 
in the sediments compartments and the accumulated amounts are mainly controlled 
by the characteristic of the used sediments. 
14- Sediments play an important role as a sink and at the same time as a source for polar 
transformation products of diclofenac. 
15- Presence of sediments diversely affects the occurrence of the phototransformation 
products of diclofenac and hence should be involved in environmental monitoring 
programs.  
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16- Application of different analytical techniques is necessary for identification of 
transformation products, i.e., GC/MS, HPLC/UVD, HPLC/DAD, LC/MS/MS, and NMR. 
17- In case of availability of alternative techniques, GC/MS should not be used in the 
analysis of diclofenac. 
18- LC/MS/MS-QTRAP is a powerful technique for identification of unknowns as well as 
quantitation of known compounds.  
19- The strategy used in the present study for identification of phototransformation of 
diclofenac which based on application of different scan modes can easily be applied 
for identification of any other unknown compound. 
20- Further efforts should be done to make the transformation products available as 
authentic reference standards. Otherwise, method development for quantitative 
analysis would not be possible. 
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6. Summary and future perspectives 
 
Recently, pharmaceuticals have been identified as a new class of environmental 
contaminants. Polarity, excessive use and insufficient treatment of either pharmaceutical 
industrial wastes or wastewater could be the main reasons for presence of considerable 
amounts of pharmaceutical residues in the aquatic environment. The non-steroidal anti-
inflammatory drug diclofenac is considered one of the most environmentally relevant 
pharmaceutical compounds. It has been frequently detected in almost all environmental 
surveys at concentrations ranging from 0.001 µg/L to 30 µg/L. 
 
Due to its importance, diclofenac was subjected in the present study to comprehensive 
investigations in water/sediment systems aiming for more accurate environmental risk 
assessment. Therefore, the following studies were included in the current work: 
1- Biotransformation and photoinduced transformation tests accompanied by 
sorption/desorption experiments using radiotracer technique in water/sediment 
systems. 
2- Identification of its phototransformation products in water and water/sediment 
systems using GC/MS, HPLC, and LC/MS/MS techniques. 
3- Isolation and structural confirmation of the most abundant phototransformation 
product of diclofenac using preparative reversed-phase column chromatography and 
semi-preparative HPLC followed by 1H- and 13
 
C-NMR analysis using 1D and 2D NMR 
techniques.  
For the environmental risk assessment, fate of diclofenac in water/sediment systems is of 
major relevance. In accordance to regulatory recommendations, therefore, the OECD 308 
water/sediment simulation test was performed under aerobic conditions. Within the 100-day 
incubation period, 14C-diclofenac continuously disappeared from the aqueous phase while 
the residues increased in the sediment. After a first increase up to 22 %, the ethyl acetate 
extractable residues dropped to 0.2 % while the non-extractable residues continuously 
increased and finally reached 82 %. Mineralization increased up to 13 %. At least 28 days 
were needed for 14C-diclofenac in order to almost disappear from the water phase. At 
maximum, the DT50 and DT90 
 
of diclofenac were estimated at 13 and 42 days, respectively. 
In the worst case, these results indicated that diclofenac could be classified as moderately 
persistent pharmaceutical compound in dark regions of the aquatic environment.  
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Furthermore, laboratory batch experiments were conducted to study the sorption and 
desorption behavior of 14C-diclofenac in addition to their isotherms. Distribution coefficient 
(Kd) of sorption onto the sediment was 5.5 L/kg. On the other hand, desorption percentage of 
14C-diclofenac from the sediment was found to be 20 %. The isotherms fitted by Freundlich 
equation showed that they were closed to linear. The Freundlich coefficient KF values of 
adsorption and desorption were 7.5 and 15.8 µg1-1/n L1/n
 
/kg, respectively. 
Since diclofenac is known as a photosensitive substance and may thus undergo 
phototransformation in surface water, water/sediment tests have been also conducted in a 
special irradiation apparatus to advance the fate monitoring under laboratory conditions. In 
contrast to the incubation in the dark, up to 70 % of non-extractable residues were formed 
under irradiation within 3 days even though the formation of more polar phototransformation 
products with lower affinity to the sediment was expected. Therefore, the identification of 
phototransformation products of diclofenac was demanded. 
 
Because transformation processes may result in formation of unknown compounds with 
different physico-chemical properties, several techniques based on GC/MS, HPLC/UV, 
HPLC/DAD and LC/MS/MS were applied after numerous irradiation experiments either in 
pure water or in water/sediment systems for identifying phototransformation products of 
diclofenac. The analyses were carried out after enrichment of the analytes from the water 
phases and the sediments by means of liquid/liquid, solid phase or liquid/solid extraction. 
 
In the irradiated water samples, phototransformation products could not be detected by 
means of GC/MS, even though polar analytes were derivatized by pentafluorobenzylation. 
This analysis was interfered because diclofenac underwent an intramolecular cyclization 
forming the thermal artifact 1-(2,6-dichlorophenyl)indolin-2-one in the split/splitless injector. In 
contrast, three UV detectable transformation products could be detected besides diclofenac 
when HPLC/UVD and HPLC/DAD were applied.  
 
The structure elucidation of these compounds was then performed by LC/MS/MS analysis 
using for the first time a hybrid triple quadrupole linear ion trap mass spectrometer operated 
in negative electrospray ionization mode. Application of different scan techniques such as 
enhanced MS and enhanced product ion scan using information depending acquisition 
method followed by precursor ion scan were necessary for determination of the target 
nominal masses of the expected transformation compounds.  
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By means of mass spectra interpretation, the formation of 8-chloro-9H-carbazole-1-acetic 
acid, 8-hydroxy-9H-carbazole-1-acetic acid and 8-chloro-9H-carbazole-1-methanol was 
indicated in case of irradiated water samples. In contrast, only 8-chloro-9H-carbazole-1-
acetic acid was found besides diclofenac in case of water/sediment irradiation experiments. 
These results indicated the impact of the sediment on fate and behavior of 
phototransformation products in aquatic environment and demonstrated that the formation of 
non-extractable residues in the sediment could be mainly attributed to 8-hydroxy-9H-
carbazole-1-acetic acid and 8-chloro-9H-carbazole-1-methanol.  
 
Due to the lack of authentic reference standards, isolation of phototransformation products 
was necessary for structural confirmation by means of NMR techniques. Because of its 
environmental relevance, the most abundant phototransformation product of diclofenac 8-
chloro-9H-carbazole-1-acetic acid was primary enriched by means of preparative reversed 
phase column chromatography and semi-preparative HPLC. Finally, the structure was 
confirmed by NMR spectra interpretations where the 1H and 13
 
C chemical shifts and the 
detected spin systems were found to be compatible with the proposed carbazole structure. 
Data based on transformation of pharmaceuticals in water/sediment systems should be 
involved in the risk assessment procedure of diclofenac. For this purpose, further data on the 
fate in anaerobic sediments should be gathered. Biotransformation products of diclofenac in 
water/sediment systems should be structurally identified and prepared as authentic reference 
standards. Thereafter, thorough ecotoxicological tests have to be performed. Similarly, 
monitoring programs are strongly recommended for other pharmaceuticals detected as 
environmental contaminants. The results should be then used to list the pharmaceuticals 
priority to which the environmental risk assessment is necessary. Based on the risk quotient 
later on, risk reduction measures should be proposed, discussed, tested and finally applied. 
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Appendix 
 
Table A1: Extraction efficiency tests of SPE materials for 14
 
C-diclofenac from pure 
water 
A [Bq] (fortified in 
the water phase) 
A [Bq] (found in the 
methanol eluent after SPE) 
Recovery 
[%] 
Sample 1 7000 6742 96 
Sample 2 7000 6542 93 
Sample 3 7000 6565 93 
Sample 3 7000 6240 89 
Mean  93 
SD    3 
RSD  3.2 
A = radioactivity amount 
 
Table A2: Extraction efficiency of ethyl acetate for diclofenac from pure water as 
determined by radiotracer technique  
 Fortified [Bq]  Found [Bq]  Recovery [%] 
Sample1 35647 33980 95 
Sample 2 35647 33152 93 
mean  94 
SD  1.6 
 
Table A3: Extraction efficiency of ethyl acetate for diclofenac from pure water as 
determined by GC/MS  
 Fortified [ng/µL]  Found [ng/µL]  Recovery [%] 
Sample1 10 8.8 88 
Sample 2 10 9.0 90 
mean  89 
SD  1.4 
 
Table A4: Extraction efficiency of ethyl acetate for diclofenac from pure water as 
determined by HPLC/UVD 
 Fortified [ng/µL]  Found [ng/µL]  Recovery [%] 
Sample 1 100 93.1 93.1 
Sample 2 100 89.0 89.0 
Sample 3 100 91.6 91.6 
Mean  92.0 
SD    2.2 
RSD    2.4 
 
Table A5: Extraction efficiency of ethyl acetate for diclofenac from pure water as 
determined by LC/MS/MS  
 Fortified [ng/µL]  Found [ng/µL]  Recovery [%] 
Sample 1 10 8.77 87.7 
Sample 2 10 9.00 90.0 
Sample 3 10 8.90 89.0 
Mean  88.9 
SD    1.2 
RSD    1.4 
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Table A6: Test on solvent exchange step from ethyl acetate to methanol as 
determined by HPLC/UVD 
 [ng/µL] fortified from 
ethyl acetate solution 
[ng/µL] found after  
dissolution in methanol 
Recovery 
 [%] 
Sample 1 50 49.3   98.5 
Sample 2 50 49.5   99.0 
Sample 3 50 51.6 103.2 
Mean  100.2 
SD      2.6 
RSD      2.6 
 
Table A7: Recovery rates of diclofenac after extraction with ethyl acetate from 
wet sediment and clean up with GPC as determined by HPLC/UVD 
 Fortified [ng/µL]  Found [ng/µL]  Recovery [%] 
Sample 1 40 40.5 101.3 
Sample 2 40 39.9   99.6 
Sample 3 40 38.8   97.1 
Sample 4 40 40.6 101.5 
Sample 5 80 71.3   89.1 
Mean    97.7 
SD      5.1 
RSD      5.3 
 
Table A8: Calibration curve parameters for the determination of diclofenac 
concentrations 
 Linearity range Regression equation R2 
GC/MS (DCF-PFB ester)         0.3 - 30    ng/µL PA x 10-5 0.997 = 2.70 C + 1.30 
GC/MS (DCF)         1.0 - 10    ng/µL PA x 10-4 0.997 = 3.30 C – 3.00 
HPLC/UVD         0.2 - 100  ng/µL PA x 10-5 0.999 = 2.20 C + 1.30 
LC/MS/MS   0.0001 - 10    ng/µL PA x 10-3 0.995 = 7.74 C +  736 
LC/MS/MS         1.0 - 20    ng/µL PA x 10-6 0.996 = 4.00 C + 4.00 
PA = a ± bc (PA, peak area; a, intercept; b, slop), DCF = diclofenac, DCF-PFB ester = 
diclofenac pentafluorobenzyl ester 
 
Table A9: Determination of sorption coefficient (Kd
Set 
) at different 
concentrations 
Cw C 
Bq/60mL 
w C 
Bq/L 
w Log C 
µg/L 
w C 
µg/L Bq/20g 
s Cs
C Bq/kg s
Log 
C µg/kg s 
K
µg/kg 
d
n = 4 
 (L/kg) 
S 1 3732 62207   8.4 0.9 7241 362030   48.8 1.7   5.8 ± 0.8 
S 2 6192 103202 13.9 1.1 11755 587744   79.3 1.9   5.7 ± 0.7 
S 3 14699 244993 33.0 1.5 21876 1093821 147.5 2.2   4.5 ± 1.0 
S 4 30532 508875 68.6 1.9 24332 1216600 164.1 2.2   2.4 ± 0.1 
S 5 23591 393190 53.0 1.7 49561 2478030 334.2 2.5   6.4 ± 1.3 
S 6 36378 606294 81.8 1.9 59094 2954717 398.5 2.6   4.9 ± 0.5 
Mean    5.5 ± 0.8 
S = set, Cs = sorbed concentrations, Cw
 
 = aqueous concentrations, n = number of replicates 
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Table A10 : Determination of desorption coefficient (Kdes
 
) at different concentrations 
Set 
Cw
60 mL 
 
Bq/ Cw  Bq/L 
Cw
Log 
C µg/L w
Cs 
Bq/20g  µg/L 
Cs 
 Bq/kg 
Cs
Log 
C µg/kg s 
K
µg/kg 
(L/kg) 
des 
n = 4 
S 1 nd nd nd nd nd nd nd nd nd 
S 2 2652 44202 6.0 0.7 9103 455139   61.4 1.8  10.2 ± 1.7 
S 3 3447 57457 7.7 0.9 18429 921449 124.3 2.1  16.1 ± 2.5 
S 4 5594 93240 12.6 1.1 18738 936879 126.3 2.1  10.0 ± 1.9 
S 5 8794 146571 19.8 1.3 40766 2038317 274.9 2.4  13.9 ± 0.5 
Mean     13.0 ± 3.0 
S = set, Cs = sorbed concentrations, Cw
 
 = aqueous concentrations, n = number of replicates 
Table A11: Relative radioactivity amounts of 14
 
C-DCF and its BTPs in the water 
phase of water/sediment system WS1 after incubation in the dark as 
shown by solvent 1 (n-hexane/ethyl acetate/acetic acid; 50:50:1 v/v/v) 
Laboratory batch system 
DAA DCF [%] BTP1 [%] BTP 2 [%] BTP 3 [%] BTP 4 [%] BTP 5 [%] 
    0  81.5   3.7 3.8 7.4   1.6   7.5 
    1 66.1   3.2 3.5 4.4   6.4   2.0 
    3 62.5   2.6 nd nd    8.2   3.5 
    7 43.6   3.3 0.9 1.3 12.1   9.7 
  14 43.5   4.1 nd nd 13.0   9.5 
  28  1.3 13.9 3.2 nd   4.0 10.0 
  56  1.6 14.2 1.5 nd   1.7 nd 
100 0.5  9.4 0.6 nd   0.2 nd 
Biometric flask system 
DAA DCF [%] BTP 1 [%] BTP 2 [%] BTP 3 [%] BTP 4 [%] BTP 5 [%] 
    3 61.2   2.4 nd nd 9.0 4.2 
  56   1.5 16.2 1.6 nd 1.4 0.4 
100   0.9   9.8 1.0 nd 0.2 0.3 
DCF = diclofenac, BTP = biotransformation product 
 
Table A12: Relative radioactivity amounts of 14
 
C-DCF and its BTPs in the water 
phase of water/sediment system WS1 after incubation in the dark as 
shown by solvent 2 (dichloromethane/methanol/25% ammonia; 85:14:1; 
v/v/v) 
Laboratory batch system 
DAA DCF [%] BTP 1 [%] BTP 2 [%] BTP 3 [%] BTP 4 [%] 
  0 80.4 7.8 nd 3.1 14.2 
  1 60.0 5.6 nd 1.8 18.2 
  3 65.5 4.3 nd nd   7.0 
  7 48.6 7.1 2.9 nd 12.3 
14 61.5   2.8 nd nd 5.8 
28 15.0 13.5 2.2 0.3 1.4 
Biometric flask system 
  3 69 3 nd nd 4.8 
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Table A13: Relative radioactivity amounts of 14
Laboratory batch system 
C-DCF and its BTPs in the water 
phase of water/sediment system WS2 after incubation in the dark as 
shown by solvent 1 (n-hexane/ethyl acetate/acetic acid; 50:50:1 v/v/v) 
DAA DCF  [%] 
BTP 1 
[%] 
BTP 2 
[%] 
BTP 3 
[%] 
BTP 4 
[%] 
BTP 5 
[%] 
BTP 6 
[%] 
    0 77.3 3.40 8.60 8.40 1.60   6.30 Nd 
    1 65.1 2.30 4.00 5.30 6.50   3.20 Nd 
    3 38.3 2.50 2.60 nd 8.30 23.10 nd 
    7 36.1 3.10 3.20 nd 6.50 15.20 nd 
  14 35.4 4.50 1.90 nd 6.60   3.10 nd 
  28 20.8 4.20 1.30 1.00 6.00   0.60 nd 
  56 5.20 7.34 nd nd 3.70   0.86 1.36 
100 0.74 6.63 0.19 nd nd nd 1.49 
 
Biometric flask system 
DAA DCF  [%] 
BTP 1 
[%] 
BTP 2 
[%] 
BTP 3 
[%] 
BTP 4 
[%] 
BTP 5 
[%] 
BTP 6 
[%] 
    3 54.80 1.70 0.90 2.00 6.70 7.60 nd 
  56   4.95 7.10 nd nd 4.29 1.76 1.32 
100   1.69 6.86 nd nd 1.12 0.10 1.70 
 
Table A14: Relative radioactivity amounts of 14
Laboratory batch system 
C-DCF and its BTPs in the water 
phase of water/sediment system after WS2 incubation in the dark as 
shown by solvent 2 (dichloromethane/methanol/25% ammonia; 85:14:1; 
v/v/v) 
DAA DCF [%] BTP 1 [%] BTP 2 [%] BTP 3 [%] BTP 4 [%] 
    0 83.70 7.30 14.60 nd nd 
    1 73.00 4.70   8.70 nd nd 
    3 37.90 3.10 33.80 nd nd 
    7 38.40 3.60 16.70 nd nd 
  14 37.70 8.00   5.80 nd nd 
  28 22.60 8.00   1.60 nd 1.7 
  56   9.20 6.80   2.46 nd nd 
100   1.60 7.25   0.20 nd nd 
Biometric flask system 
DAA DCF [%] BTP 1 [%] BTP 2 [%] BTP 3 [%] BTP 4 [%] 
    3 67.80 3.60 2.30 nd nd 
  56   9.78 6.26 2.78 0.60 nd 
100   1.70 8.10 1.40 0.27 nd 
 
 
Table A15: Extraction efficiency test for 14
Type of solvent 
C-diclofenac in wet sediment using 
different solvents 
ER [%] NER [%] Recovery [%] 
Ethyl acetate 90 ± 3.5   9 ± 0.6    99 ± 4.0 
Acetone 69 ± 4.7 25 ± 2.2    94 ± 2.4 
Acetonitrile 69 ± 3.6 21 ± 4.6    90 ± 3.0 
Methanol 57 ± 2.9 18 ± 3.6    75 ± 2.0 
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Table A16: Tests on remaining radioactivity of 14
Method of 
extraction 
C-diclofenac in pore water after 
direct solvent extraction 
MIN [%] AP [%] ER [%] NER [%] Recovery [%] 
DE 1 ± 0.02 41 ± 0.5 40 ± 2.4 11 ± 4.6 93 ± 1.7 
RE 1 ± 0.02 53 ± 0.0 30 ± 0.9 15 ± 3.1 99 ± 2.2 
DE = direct extraction, RE = Rinsing before extraction 
 
Table A17: Relative radioactivity amounts of 14
Laboratory batch system 
C-DCF and its BTPs in the ethyl 
acetate extracts of water/sediment system WS1 after incubation in the 
dark as shown by solvent 1 (n-hexane/ethyl acetate/acetic acid; 50:50:1 
v/v/v) 
DAA DCF [%] 
BTP 1 
[%] 
BTP 2 
[%] 
BTP 3 
[%] 
BTP 4 
[%] 
BTP 5 
[%] 
BTP 6 
[%] 
BTP 7 
[%] 
  1   6.20 0.25 1.50 0.50 nd nd nd nd 
  3   9.07 0.38 2.95 1.20 nd nd nd nd 
  7   9.70 0.33 2.47 0.85 2.40 nd nd nd 
14 10.00 0.18 2.79 0.50 2.30 nd nd nd 
28   2.05 0.48 2.62 0.28 1.22 0.20 0.36 0.35 
 
Biometric flask system 
  3 8.63 0.45 3.69 1.31 0.83 nd nd nd 
 
Table A18: Relative radioactivity amounts of 14
Laboratory batch system 
C-DCF and its BTPs in the ethyl 
acetate extracts of water/sediment system WS1 after incubation in the 
dark as shown by solvent 2 (dichloromethane/methanol/25% ammonia; 
85:14:1; v/v/v) 
DAA DCF [%] 
BTP 1 
[%] 
BTP 2 
[%] 
BTP 3 
[%] 
BTP 4 
[%] 
BTP 5 
[%] 
BTP 6 
[%] 
BTP 7 
[%] 
  1   6.35 0.50 0.30 0.80 0.50 nd nd nd 
  3 10.75 0.62 0.62 1.11 0.50 nd nd nd 
  7 13.27 0.29 0.42 1.27 0.50 nd nd nd 
14 14.34 nd nd 1.42 nd nd nd nd 
28   4.99 0.38 nd 1.54 nd nd 0.21 0.44 
 
Biometric flask system 
  3 11.85 0.80 0.54 1.00 0.72 nd nd nd 
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Table A19: Relative radioactivity amounts of 14
Laboratory batch system 
C-DCF and its BTPs in the ethyl 
acetate extracts of water/sediment system WS2 after incubation in the 
dark as shown by solvent 1 (n-hexane/ethyl acetate/acetic acid; 50:50:1 
v/v/v) 
DAA DCF [%] BTP 1 [%] BTP 2 [%] BTP 3 [%] 
  1 10.4 0.2 2.9 1.4 
  3 13.0 0.2 3.3 2.4 
  7 16.0 0.3 4.0 1.9 
14 14.4 0.6 5.0 1.9 
28   6.4 0.9 4.4 1.6 
56   1.0 0.8 2.3 0.6 
 
Biometric flask system 
DAA DCF [%] BTP 1 [%] BTP 2 [%] BTP 3 [%] 
  3 14.0 0.3 3.7 2.5 
 
Table A20: Relative radioactivity amounts of 14
Laboratory batch system 
C-DCF and its BTPs in the ethyl 
acetate extracts of water/sediment system WS2 after incubation in the 
dark as shown by solvent 2 (dichloromethane/methanol/25% ammonia; 
85:14:1; v/v/v) 
DAA DCF  [%] 
BTP 1 
[%] 
BTP 2 
[%] 
BTP 3 
[%] 
BTP 4 
[%] 
BTP 5 
[%] 
BTP 6 
[%] 
  1 11.4 0.6 0.7 0.2 0.3 0.7 1.0 
  3 14.6 0.3 0.6 0.1 0.3 1.3 1.7 
  7 20.0 0.3 nd nd nd 0.7 1.2 
14 19.4 0.6 nd nd nd 0.5 1.4 
28 11.1 0.5 nd nd nd 0.3 1.4 
56   3.6 0.4 nd nd nd nd 0.7 
 
Biometric flask system 
DAA DCF  [%] 
BTP 1 
[%] 
BTP 2 
[%] 
BTP 3 
[%] 
BTP 4 
[%] 
BTP 5 
[%] 
BTP 6 
[%] 
  3 16.0 0.5 0.6 nd 0.3 1.4 1.7 
56   2.7 0.4 nd nd nd nd 0.5 
 
Table A21: Balances of the biotransformation test series of 14
DAA 
C-diclofenac in 
water/sediment system WS1 using laboratory batch system 
MIN [%] AP [%] ER [%] NER [%] Recovery [%] 
    0 nd 106 ± 0.5   0.7 ± 0.1   2.0 ± 0.1 109 ± 0.5 
    1   0.1 ± 0.0   86 ± 0.2     9.0 ± 1.0 13.0 ± 2.4 109 ± 3.6 
    3   0.4 ± 0.1   77 ± 2.0 14.0 ± 1.0 17.0 ± 1.3 108 ± 2.1 
    7   0.8 ± 0.0   71 ± 0.3 16.0 ± 1.4 21.0 ± 3.5 108 ± 1.8 
  14   1.0 ± 0.0   70 ± 1.0 16.0 ± 2.6 21.0 ± 2.8 108 ± 0.7 
  28   3.0 ± 0.5   32 ± 3.0   8.0 ± 0.1 63.0 ± 1.6 106 ± 3.7 
  56   6.0 ± 0.2   19 ± 1.0   4.0 ± 0.3 76.0 ± 0.2 106 ± 1.8 
100 13.0 ± 0.2   10 ± 1.0   0.2 ± 0.0 83.0 ± 0.0 106 ± 0.7 
DAA = Days after application 
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Table A22: Balances of the biotransformation test series of 14
DAA 
C-diclofenac in 
water/sediment system WS2 using laboratory batch system 
MIN [%] AP [%] ER [%] NER [%] Recovery [%] 
    0 nd   106 ± 1.5   0.8 ± 0.1   2 ± 0.4 109 ± 1.7 
    1   0.1 ± 0.0  86 ± 1.1 15.0 ± 1.0   8 ± 0.2 109 ± 2.3 
    3   0.1 ± 0.1  75 ± 1.0 19.0 ± 2.7 14 ± 0.2 109 ± 4.0 
    7   0.5 ± 0.0  64 ± 0.8 22.0 ± 0.5 25 ± 0.4 112 ± 1.8 
  14   0.9 ± 0.1  52 ± 1.2 22.0 ± 1.0 32 ± 3.7 107 ± 1.3 
  28   3.0 ± 0.2  34 ± 0.1 13.0 ± 0.6 55 ± 2.6 105 ± 3.1 
  56   6.0 ± 0.7  19 ± 0.7   5.0 ± 2.8 77 ± 1.1 107 ± 0.0 
100 13.0 ± 0.1    9 ± 0.2   0.8 ± 0.1 82 ± 0.1 105 ± 0.2 
 
Table A23: Balances of the biotransformation test series of 14
DAA 
C-diclofenac in 
water/sediment system WS1 using the biometric flask system 
MIN [%] AP [%] ER [%] NER [%] Recovery [%] 
    3   0.6 ± 0.0 77 ± 2.8 15.0 ± 0.2 16 ± 7.0 108 ± 3.9 
  56   6.0 ± 0.0 21 ± 1.5   4.0 ± 0.1 75 ± 0.5 106 ± 0.0 
100 13.0 ± 3.5 12 ± 1.8   0.4 ± 0.1 82 ± 0.5 107 ± 2.0 
 
Table A24: Balances of the biotransformation test series of 14
DAA 
C-diclofenac in 
water/sediment system WS2 using the biometric flask system 
MIN [%] AP [%] ER [%] NER [%] Recovery [%] 
    3   0.2 ± 0.0 74 ± 3.4 21 ± 2.8 13 ± 1.6 108 ± 7.8 
  56   5.0 ± 3.6 19 ± 0.7   4 ± 2.0 75 ± 0.3 103 ± 6.5 
100 13 ± 1.8 12 ± 1.3   1 ± 0.8 82 ± 4.5 108 ± 4.8 
 
Table A25: Balances of the phototransformation test of 14
 
C-diclofenac irradiated 10 
h/d for three days using laboratory batch systems 
MIN [%] AP [%] ER [%] NER [%] Recovery [%] 
WS1 1 ± 0.2 35 ± 4.2   3 ± 0.7 65 ± 1.8 104 ± 2.8 
WS2 1 ± 0.3 26 ± 3.8 10 ± 0.6 70 ± 0.1 107 ± 4.7 
QS 1 ± 0.0 66 ± 0.0 10 ± 0.0 19 ± 0.0 96 ± 0.0 
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Table A26: Relative radioactivity amounts of 14C-DCF and its PTPs after irradiation 
of 14
Water/sediment 1 
C-DCF 10 h/d for three days using laboratory batch systems  
 DCF 
[%] 
PTP 1 
[%] 
PTP 2 
[%] 
PTP 3 
[%] 
PTP 4 
[%] 
PTP 5 
[%] 
PTP 6 
[%] 
PTP 7 
[%] 
AP a 2.00 29.00 1.00 4.70 nd nd nd nd 
AP b nd 36.70 nd nd nd nd nd nd 
ER a 1.22 0.28 0.32 0.28 0.63 0.27 0.13 0.10 
ER b 1.96 0.20 0.16 0.71 0.20 nd nd nd 
 
Water/sediment 2 
 DCF 
[%] 
PTP 1 
[%] 
PTP 2 
[%] 
PTP 3 
[%] 
PTP 4 
[%] 
PTP 5 
[%] 
PTP 6 
[%] 
PTP 7 
[%] 
AP a 2.2 15.9 2.7 2.5 0.1 0.2 2.3 nd 
AP b 4.0 17.9 1.5 nd nd nd nd nd 
ER a nd 
ER b nd 
 
Pure water/Quartz sand sediment 
 DCF 
[%] 
PTP 1 
[%] 
PTP 2 
[%] 
PTP 3 
[%] 
PTP 4 
[%] 
PTP 5 
[%] 
PTP 6 
[%] 
PTP 7 
[%] 
AP a 7.0 45.0 6 15 nd nd nd nd 
ER a nd 
 
Water samples 
 DCF 
[%] 
PTP 1 
[%] 
PTP 2 
[%] 
PTP 3 
[%] 
PTP 4 
[%] 
PTP 5 
[%] 
PTP 6 
[%] 
PTP 7 
[%] 
NW a 3.5 63.75 3.35 6.00 nd nd nd nd 
PW a nd 73.00 5.10 16.08 11.4 nd nd nd 
AP = aqueous phase, ER = ethyl acetate extract, NW = Native water, PW = Pure water, a = 
solvent 1, b = solvent 2, DCF = diclofenac, PTP = phototransformation product, nd = not 
determined 
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Table A27: Relative radioactivity amounts of 14
Laboratory batch system (dark experiments) 
C-DCF and its TPs detected in the 
percolate and methanol eluent after SPE 
DAA WS1 WS2 
 P ME P ME 
    0 2.9 ± 0.6 80.6 ± 2.0 4.2 ± 0.5 79.6 ± 3.6 
    1 1.7 ± 0.1 60.9 ± 0.8 1.9 ± 0.3 76.5 ± 0.8 
    3 1.2 ± 0.1 63.0 ± 1.8 1.4 ± 0.0 67.6 ± 0.8 
    7 1.0 ± 0.1 63.5 ± 0.2 1.0 ± 0.1 58.7 ± 0.8 
  14 1.0 ± 0.0 63.0 ± 0.6 1.2 ± 0.1 41.4 ± 0.2 
  28 2.3 ± 0.2 23.9 ± 1.8 0.7 ± 0.2 25.6 ± 1.4 
  56 1.4 ± 0.1 12.7 ± 0.9 0.7 ± 0.0 12.7 ± 2.9 
100 1.0 ± 0.3   6.7 ± 0.6 0.7 ± 0.0   6.1 ± 0.1 
Biometric flask system 
    3  1.3 ± 0.3 59.0 ± 2.0 1.3 ± 0.0 55.6 ± 2.4 
  56  1.5 ± 0.2 12.7 ± 2.8 0.9 ± 0.3 14.6 ± 1.0 
100  0.7 ± 0.2   7.8 ± 0.9 0.7 ± 0.2   8.1 ± 1.0 
Laboratory batch system (Irradiation experiments) 
3 3.4 ± 0.1 19.4 ± 5.2 2.0 ± 0.5 15.7 ± 3.0 
P = percolate, ME = methanol eluent, TPs = transformation products,  
 
Table A28: Chemical characterization of the non-extractable residues of WS1 by 
means of sequential extraction technique after the 3-d irradiation 
experiment 
 Radioactivity [%] 
MIN     0.9 ± 0.2 
AP   35.0 ± 4.2 
Ethyl acetate ER     3.0 ± 0.7 NER   64.6 ± 1.8 
Methanol/ 
Hydrochloric acid 
ER     9.0 ± 1.3 
NER   51.0 ± 7.0 
Dimethylformamide/ 
Chlorotrimethylsilane 
ER   26.0 ± 0.4 
NER   26.0 ± 1.7 
Recovery [%] 100.0 ± 6.4 
 
Table A29: Concentrations of irradiated diclofenac in pure water as determined by 
GC/MS 
Time (h) Fortified [ng/µL]  Found [ng/µL]  Recovery [%] 
1 10.00 5.72 57.20 
2 10.00 4.77 47.70 
3 10.00 3.22 32.20 
4 10.00 3.14 31.40 
5 10.00 2.09 20.90 
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Table A30: Concentrations of irradiated diclofenac in pure water as determined by 
HPLC/UVD 
Time (h) Fortified [ng/µL]  Found [ng/µL]  Recovery [%] 
  2 100 32.7 32.7 
  4 100 21.7 21.7 
  6 100 12.8 12.8 
  8 100   7.8   7.8 
10 100   3.7   3.7 
 
Table A31: Concentrations of irradiated diclofenac in pure water as determined by 
LC/MS/MS 
Time (h) Fortified [ng/µL]  Found [ng/µL]  Conc [ng/µL]  (Dilution factor = 2) 
Recovery 
[%] 
  2 100 17.2 34.4 34.4 
  4 100 11.5 23.0 23.0 
  6 100   6.8 13.6 13.6 
  8 100   4.5   9.0   9.0 
10 100   2.2   4.4   4.4 
 
Table A32: Concentrations of irradiated diclofenac in real water/sediment system 
WS3 as determined by LC/MS/MS 
Water phase 
 Fortified [ng/µL] Found [ng/µL] Recovery [%] 
Sample 1 20 7.63 38.15 
Sample 2 20 8.08 40.40 
Mean  39.30 
SD    1.60 
RSD    4.10 
 
Ethyl acetate extracts 
Sample 1 20 0.516 2.6 
Sample 2 20 0.457 2.3 
Mean  2.4 
SD  0.2 
RSD  8.6 
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Table A33: Concentrations of diclofenac in real water/sediment system WS3 as 
determined by LC/MS/MS after the dark experiments 
Water phase 
 Fortified [ng/µL] Found [ng/µL] Recovery [%] 
Sample 1 20 11.6 58.0 
Sample 2 20 12.1 60.5 
Mean  59.3 
SD    1.8 
RSD    3.0 
 
Ethyl acetate extracts 
Sample 1 20 3.90 19.5 
Sample 2 20 3.79 19.0 
Mean  19.2 
SD    0.4 
RSD    2.0 
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